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 ABSTRACT 
 The mutant-prevention concentration (MPC) is a novel susceptibility 
measurement defined by a concentration threshold that would require cells to contain 
two concurrent resistance mutations for growth.  Pneuococcal pneumonia, infections 
caused by Pseudomonas aeruginosa, and urinary tract infections caused by Gram-
negative bacilli represent three distinct clinical situations for which fluoroquinolone-
resistance occurs.  MPC results were defined and measured for fluoroquinolones against 
clinical isolates of Citrobacter freundii, Enterobacter cloacae, Escherichia. coli, 
Klebsiella pneumoniae, P. aeruginosa, and Streptococus  pneumoniae.  Against clinical 
isolates of S. pneumoniae, MPC results for six fluoroquinolones were measured. Based 
on their potential for restricting the selection of resistant mutants, the six 
fluoroquinolones, in descending order, were found to be gemifloxacin > moxifloxacin 
> trovafloxacin  >  gatifloxacin  >  grepafloxacin > levofloxacin. For several 
compounds, 90% of clinical isolates that lacked a known resistance mutation had a MPC 
value that was close to or below the serum levels that could be attained with a dosing 
regimen recommended by the manufacturers.  These data identify gemifloxacin, 
moxifloxacin and gatifloxacin as good candidates for determining whether MPC can be 
used as a guide for choosing and eventually administering fluoroquinolones to 
significantly reduce the development of fluoroquinolone –resistant S. pneumoniae.  
MPC90 results for 155 clinical isolates of P. aeruginosa against ciprofloxacin and 
levofloxacin were 4 and 16 μg/ml, respectively.  Serum drug concentrations reported 
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previously for standard doses were above MPC90 for 5.5 hr for ciprofloxacin and 0 hr 
for levofloxacin.   These data suggest that superior clinical performance of 
ciprofloxacin correlates with activity against resistant mutant subpopulations measured 
in vitro.  MPC results were compared with minimum inhibitory concentrations (MIC) 
measurements preformed by agar dilution, and microbroth dilution and minimal 
inhibitory concentrations (MBC) for 100 clinical isolates of C. freundii (n=20), E. 
cloacae (n=20), E. coli (n=20), K. pneumoniae (n=20), and P. aeruginosa (n=20) for 
ciprofloxacin, levofloxacin and garenoxacin.  MPC results were 2-to-8 fold higher than 
MIC or MBC results.  Ciprofloxacin MPC results for E.coli, C. freundii, E. cloacae, K. 
pneumoniae, and P. aeruginosa were 0.5, 2, 1, 1, and 4 μg/ml, respectively.  
Levofloxacin, MPC results were were 1, 2, 4, 1, and 16 μg/ml, respectively.  
Garenoxacin, MPC were 1, 8, >8, 4, and >32 μg/ml, respectively.  Garenoxacin had the 
highest MIC and MPC results and was the least active compound tested against isolates 
of C. freundii, E. cloacae, and P. aeruginosa.   These data support the rational use of 
quinolones in the treatments of urinary tract infections and suppression of resistance.  
Incorporation of the MPC measurement into dosing strategies may preserve the 
longevity of antimicrobial compounds for future infectious diseases.   
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1.0       INTRODUCTION  
 
 1.1 Quinolone Antibiotics 
 
 The fluoroquinolones represent a relatively new class of broad-spectrum, 
systemically active antibacterial agents.  Since the introduction of nalidixic acid in 1967 
(304), fluoroquinolone usage has expanded far beyond an early role in the treatment of 
urinary tract infections (UTIs) and fluoroquinolones are now used in front-line therapies 
for the treatment of a number of different bacterial infections present at different 
anatomical sites.  Collectively, the fluoroquinolone spectrum of activity now includes 
Gram-negative, Gram-positive, atypical and anaerobic pathogens (28, 33, 69), as well as 
multi-drug resistant organisms (MDR) (17, 164, 165, 246, 282), since the mechanism of 
quinolone action is distinct from existing classes of antimicrobials (165).  Examination 
of many new derivatives has improved our understanding of quinolone activity and has 
led to structural changes in quinolone chemistry that in turn have produced compounds 
with longer elimination half lives, better dosing profiles, more extensive bacterial 
coverage, greater potency and acceptable safety profiles (30, 68, 96, 113, 132).  Overall, 
the introduction of fluoroquinolones into clinical practice, particularly as orally 
administered antibiotics, has revolutionized the management of a number of infections 
that were previously treatable only with parenteral antimicrobial agents.  Thus, 
preserving the current and future clinical utility of fluoroquinolones is of paramount 
importance.  The following chapter discusses quinolone history, structure/activity 
relationships, and development of resistance and introduces a novel susceptibility 
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parameter, termed, mutant-prevention concentration (MPC) which is designed to 
minimize fluoroquinolone resistance while maximizing therapeutic outcome.    
1.2 History and Development of Quinolone Agents: Structure - Activity 
Relationships 
 
The discovery of quinolone antibiotics began by chance during the early 1960s 
when a by-product of the commercial preparation of the antimalarial drug chloroquine 
was found to have antibacterial properties (201).  The compound 7-chloro-1-ethyl-1, 4-
dihydro-7 methyl-4-oxo-1, 8-napthyrlidin-3-carboxylic acid was subsequently modified 
with the additions of N-1 ethyl and C-1 methyl groups which resulted in nalidixic acid, 
the first quinolone antibiotic.  Nalidixic acid was introduced for the treatment of 
uncomplicated UTIs in 1964 (132, 201, 304) and marked the beginning of four decades 
of quinolone use and development.   
In addition to nalidixic acid, there are nine quinolone agents currently approved 
for use in Canada and in the United states, including ciprofloxacin, enoxacin, 
gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, and  
ofloxacin (15, 16, 262).  Additional members of the class, such as perfloxacin, 
fleroxacin and tosufloxacin, are in use outside North America (54, 187, 191).  
Gemifloxacin was recently approved for use in North America (2004) and is now in 
clinical practice in the U.S.A. and expected to be approved for use in Canada.  
Classification of the quinolones has not been officially formalized and various criteria, 
including spectrum of activity, chemical structure, clinical utility and decade of 
development have all been proposed as a means for grouping members of the 
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fluoroquinolone class of antimicrobials (12, 28, 132, 253, 272).  For example, Ball (12) 
has proposed that first generation compounds, such as nalidixic acid and flemequin, 
provide coverage primarily for the Enterobacteriaceae.  Second-generation compounds, 
such as ciprofloxacin, levofloxacin and sparfloxacin are further divided into those with 
enhanced, predominant Gram-negative coverage with balanced broad-spectrum activity 
including some Gram-positive bacteria.  Third-generation agents, such as moxifloxacin 
and gatifloxacin, display enhanced Gram-positive activity, particularly against 
Streptococcus  pneumoniae (12, 30).  Gootz et al (132) proposed a classification of 
quinolones based on incorporating key modifications in the chemical structure that 
correlate with the decade of development.  Despite these distinctions, quinolone 
chemistry and activity are inextricably linked and quinolones generally fall into one of 
three distinct groups consisting of first, second, or third-generation agents (9, 28, 30, 81, 
132).  All currently approved quinolones share a common core structure with that of the 
original quinolone, nalidixic acid, consisting of two fused 6-member heterocyclic nuclei 
containing one to four nitrogen atoms (12, 81, 132)  (Figure 1.1.). 
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Side chains present at positions N-1 and R-1 have been shown to control theophylline 
interactions and genetic toxicity.  An R-5 moiety influences phototoxicity and genetic 
toxicity.  A fluorine atom at the C-6 carbon position has been associated with increased 
potency; all currently available “fluoroquinolones” retain a 6-fluorine atom.  Side 
chains at the C-7 postion has been associated with gamma amino buteric acid (GABA) 
binding and theophylline interactions.  C-8 rings have been associated with enhanced 
killing and increased activity against S. pneumoniae.   
 
Figure 1.1  Chemical Structure of the Quinolone Nucleus 
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Nalidixic acid was the first clinically useful quinolone that possessed excellent 
in vitro activity against a variety of different Gram-negative species from the 
Enterobacteriaceae (304, 329).  However, it proved ineffective against various genera 
and species of Gram-positive bacteria, Pseudomonas aeruginosa and Serratia 
marcescens (10, 73, 107, 233), and never became a useful agent in the treatment of 
systemic infections because it possessed poor pharmacological properties.  Other early 
compounds such as rosoxacin, oxolinic acid and cinoxacin followed, however, none of 
these compounds significantly improved upon the activity or clinical utility of earlier 
generation agents and, as a result, did not obtain secure status within the quinolone class 
(227).  Overall, first generation agents are characterized by their Gram-negative 
coverage (excluding P. aeruginosa).  However, resistance among Gram-negative 
bacteria was quick to develop and first generation agents possessed low adsorption and 
tissue penetration  (< 0.5 mg/ml peak serum concentrations) which relegated their use to 
infections of the urinary tract (173, 304). 
Development in the 1970s focused on producing more potent second-generation 
agents and two significant breakthroughs in the evolution of the quinolone class 
occurred with the additions of a piprazynl ring, or piperazine derivative, at the C-7 
position and a fluorine atom on the C-6 carbon.  Addition of a 7-piperazine ring created 
pipemidic acid, a quinolone with enhanced penetration of the bacterial cell wall which 
improved activity against Gram-negative bacteria and some Gram-positive bacteria (12, 
326).  The incorporation of a fluorine atom at position C-6 resulted in flemequine.  The 
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C-6 fluorine was shown to enhance both gyrase inhibition and bacterial cell penetration 
(82), improving activity against Gram-negative and Gram-positive organisms.  The high 
degree of intrinsic activity associated with compounds possessing a C-6 fluorine has led 
to acceptance of the fluorine atom in overall “fluoroquinolone” chemistry (103, 273).  
Subsequently, all currently approved quinolones retain a fluorine atom at position C-6.   
In 1980, Koga et al (188) discovered that inclusion of a C-7-piperazinyl ring in 
the quinolone nucluess further increased the spectrum of activity of the quinolones 
(185).  The exchange of a carbon molecule for nitrogen at position 8, coupled with the 
C-6 fluorine atom and a C-7 ring, resulted in norfloxacin-the first of the modern day 
fluoroquinolones.  Norfloxacin was approved for clinical use in 1984 (103, 268) and 
was characterized as having high activity (and improved activity) against various genus 
and species of Aeromonas hydrophila, Haemophilus influenzae, P. aeruginosa, 
Pasteurella multocida, Neisseria  spp. and (228).  The introduction of norfloxacin 
signified the beginning of a period of rapid development of other oral second generation 
quinolones such as ciprofloxacin, enoxacin, fleroxacin, ofloxacin, and perfloxacin.  Of 
these, only ciprofloxacin and ofloxacin became widely established for the treatment of 
infections involving sites other than the urinary tract (12).   
Ciprofloxacin, released in 1987, incorporated the addition of an N-1 cyclopropyl 
group and was characterized as having improved activity against Gram-positive 
organisms such as Enterococcus faecalis, Staphylococcus aureus, S. pneumoniae, and 
against Gram-negative organisms such as Escherichia coli, H. influenzae, K. 
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pneumoniae and Neisseria gonorrhoeae.  Ciprofloxacin was also active against atypical 
organisms such as Chlamydia spp., Legionella spp., and Mycoplasma pneumoniae, 
showed good oral bioavailability (20, 163, 311, 356).  Ciprofloxacin marked two 
important milestones in the development of fluoroquinolones.  It was the first available 
intravenous (I.V.) agent allowing for sequential or step down from intravenous to oral 
therapy in hospitalized patients with serious systemic infections.  This proved to be a 
significant cost containment benefit (311).  It was also first the first orally available 
antimicrobial agent with reliable activity against P. aeruginosa at sites other than the 
urinary tract (36, 39, 51, 72, 167).  Ofloxacin, a chiral fluorinated 1,8-cylco compound 
developed in the mid 1980s, also had broad spectrum applications and was approved for 
use in 1990 (338).  In comparison with ciprofloxacin, ofloxacin is rapidly absorbed 
from the gastrointestinal tract, achieves higher serum concentrations and has a longer 
elimination half-life (28, 202, 312, 313).  Enterobacteriaceae, enteropathogens 
(bacterial) and fastidious Gram-negative bacteria are highly susceptible to ofloxacin 
which display minimal inhibitory concentrations (MICs) of < 2 μg/ml.  Ofloxacin MICs 
against P. aeruginosa are generally 2-to-8 fold higher than those observed for 
ciprofloxacin (341).  Levofloxacin, a racemic mixture of the active component of 
ofloxacin present in the L-isomer form was released shortly after ofloxacin and 
approved for use in United States in 1999 (269).   
Levofloxacin expanded upon the Gram-negative coverage of ofloxacin and is 
generally considered to be 2-fold more potent than ofloxacin based on lower MICs (72, 
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170).  Levofloxacin possesses Gram-positive coverage against S. aureus, borderline 
(near-breakpoint) activity against S. pneumoniae and became the first quinolone 
approved for once daily therapy of community-acquired pneumoniae in North America.  
Molecular substitutions based on the 6-fluorine, 7-piperazinyl molecule yielded 
additional second-generation agents such as sparfloxacin and clinafloxacin which 
demonstrated increased activity against S. aureus and S. pneumoniae relative to earlier 
generation agents, but which for a variety of reasons did not reach wide-spread clinical 
use.  For example, the pharmacokinetics of clinafloxacin were such that it necessitated 
twice or three times daily dosing (132, 297, 298).  Collectively, norfloxacin, 
ciprofloxacin, ofloxacin/levofloxacin, sparfloxacin and clinafloxacn represent second-
generation agents or extended spectrum quinolones, which were introduced into clinical 
practice in the late 1980s and 1990s.  The primary advantage of second-generation 
agents is an improved spectrum that includes H. influenzae, Moraxella catarrhalis, 
Neisseria spp., P. aeruginosa, and, Staphylococcus spp. and atypical pathogens such as 
Chlamydia spp., Legionella spp., and Mycoplasma spp. 
The search for broader-spectrum fluoroquinolones with greater potency against 
Gram-positive and anaerobic bacteria fuelled the development of quinolones in the mid 
to late 1990s.  A large number of the investigational compounds possessed excellent 
activity against gram-positive organisms, but frequently lost potency against Gram-
negative organisms.  However, a small number of derivatives were discovered that had 
improved activity against Gram-positive bacteria and also retained good anti-Gram-
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negative properties.  These newer derivatives represent third-generation quinolones, or 
“respiratory quinolones”.  Third-generation agents contain variations of C-7 rings (7-3-
methyl-piperazinyl in the case of gatifloxacin and a 7-azabicyclo ring in the case of 
moxifloxacin) and improved activity against S. pneumoniae and anaerobic bacteria.  
Currently, all approved third generation agents also posses C-8 methoxy residues which 
are associated with increased bacterial killing (221, 368).  Trovafloxacin, grepafloxacin 
and garenoxacin are no longer considered clinical alternatives, but are noteworthy in the 
overall development of third-generation agents because structural modifications to C-3, 
C-5 and C-7 carbon atoms have led to increased understanding of the structure-activity 
relationship of fluoroquinolones (35, 59-62, 171).  Garenoxacin can be further 
distinguished from other fluoroquinolones because it was the first quinolone lacking a 
fluorine atom at the C-6 position to advance to stage III clinical trials (120).  Figure 1.2 
outlines the development of selected fluoroquinolones.  
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1,8-napthyridine 1960 
Nalidixic Acid 1962 
 
Pipemidic Acid 1975 
Flemequin 
Enterobacteriaceae 
1st GENERATION
Ciprofloxacin 1986 
Ofloxacin 1985 
Clinafloxacin  
Sparfloxacin 1993 
Levofloxacin 1993 
Gatifloxacin 1999 
Moxifloxacin 1999 
-Grepafloxacin 
-Trovafloxacin 
-Gemifloxacin 
 
-BMS 284756/Genrenoxacin
Enterobacteriaceae + P.aeruginosa + S. aureus + M. 
catarrhalis + N. gonorrhoeae + S. pneumonaie 
2nd GENERATION 3rd GENERATION 
S. pneumoniae + S. aureus 
+  anaerobes 
Selected quinolone agents highlight developments in quinolone antimicrobial agents.  Quinolones are grouped by first, second, or third-generation based 
on the combination of decade of development and spectrum of activity.   
Figure 1.2 Evolution of Quinolone Development  
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1.3 Intracellular Quinolone Targets and Quinolone Action 
 
Quinolones interact with two related, but distinct bacterial topoisomerase 
enzymes.  Bacterial topoisomerases are a class of enzymes essential in maintaining a 
chemically stable and biologically active form of cellular DNA (169).  There are four 
bacterial topoisomerases, classified as either type I or type II enzymes.  Type I 
topoisomerases are active during the replication of single-strand DNA, whereas type II 
topoisomerases are required for double-stranded DNA replication (204, 324).  
Quinolone antibiotics are strong inhibitors of the type II enzymes, which include DNA 
gyrase (topoisomerase type II) and topoisomerase type IV.  Type I enzymes are not 
sensitive to the inhibitory activity of quinolones (244).  DNA gyrase and 
Topoisomerase IV exist as a tetrameric protein, each consisting of two subunit dimers.  
GyrA and gyrB comprise DNA gyrase and are encoded by the gyrA and gyrB genes, 
while ParC (GrlA in S. aureus) and ParE (GrlB in S. aureus) are encoded by the parC 
and parE genes, and comprise topoisomerase IV.   DNA gyrase and topoisomerase IV 
facilitate bacterial replication by breaking both strands of duplex DNA, passing another 
strand of DNA through the break and resealing initial broken strands (122, 165, 350).  
The activity of gyrA and parC subunits are responsible for cutting double stranded 
DNA utilizing the free energy of ATP hydrolysed by the gyrB or parE subunits (18).  
Once the DNA is cut, another strand of DNA is passed through the gap and the DNA is  
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re-ligated.  DNA gyrase differs from topoisomerase IV in that it can wrap DNA around 
itself and cause strand passage of the molecule of DNA that it has cut.  In the case of 
topoisomerase IV, strand passage occurs during a process which utilizes two different 
DNA molecules.  This process occurs in such a way that after each catalytic event, the 
linear DNA double helix becomes twisted, resulting in a superhelix structure.  This 
superhelical twisting is referred to as negative supercoiling and occurs in the opposite 
direction to the right-handed coiling of the internal helix of the DNA strand. Negative 
supercoiling, induced by the actions of DNA gyrase, allows chromosomal DNA to 
become tightly packaged within the bacterial cell and ensures the correct conformation 
for the initiation of DNA replication (88, 166).  DNA gyrase also allows the 
continuation of DNA replication by producing negative supercoils in front of the DNA 
replication fork, thereby counteracting the positive supercoiling introduced by the 
action of DNA replication (223, 349).  The bi-directional nature of the DNA replication 
process is such that daughter molecules are interlinked, or catenated, after replication.  
Topoisomerase IV is the principal enzyme that decatenates or removes the interlinking 
of daughter chromosomes at the completion of each round of DNA replication, thus 
allowing their segregation into daughter cells (361). 
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 1.4 Mechanisms of Quinolone Action 
 
 During replication, bacterial DNA interacts with type II topoisomerase enzymes, 
resulting in a DNA-enzyme cleavage complex, which becomes the substrate for 
quinolone binding (153).  Interaction of quinolones with DNA-enzyme complexes 
(DNA with DNA gyrase or topoisomerase IV) results in conformational changes to both 
enzyme and enzyme-bound DNA (180, 193, 228, 229).  Topoisomerase enzymes break 
DNA strands and the interaction of the quinolone-enzyme-DNA complex prevents re-
ligation of the broken DNA strands (123, 151, 331).  Although not completely 
understood, quinolone action involves a two-step process beginning with the 
stabilization of quinolone-enzyme-DNA complexes leading to trapping of double-
stranded DNA breaks and the subsequent release of double-stranded DNA breaks (88).  
Although quinolone-enzyme-DNA complex formation and cell death are clearly related, 
the bacteriostatic and bactericidal actions of quinolones action appear to represent 
distinct events.  For example, the formation of quinolone-enzyme-DNA complexes 
cannot result in cell death because complex formation, as monitored by inhibition of 
DNA synthesis, is reversible (134, 155).  Analysis of closely related fluoroquinolones 
has demonstrated that a compound can be more effective at preventing colony 
formation, but less effective at killing cells (131, 245, 369).  A generalized model of the 
bactericidal action of quinolone antibiotics proposes that drug-enzyme-DNA complexes 
are sufficient in blocking cell growth, while the release of DNA breaks from drug-
enzyme-DNA complexes is the lethal event.  This assumption correlates well with in 
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vitro findings demonstrating that quinolone concentrations required to release double-
stranded breaks from chromosomal drug-enzyme-DNA complexes correlate better with 
cell death than with inhibition of growth (52, 90).  Therefore, quinolones that trap pairs 
of single-stranded breaks, or more readily cause release of pairs of single-stranded 
breaks, are expected to be more lethal. 
 1.5 Mechanisms of Quinolone Resistance 
 
The most common mechanisms of quinolone resistance occur via mutations 
within the target genes gyrA/gyrB and parC/parE.  Resistance to fluoroquinolones 
develops in a step-wise fashion, with incremental rises in quinolone MICs at each stage 
(281).  Reductions in susceptibilities are associated with initial, first-step mutations that 
occur at specific sites within gyrA and parC genes, known as quinolone-resistance-
determining regions (QRDR) (28, 88, 165, 166).  Subsequent second-step mutations can 
occur in QRDR of the gyrB and parE genes which lead to high-level resistance.  A 
common model of quinolone target modifications proposes that amino acid changes in 
the QRDR of DNA gyrase and topoisomerase IV alter the structure of the quinolone 
binding site near the interface of the enzyme and DNA; subsequent resistance is then an 
effect of reduced drug affinity for the modified enzyme-DNA complex (166).  
However, direct structural information on the site of quinolone-binding within the 
complex is not yet available.   
  The affinity of a quinolone against any bacterial pathogen appears to result from 
the relative sensitivities of DNA gyrase and topoisomerase IV.  The more sensitive 
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enzyme generally determines the primary quinolone target for a given organism, 
independent of the sensitivity of the secondary target.  For Gram-negative bacteria, 
purified DNA gyrase is more sensitive to quinolones than purified topoisomerase IV, 
leading to the hypothesis that DNA gyrase is the primary quinolone target among 
Gram-negative bacteria.  Initial genetic studies with nalidixic acid-resistant mutants of 
E. coli demonstrated that first-step mutations occurred in a region of the GyrA, between 
amino acid sites 67-106 (123, 140, 255, 360).  Resistance mutations in gyrB of Gram-
negative bacteria develop as secondary mutations to those of gyrA and are associated 
with highly resistant organisms (166).  Conversely, in S. aureus purified topoisomerase 
IV is more sensitive to quinolone action than DNA gyrase (24, 165).  Proof that 
topoisomerase IV is a primary quinolone target among Gram-positive bacteria came 
from studies in which first-step quinolone resistance mutations were found in regions of 
the parC (grlA) genes for clinical isolates of S. aureus and S. pneumoniae (104, 105, 
260).  Thus, primary target affinity for Gram-negative organisms appears to be DNA 
gyrase while topoisomerase IV is the primary target in Gram-positive bacteria.   
However, this simplified stratification of quinolone target affinity is incomplete 
when examining newer third-generation agents such as moxifloxacin and gemifloxacin 
which have been shown to target DNA gyrase in Gram-positive organisms while 
retaining affinity for topoisomerase IV.  For example, in S. pneumoniae, sparfloxacin 
and gatifloxacin selected first step gyrA mutants (117, 278), and purified S. pneumoniae 
DNA gyrase was found to be less sensitive to sparfloxacin and clinafloxacin than 
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purified topoisomerase IV (246, 277).  The explanation for the apparently anomalous 
behaviour of sparfloxacin, gatifloxacin and clinafloxacin is yet unclear, but has 
prompted the argument that quinolone chemistry may determine target affinity (81, 88).  
As such, compounds may become classified into one of three archetypal mechanistic 
classes (32, 152, 276, 278):  (1) compounds which select gyrase mutations before 
topoisomerase IV mutations and likely act through DNA gyrase in vivo, (2) compounds 
that select for QRDR mutations in the genes encoding topoisomerase IV first before 
those in DNA gyrase, thereby suggesting that the drugs act preferentially through 
topoisomerase IV in vivo and (3) compounds which posses dual target activity and act 
through both DNA gyrase and topoisomerase IV.  Fluoroquinolones with comparable 
target affinity (i.e., both DNA gyrase and topoisomerase IV) have changed the 
perception of how resistance mutations are thought to accumulate in target genes.  For 
resistance mutations in the primary target enzyme, the level of sensitivity of the 
unmutated secondary target enzyme, which becomes the more sensitive enzyme when 
the primary target is resistant, may determine the degree of resistance.  This hypothesis 
implies that for different quinolones, the level of resistance conferred by a mutation in 
the primary target enzyme would decrease as the level of drug sensitivity of the 
secondary target approaches that of the primary target.  Furthermore, it implies that 
concurrent mutations in both target enzymes would be required for resistance due to 
target alterations for any quinolone that had equal potency against DNA gyrase and 
topoisomerase IV.  This suggestion appears to be the case with S. pneumoniae and 
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clinafloxacin (277).  Mutants of S. pneumoniae selected with clinafloxacin occur at a 
low frequency and gyrA mutations selected in first-step experiments had a minimal 
impact on clinafloxacin resistance.  Second and third-step mutants of gyrA and parC, 
however, exhibit substantial resistance (165, 276, 278).    
 1.6 Reduced Intracellular Concentration 
In order to reach their targets in the cell cytoplasm, fluoroquinolones must cross 
the cytoplasmic membrane and, in Gram-negative bacteria, the outer membrane as well.  
Thus, alterations in drug permeation contribute to overall decreases in quinolone 
susceptibility.  In addition to passive membrane diffusion, the relative size and charge 
of fluoroquinolones facilitate active transport across the outer membrane through porin 
proteins which form general diffusion channels allowing access to the cell (132, 164, 
266).  Quinolone-resistant clinical isolates of Gram-negative bacteria have been found 
to posses reduced numbers of outer membrane porins.  For example, deficiencies in the 
outer membrane proteins (OMP) OmpF and D2 of E.coli  and  P. aeruginosa have been 
associated with resistance to a fluoroquinolones (237, 242).  Reductions in the relative 
amount of OMPs result in decreased diffusion of quinolones across outer membranes 
(157, 158, 288), however, examination of diffusion rates suggest that porin reductions 
alone are generally not sufficient to account for high-level resistance (266). 
 Recently, resistance caused by reduced accumulation has been shown to result 
from enhanced expression of efflux systems that actively pump drug from the 
cytoplasm.  In Gram-negative bacteria, these systems typically have three components: 
 18
the efflux pump located in the cytoplasmic membrane, an OMP and a membrane fusion 
(or linker) protein (164, 291).  Efflux systems actively extrude drug from the cytoplasm 
or cytoplasmic membrane across the periplasm and outer membrane to the cell exterior.  
The energy for this process is derived from the proton gradient across the membranes.  
Efflux expression is regulated and resistance occurs by chromosomal mutations that 
causes coordinated increased expression of pump components (164).  The conditions 
that contribute to increased expression of efflux system components remain largely 
unknown.  Efflux mechanisms that contribute to MDR, including resistance to 
fluoroquinolones, have been identified in many clinical isolates.  These include: 
Bacillus subtilis, Citrobacter spp., E. coli, Enterobacter spp., H. influenzae, K. 
pneumoniae, Mycobacterium spp., N. gonorrhoeae, P. aeruginosa, Salmonella 
typhimurium, S. aureus, and   S. pneumoniae (263, 308).  Chemical structures of various 
fluoroquinolone may determine the extent to which efflux systems operate in specific 
bacterial species.  The correlation between chemical structure and efflux activity have 
not been fully defined, but appear to correlate with the relative degree of hydrophilicity 
for various compounds (63, 354, 360).   
1.7 Key Pharmacokinetic and Pharmacodynamic Factors for 
 Fluoroquinolone Antibioitcs  
 
Many methods have been used to evaluate in vitro activities of antibacterial 
agents.  Most commonly, MIC and minimal bactericidal concentrations (MBC) 
measurements are used to assess antibacterial potency as assessed by inhibition or 
killing of a pathogen at an endpoint of 18-24 hr.  Determination of MIC/MBC endpoints 
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following the incubation of an organism in the presence of a constant antibiotic 
concentration reflects a static measurement of the antibiotic’s bacteriostatic/bactericidal 
activity (68).  As a result, MIC/MBC measurements do not provide data on the time-
course of antimicrobial action, including the duration of drug exposure required for 
bacterial eradication, the rate of bactericidal activity or persistent effects of the 
antimicrobial agents (65, 68, 364).  Thus, the selection of optimal fluoroquinolone 
dosing regimens requires careful consideration of microbiological responses to an 
infecting organism (pharmacokinetics (PK)) and patient-specific factors related to drug 
exposure, most notably toxicity (pharmacodynamics (PD) (65).  Understanding the 
PK/PD relationship of fluoroquinolone antibiotics can facilitate selection of optimal 
dosing regimes which serve to hasten the antimicrobial response to an invading 
pathogen, prevent treatment failures, minimize the development of resistance and 
maintain the therapeutic lifespan of the antimicrobial agent.  Therefore, experimental 
models that reflect PK/PD dynamics for specific quinolones against specific pathogens 
present at specific anatomical sites should provide additional clinically meaningful 
information about the potential of an antibiotic. 
Generally, antibacterial effects correlate with one of three pharmacokinetic 
parameters: 
 
1. The ratio of peak drug concentration (Cmax) of an agent to its MIC for the bacterium 
(Cmax/MIC), termed concentration dependent.  
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2. Time (T) of exposure of a bacterium to serum drug concentrations exceeding the 
MIC (T>MIC), termed time dependent. 
3. The ratio of the area under the drug concentration versus-time curve (AUC).   
 
On the basis of the PK principle dictating their action, antibiotics are typically 
characterized as either concentration-dependent or time-dependent agents (68, 318).  
For example, the time above the MIC is an important parameter used with β-lactam 
compounds because bacterial inhibition and kill rates at high concentrations are 
virtually identical to rates at concentrations near the middle of a concentration time 
curve, or even at the MIC drug concentration (92).  Thus, for β-lactams, the most 
important principle in bacterial eradication is not increasing concentration, but the 
length of time achieved above a defined drug concentration, usually the MIC.  By 
comparison, for concentration-dependent antimicrobial agents, the kill rate at 
concentrations near the peak is greater than that at concentrations near the middle of the 
curve (91).  Fluoroquinolones exhibit concentration-dependent responses which 
traditionally have been described by measuring (Cmax) in relation to the MIC 
(Cmax/MIC) (93, 94, 321).  Cmax/MIC ratios of 8-to-10 correlate with increased clinical 
success and reduced likelihood of selecting resistant strains (318). 
 The AUC represents the newest pharmacological measure which is used to 
predict the therapeutic response of microorganisms to antimicrobials.  The AUC 
correlates drug exposure with a defined dosing interval which is then reported as the 
area under the plasma drug concentration time curve (320, 321).  The AUC is an 
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empirically derived formula based on the MIC measure of drug potency.  For example, 
upon introduction of an antibiotic into tissue/serum, the drug accumulates and achieves 
(Cmax), which is dictated by both the properties of the antibiotic and the infected 
anatomical site.  As the concentration declines over time, it intersects with of the MIC 
of a particular pathogen.  The area created between the Cmax and MIC as drug levels 
decline is represented by a numerical value defined as the AUC.  The AUC is normally 
calculated over 24 hr and is designated as the AUC24.  The ratio of the AUC/MIC 
defines the area under the inhibitory concentration time curve (AUIC) (Figure 1.3).  A 
landmark study by Forrest et al  (115) reported that an optimal AUC24/MIC (AUIC24) 
for ciprofloxacin of >125 was associated with bacterial eradication in critically ill 
patients with lower respiratory tract infections caused by Gram-negative bacilli.  
Reduced drug exposure and low AUIC ratios correlate directly with emergence of 
resistance and ratios below 100 have correlated with a 50-83% probability that 
resistance will develop (133, 318, 336).  Therefore, for fluoroquinolones, an AUIC of at 
least 125 (serum inhibitory titre-1) should be targeted, because values <100 have been 
associated with the development of resistance (115, 133, 317). 
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Figure 1.3 The Area Under the Concentration Time Curve (AUC) 
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The AUC is an empirically derived formula used to predict clinical success and development of resistance for 
fluoroquinolones based on the relationship between clinical pharmacokinetics and the MIC of a particular pathogen.  
Upon administration of an antimicrobial, the antibiotic concentrates and eventually reaches the Cmax drug concentration 
which typically falls within a safe and tolerable dose for the patient.  As the concentration declines over time,  it 
eventually intersects with the MIC of the pathogen.  The half-life of the antimicrobial agent represents the time it takes 
for drug concentrations to achieve half the Cmax for a given dose.  The Area created between the Cmax and the MIC for 
a given drug-organism combination defines the AUC.  AUC values > 125 and Cmax /MIC ratios of 8-to-10 correlate with 
in vivo success for fluoroquinolones against Gram-positive and Gram-negative organisms.    
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been found to be associated with clinical efficacy (11, 198, 213, 214, 224) and has 
prompted the question of whether AUIC values  >125 need to be achieved against  
Gram-positive pathogens (91, 249).  In a clinical study with levofloxacin and S. 
pneumoniae, clinical success was observed in patients where AUIC values < 50 were 
documented (295) and acceptance of lower AUIC values of 30-to-50 was proposed on 
the premise that successful clinical outcomes would occur even with low AUIC values 
(<125).  However, 85% of patients had mean AUIC values >100 and it is likely that few 
patients enrolled in the study had AUIC values in the 30-to-50 range because organisms 
with MIC values of 2 µg/ml to levofloxacin were uncommon during the early 1990s.  
Currently, organisms with MICs of 1-2 μg/ml to levofloxacin are now being identified 
(31, 159) and these organisms would confer levofloxacin AUIC values of 
approximately 25.7 (318), thereby re-raising the argument that AUIC values of >100 
should be targeted for Gram-positive organisms.  Recently, an in vitro 
pharmacodynamic model, specifically designed to incorporate MPC measurements 
demonstrated that AUIC values of <100 were associated with decreases in S. aureus 
susceptibility to fluoroquinolones, while values >100 did not result in changes in MICs 
(371) 
   The question as to which ratio (i.e., Cmax/MIC or AUC/MIC) is a better predictor 
of antimicrobial efficacy remains unresolved.  Some studies have shown that 
AUC24/MIC is the best predictor for success with quinolones (43, 224-226), while 
others have suggested that the Cmax/MIC is a better predictor of bacterial eradication 
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(25).  Ultimately, the activity of an antimicrobial compound and the subsequent clinical 
success is dependent on the combination of specific binding to intracellular targets in 
the pathogen and occupation of the critical binding sites for a minimum period of time.  
Therefore, neither the Cmax /MIC ratio nor the AUIC alone will predict a compound’s 
antibacterial effect.  Recently, it has been suggested that if a Cmax/MIC ratio greater than 
10 is achieved, Cmax/MIC will be the most important parameter in determining 
outcomes (295), whereas at Cmax/MIC ratios of <10, the AUC24/MIC ratio is a better 
predictor of clinical outcome and decreased incidence of resistance (43, 226, 295, 318).  
Scaglione et al  (314) rationalized these distinctions by examining the effect of protein 
binding on the relative contributions of  AUC/MIC and Cmax/MIC ratios to the overall 
fluoroquinolone effect.  Based on their findings, the authors concluded that a larger 
fraction of free drug exists at peak concentrations than at lower concentrations and a 
larger fraction of free drug may have a greater effect because even with the same AUC, 
a higher peak concentration will result in a larger fraction of free drug. Thus, it is not the 
peak concentration itself that leads to a better outcome, but the fact that the AUC of the 
free fraction is larger if the peak concentration is higher (314).   
 25
1.8 The Mutant-Prevention Concentraton (MPC):  In vitro 
 Masurement of the MPC and Experimental Determination of the 
 Mutant-Selection Window 
 
 Fluoroquinolone antibiotics are important antimicrobial compounds used to 
treat infections caused by Gram-negative and Gram-positive bacteria at a number of 
different anatomical sites.  The use of newer more potent agents for front line therapy 
is advocated as the most prudent use of antibiotics (78).  Today’s modern-generation 
fluoroquinolones are highly active against Gram-positive organisms such as S. aureus 
and S. pneumoniae, but reports of treatment failures and documented in vitro resistance 
has raised concerns that resistance may develop to these new agents (7, 41, 53, 70, 89, 
315, 371).  The development of antibiotic resistance correlates with increased use.  For 
example, since the late 1980s and early 1990s, ceftazadime, a third-generation 
cephalosporin, has been widely used against Gram-negative pathogens, Citrobacter 
spp., E. coli, Enterobacter spp., K. pneumoniae, and P. aeruginosa.  The subsequent 
emergence of broad spectrum β-lactamase-producing Gram-negative bacteria has been 
attributed to indiscriminate use of third-generation cephalosporins (58, 236, 301, 302, 
315).  However, increases in consumption cannot fully account for changes in 
resistance patterns.  Eliminating the misuse and overuse involved in antibiotic 
utilization will fail to correct resistance problems because traditional dosing strategies 
are only one mutational step ahead of the pathogen, a factor which will ultimately 
erode new agents, if and when they become available.  Therefore, strategies 
specifically designed to minimize the development of resistance must accompany the 
development and use of antimicrobial agents.   
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It has been suggested that if bacterial cells must attain two concurrent 
resistance mutations for growth in the presence of a quinolone, then few mutants would 
be selectively amplified because double mutations should rarely occur (32, 41, 87, 142, 
367, 369).  Bacterial populations may reach 1010 cells in human infections, but at a 
mutation frequency of 10 7, more than 1014 bacteria (107 × 107) would be required to 
detect two concurrent fluoroquinolone-resistant mutations.  Current susceptibility 
practices rely on standardized inoculums, based on the application of 105- 106 colony 
forming units (CFU), which is too low to account for the presence of first-step resistant 
subpopulations that are present at the sites of infections. Figure 1.4 illustrates the 
factors involved in the MPC measurement.  When we examined the effect of 
fluoroquinolone concentration on the selection of resistant mutants of Citrobacter  
freundii, Enterobacter cloacae,  E. coli, K. pneumoniae, P. aeruginosa, and S. 
pneumoniae, we found a concentration with each organism at which no mutant was 
recovered when 109 to 1010 cells were applied to agar plates (41, 143, 145, 148, 149).  
This drug concentration, which we designated as the MPC, would require a bacterial 
cell to develop more than one resistance mutation for growth.  Thus at concentrations 
above the MPC, a bacterial population greater than that normally present during 
infection would be necessary to observe outgrowth of a resistant mutant.  Since 
fluoroquinolone structure affects the value of the MPC (83), it appears that the MPC 
might serve as a simple measure of antibiotic potency that incorporates the ability of a 
compound to restrict selection of resistant mutants (41, 89, 149, 367).  
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Figure 1.4   MPC Dynamics     
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As the bacterial populations exceed the fluoroquinolone mutational frequency of 10-7 (107 CFU/ml), 
mutant subpopulations (denoted by stars) arise.  At concentrations >109 CFU/ml, mutant populations 
which confer reduced susceptibilities are readily recovered.   Infections containing >109 cells will 
have many resistant mutants that are not inhibited the MIC.  Current susceptibility tests utilize a 
dilution of the 0.5 McFarland standard which results in the application of 105-106 CFU/ml during the 
testing process.  This inoculm is too low to account for the presence of first-step resistant mutants 
present in large bacterial populations.  The MPC reflects the antimicrobial concentration required to 
inhibit first-step resistant mutants when >109 CFU/ml are tested (33, 144). 
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Experimentally, the MPC measurement can be measured as a characteristic  
two-stage decline in CFUs when large (>1010 CFU/ml) susceptible cultures are 
exposed to varying quinolone concentrations (83, 143).  Increasing drug concentrations 
results in an initial sharp decline in colony recovery that occurs at concentrations at (or 
near) the MIC for wild-type susceptible populaton of cells.  This first stage of colony 
decline occurs across a bacterial population of approximately 105-to-106 CFU/ml.   At 
concentrations above the MIC of the wild-type strain, a plateau in colony recover 
occurs which corresponds to the outgrowth of mutant sub-populations.  Mutant 
colonies require concentrations above the MIC of the wild-type strain in order to 
prevent their growth and a second sharp decline in colony recovery occurs when drug 
concentrations are reached which block the growth of all single-step mutants (41, 84, 
149, 327).  This later concentration defines the MPC.  Thus, the MPC is a measure of 
the minimal antibiotic concentration required to prevent mutant growth recovered 
when large (> 109 CFU) numbers of cells are applied to antibiotic containing agar 
plates (83).  In principle, the MPC represents a dosing threshold above which mutants 
should rarely arise; use of MPC would add consideration of the development of 
resistance to the traditional goal of clearing infection.   
Conventional dosing strategies, based on the MIC as a measure of drug potency, allow 
concentrations to fluctuate within a range that enrich mutant fractions of heterogeneous 
pathogen populations.  Thus, concentrations perceived to inhibit the majority of 
susceptible cells in cultures are the very concentrations that selectively enrich mutant 
subpopulations.  If host defences fail to remove resistant mutants faster than they are 
 29
enriched, the mutant fraction will gradually increase (Figure 1.5).  The concentration 
spectrum within which mutants are selectively enriched is termed the Mutant-Selection 
Window (MSW) and is defined by an upper and lower boundary based on the MPC 
and MIC, respectively (Figure 1.6) The MSW emerged from suggestions of Baquero et 
al (14) who indicated that a dangerous concentration range exists in which mutants are 
most frequently selected.  The boundaries of the concentration range were later defined 
when the MPC measurements were determined for fluoroquinolones (41, 84, 142, 144, 
149, 327, 367).  When fluoroquinolone concentrations are below the MIC, neither 
susceptible cells nor first-step resistant mutants will be inhibited as the drug 
concentration is too low and the selective amplification of resistant subpopulations will 
not occur.  When drug concentrations are in excess of the MPC, both susceptible and 
first-step resistant cells are inhibited and selective amplification of resistant cells does 
not occur.   However, when drug concentrations fall within the MSW, the number of 
susceptible cells decline, thereby, creating conditions which result in the selective 
amplification of resistant populations.  Selection of fluoroquinolone-resistant 
subpopulations will ultimately affect the entire fluoroquinolone class of antimicrobials 
because all agents share the small intramolecular targets.  Thus, mutants selected by 
one compound will ultimalty affect the entire class.  Continued use of antimicrobial 
agents against bacterial populations that have already been enriched for first-step 
mutants facilitates  the selection of second- and third-step mutants (17, 85, 221), which 
confer even higher levels of resistance (41, 149, 370).     
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Figure 1.5 Selective Amplification of Resistant Mutants 
  
 
Bacterial populations may contain resistant cells which may become selectively enriched during antibiotic therapies if MPCs are not targeted during 
dosing.  First-step resistant mutants (dark colored stars) are present in bacterial cultures containing between 107-to-109 CFU/ml.  Increasing levels of 
resistance, concurrent/acute infections, and immunocompromised hosts place heavy reliance on the antimicrobial to control bacterial growth.  Under 
these conditions resistant cells are selectively enriched during successive rounds of dosing.   Eventually, the number of mutant cells may become high 
enough that mutant subpopulations become a dominant fraction of the bacterial population.  If the infection has progressed to the point where the 
antimicrobial is incapable of directly controlling the bacterial growth then clinical failures and potential spread of resistant organism may occur.   
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(A) The concentration spectrum extending from the MIC of the susceptible population 
to the MPC of the most-resistant, first-step resistant mutant present in culture represents 
the MSW.  During dosing, concentrations which fluctuate within the window are 
expected to selectively enrich mutant populations.  Concentrations above the MPC and 
below the MIC will not selectively enrich mutant populations because they offer no 
selective advantage.  (B) A MSW will be created for every antimicrobial as 
concentrations rise and decline over a dosing period.  Minimizing the length of time 
concentrations remain within the window will minimize the potential that resistant 
mutants will be selectively enriched. 
Figure 1.6 The Mutant-Selection Window  
A 
B 
 Antimicrobial concentration and 
time within the Mutant-Selection 
Window (MSW)
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Experimental evaluation of the MSW has recently been examined in an in vitro  
PD model (109).  Firsov et al adjusted fluoroquinolone concentrations to mimic dosing 
regimes, which placed concentrations in one of three experimental categories: 
concentrations above the MSW, concentrations within the MSW and concentrations 
below the MSW.   Dosing, which placed concentrations within the window for longer 
periods of time, resulted in the amplification of resistant mutants and decreases in 
susceptibility as assessed by elevated MICs (109).  Despite suggestion to the contrary 
(328), the MPC and the MSW are not mutually exclusive, rather the MPC represents the 
upper boundary of the MSW.  The relative size of the MSW for any fluoroquinolone-
pathogen relationship is dictated by an upper and lower boundary, defined by the MIC 
of the susceptible population and the MPC for the most resistant, first-step resistant 
population.  A large selection window suggests that mutant enrichment occurs over a 
wide drug concentration range and a larger fraction of the dosing interval.  Compounds 
which exceed the MPC for the majority of the dosing interval and whose MIC and MPC 
closely correlate are expected to posses narrow selection windows and a reduced 
likelihood for selecting resistant cells (41, 85, 367).  Ideally, dosing should be adjusted 
such that MPC concentrations are maintained throughout the dosing interval.  However, 
it is important to understand that as antibiotic concentrations rise and decline upon 
administration and elimination of the antimicrobial, a MSWwill be created for any 
given “bug-drug” combination.  Minimizing the time antibiotic concentrations fall 
within the MSW will be a key factor involved in minimizing the selection of resistant 
 33
cells.  Determinations of the overall time each compound falls within the MSW may not 
be as straightforward as initially perceived because the size of the window will be 
influenced by the PK profile of the drug, the relationship of the MPC to the MIC and 
the rate of bacterial killing for a given antimicrobial agent.  Thus, compounds with low 
MPCs may not necessarily be superior at preventing the selection of resistant mutants if 
MPC values do not fall within a clinically achievable range and for a long enough 
duration of the dosing period.  As we learn more about the PK/PD properties of 
quinolones, such as implications of protein binding and site-specific drug accumulation, 
we will be able to refine the MWS concept. 
   The time that fluoroquinolone concentrations are required to exceed the MPC 
is a factor that is currently unknown.  The answer to this question will ultimately lie in 
the rate at which fluoroquinolones are able to kill first-step mutants.  For example, 
maintaining the MPC for half of a 12 hr dosing interval may be sufficient at preventing 
the selection of resistant mutants if all resistant mutants can be eliminated within the 
six-hr window (Figure 1.7).  Bactericidal activity of different fluoroquinolones against 
selected first-step mutants will be an important discovery in the development of the 
MPC measurement and its potential clinical application.  One recent study (66) has 
provided insight into how long the drug concentration needs to remain in excess of the 
MSW.  Croisier  et al (66) examined the in vitro pharmacodynamic efficacy of 
gatifloxacin against S. pneumoniae in an experimental model of pneumonia, specifically 
investigating the impact of low levels of fluoroquinolone resistance on the enrichment  
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pneumoniae in an experimental model of pneumonia specifically investigating 
the impact 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
Figure 1.7 The Relationship Between the MPC and Killing by   
  Fluoroquinolones 
The relationship between the MPC measurement and bacterial killing is illustrated.  Bacterial cultures are 
represented by triangles.  Susceptible and first-step mutant populations are represented by shaded and brick 
portions.  Complete bacterial eradication of susceptible and mutant populations are shown as black filled 
portions.  Cultures are treated with one of three hypothetical fluoroquinolones represented in A, B and C.  In 
this example, all agents have comparable activity as depicted by identical MIC values (dashed lines).  The 
MPC for each hypothetical fluoroquinolone are comparable.  The rate, at which susceptible and first-step 
mutants are killed, differs with each fluoroquinolone (vertical arrows).  The length of time the dose is required 
to exceed the MPC is dependent on the rate at which first-step resistant mutants are killed.  The rate to bacterial 
eradication divided by the total time each agent is expected to exceed to the MPC should produce a value of < 1 
(T>MPC = <1).  Values >1 could result in selective amplification of resistant sub-populations during therapy 
and may require higher, or more frequent dosing to control mutant populations.     
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of resistant mutants.  They reported that when the time the drug concentration was 
within the MSW was >45%, the risk of selecting a mutant was 100%.  Experimental 
evidence regarding the concept of MPC and killing will be discussed further in chapters 
3 and 4.   
The MPC is a new method for evaluating quinolone potency based on 
concentrations that restrict the selection of resistant sub-populations (32, 83, 85, 87, 
144).  I was interested in testing whether MPC measurements could be used to identify 
intrinsic differences between various fluoroquinolone antimicrobials which could be 
used to determine microbiological and clinical differences between the agents tested.  In 
chapters 3-to-5, evidence is provided for the rationale approach for restricting the 
selection of resistant mutants based on the MPC principle using clinical isolates of S. 
pneumonaiae, P. aeruginosa, and Gram-negative enteric urinary pathogens.  MPC 
measurements and the MSW hypothesis will be examined to identify differences in the 
anti-pneumococcal activities of newer generation fluoroquinolones based on their 
propensities for restricting the selection of resistant mutants.  Many of these 
antimicrobial agents, such as levofloxacin, moxifloxacin and gatifloxacin have been 
deemed equivalent based on current perceptions of resistance and susceptibility testing.  
MPC results for clinical isolates of P. aeruginosa will be measured to see if the MPC 
and the MSW can provide insight into a number of unresolved issues relating to clinical 
differences among ciprofloxacin and levofloxacin in the treatment of P. aeruginosa.  
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Finally, MPC, MIC and MBC measurements for Gram-negative urinary tract pathogens 
will be described and discussed in relation to current measurements of susceptibility.  
MPC results for members of the Enterobacteriace will be further examined to see 
demonstrate if the ideas involved in the MPC measurement can be practically applied to 
fluoroquinolone therapies used in the treatment of UTIs.     
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2.0 MATERIALS AND METHODS 
2.1 Standard Laboratory Methods  
2.1.1  Isolate Collection and Identification 
Most of the clinical isolates of P. aeruginosa used in this study were initially 
collected from 55 medical centers throughout Canada as part of a national surveillance 
study of P. aeruginosa (36-38) .  The remaining strains were collected from February 
(2002) to September (2003) from the Clinical Microbiology Laboratory at Royal 
University Hospital, Saskatoon, SK.  Oxidase-positive Gram-negative rods suspected to 
be P. aeruginosa were identified by accepted methods including API20 or Vitek 
(BioMerieux, St. Laurent, QC) systems.  Three strains of P. aeruginosa (OCR1, MR27, 
MR2) overexpressing the MexAB-OprM (nalB) and MexEF-OprJ (nfxC) MDR efflux 
pumps, one strain possessing an altered outer porin profile (OprD), as well as the 
respective isogenic strain (PAO1), were kindly provided by Dr Xian-Zhi Li (Queen’s 
University, Kingston, ON) and Dr. Satoshi Ohya (Sankyo, Co., Ltd., Tokyo, Japan) 
(232).  A MexCD-OprN (nfxB) efflux mutant (K385) along with the isogenic strain, 
(K372) were obtained from the laboratory of Dr. Keith Poole (Queen’s University, 
Kingston, ON).  The antibiotic susceptibility patterns of efflux mutants of P. aeruginosa 
are reported in chapter 5 and elsewhere (232, 293).  
Isolates of S. pneumoniae were collected from the Clinical Microbiology 
Laboratory, Royal University Hospital, Saskatoon, SK from 1998 to 2003 (41).  No 
preselection criterion was used that would favour inclusion or exclusion of resistant 
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isolates and care was taken to avoid obtaining more than one isolate from a given 
patient.  Identification of S. pneumoniae was preformed using traditional methods, 
including catalase testing, bile solubility and optochin sensitivity (250).  A novel 
method called the Slidex Pneumo-Kit (BioMerieux), used in accordance with the 
manufacturer’s instructions, was used to identify clinical isolates of S. pneumoniae.   
Clinical strains of C. freundii, E. cloacae, E. coli and K. pneumoniae used in 
this study were part of an earlier study of Gram-negative urinary isolates (39) and were 
collected from medical centers throughout Canada.  Identification of organisms was 
preformed in each participating hospital based on the reference method of the 
American Society for Microbiology and the NCCLS standards for identification of 
Enterobacteriaceae spp. 
American Type Culture Collection (ATCC) strains for P. aeruginosa (ATCC 
27853) and S. pneumoniae (ATCC 49609) were obtained from the American Type 
Cultures Collection (Rockville, MD).   
 2.1.2  Storage of the Bacterial Isolates 
The isolates were obtained from Tryptic Soy Agar (TSA) slants (in house), 
TSA plates containing 5% sheep blood.  Organisms identified as S. pneumoniae were 
streaked for isolated colonies on a TSA plate containing 5% sheep blood and incubated 
in 5% CO2 at 35-to-37˚C for approximately 24 hr.  One or two isolated colonies were 
selected from the TSA plate with a sterile wooden applicator stick and inoculated into 
1.2 ml Corning cryovials containing 0.5 ml of skim milk.  The vials were stored at -
70˚C. 
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2.2 Susceptibility Testing 
 Antimicrobials used for in vitro experiments were obtained in powdered form 
and diluted in accordance with the manufacturers’ recommendations.  Sources of 
antimicrobials were as follows: 
Moxifloxacin, ciprofloxacin – Bayer Pharmaceutical, West Haven CT; 
Levofloxacin – The R. W. Johnson Pharmaceutical Research Institute, Raritan,  
NJ; 
Gatifloxacin – Bristol Myers Squibb, Montreal, QC; 
Grepafloxacin – Glaxo Smith Kline Pharmaceuticals, Collegeville, PA; 
Trovafloxacin – Pfizer Canada, Kirkland, QC; 
Garenoxacin – Bristol Myers Squibb, Montreal, QC; 
Gemifloxacin – Glaxo Smith Kline Pharmaceuticals, Collegeville, PA; 
Ceftazadime – Glaxo Smith Kline Pharmaceuticals, Collegeville, PA; 
Gentamicin –  Sigma-Aldrich Co., St. Louis, MO; and 
Tobramycin - Sigma-Aldrich Co., St. Louis, MO.   
 
 
2.2.1     Broth Microdilution 
MIC values were determined by the broth microdilution test for C. freundii, 
E.coli, E. cloacae, K. pneumoniae,  P. aeruginosa, and S. pneumonaie in accordance 
with the Natinal Committee for Clinical Laboratory Standards (NCCLS) guidelines.  
Ninety-six well flat bottom microtitre plates were filled with 100 µl of Mueller Hinton 
Broth (MHB) in each well of columns 2-to-12.  Antimicrobial agent was serially 
diluted down the plate with column 1 containing the highest drug concentration and 
column 12 receiving no drug (growth control).  Each isolate was standardized to a 0.5 
McFarland suspension (~1.0 X 108 CFU/ml) using a colorimeter.  The bacterial 
suspension was then diluted 1/100 with MHB (~1.0 X 105 to 106 CFU/ml).  One 
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hundred µl of diluted cells were added to each well on the plate, resulting in a final 
volume of 200 µl.  Purity of the bacterial suspension was confirmed by plating each 
sample onto a fresh TSA plate containing 5% sheep blood.  The plates (both microtitre 
and blood agar) were incubated in ambient air at 35-to-37˚C for 16-to-20 hr.   The 
growth control wells (column 12) were examined prior to MIC determination to ensure 
organism viability.  The ATTC strain 27853 was used as a control to confirm accuracy 
of each MIC test.  The MIC value was recorded as the lowest drug concentration at 
which there was no visible growth of the organism.   
Broth microdilution for S. pneumoniae isolates was done similar to that 
described for Gram-negative organisms, except Todd Hewitt Broth (THB) was used as 
was the S. pneumoniae ATCC control strain, 49619.  Microtitre trays were incubated at 
35-to-37°C in 5% CO2 for 16-to-20 hr.  Susceptible, intermediate, or resistant 
phenotypes were recorded based on current NCCLS breakpoints.    
2.2.2     Broth Microdilution using CCCP 
Carbonyl cyanide m-chlorophenylhydrazone (CCCP) has been reported to 
increase the intracellular accumulation of antibiotics, including quinolones, in bacterial 
cells (172, 230, 287, 300, 365).  Early investigators (64, 192) theorized that CCCP 
blocks an energy-dependent efflux system for quinolones with a consequent increase in 
quinolone concentration.  The CCCP effect has also been interpreted to be the result of 
a perturbation of the outer and the cytoplasmic membranes resulting in the influx of 
quinolones into bacteria (77, 287).  This was proposed to result from a collapse in the 
pH gradient of the cytoplasmic membrane by CCCP (265).  A 2-to-4 fold decrease in 
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the MIC in the presence of CCCP has been interpreted to indicate that an active efflux 
mechanism is inhibited (209).  Stock solutions (50 mM) of CCCP were dissolved in 
methanol and stored at −20°C.  A 200 µM solution of CCCP was added to the wells of 
the microtitre panels used in the microbroth dilution method for susceptibility testing.  
Panels containing organism, drug, and CCCP were incubated at 35-to-37oC in ambient 
air for 16-to-20 hr.  A 2-to-4 fold decrease in the MIC upon the addition CCCP was 
taken as a marker for a possible efflux mechanism. 
 2.2.3 MBC Testing 
The MBC defines the lowest antimicrobial concentration that kills 99.9% of a 
standardized 105 to 106 CFU/ml bacterial culture.  The MBC is performed using the 
microbroth method for susceptibility testing.  At an 18-to-24 hr endpoint, a 50 μl 
aliquot of each well (containing a specified antimicrobial concentration) for each 
isolate tested was applied to a TSA plate containing 5% sheep blood and incubated at 
35-37oC in ambient air for 18-24 hr.  Resulting growth (or lack of growth) was 
examined after 18-to-24 hr and the lowest concentration that inhibits 99.9% of the 
original culture was calculated and taken as the MBC.      
 2.2.4 E-Test 
E-tests were used to determine whether MPC testing (see section 2.2) could be 
applied to conventional susceptibility tests.  Three TSA plates containing 5% sheep 
blood were inoculated with P. aeruginosa to produce confluent lawns of bacterial 
growth and incubated at 35-to-37oC in ambient air for 18-to-24 hr.  After 24 hr, the 
contents of the plates were inoculated into 150 ml of fresh MHB, followed by 
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incubation for 16-to-20 hr at at 35-to-37oC in ambient air.  Cells were collected via 
centrifugation at 6000 rpm for 20 mins at 4°C.  The contents of the culture were 
suspended in 4 ml of fresh MHB and viable counts were performed to determine the 
number of cells per ml.  A sterile cotton swab was inoculated into the bacterial 
suspension and applied to TSA plates containing 5% sheep red blood cells.  Three E-
test strips for ciprofloxacin, containing a gradient of antimicrobial concentrations, were 
applied in an overlapping fashion across the plate.  The corresponding concentration 
that inhibited bacterial growth was taken as the MIC.   
2.2.5 Vitek Results 
A semi-automated clinical laboratory organism identification/susceptibility 
system known as Vitek (BioMeriux) is often utilized in clinical laboratories for 
identification and susceptibility testing of bacteria.  Identification cards contain various 
carbohydrate and biochemical substrates and when inoculated with organisms, positive 
and negative reactions are interpreted by the instrument (following incubation) and 
identification is reached by comparison of a computerized database of profiles.  For 
susceptibility cards, organism is inoculated to various drug concentrations and 
following incubation, growth or inhibition in reference to the drug concentrations is 
examined and compared to standardized curves whereby susceptibility or resistance is 
determined.  Cultures of P. aeruginosa were grown in MHB to cellular concentrations 
of > 1010 CFU/ml.  Cells were collected via centrifugation at 6000 rpm for 20 min at 
4°C and resuspended in 4 ml of fresh MHB.  One hundred μl of culture were 
transferred to the wells of the Vitek card (GNS-618 V4423) which was placed into the 
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Vitek system.  A printout of the respective susceptibilities against 16 different 
antimicrobials was recorded after an elapsed time of 7 hr.  The same procedure was 
repeated using a 0.5 McFarland standard. 
2.2.6 Agar Dilution 
Agar dilution was performed in accordance with NCCLS guidelines for 
susceptibility testing (258).  Each isolate was standardized to a 0.5 McFarland 
suspension (~1.0 X 108 CFU/ml) using a Colorimeter.  The bacterial suspension was 
then diluted 1/100 with MHB (~1.0 X 105 to 106 CFU/ml).  One hundred µl of diluted 
cells were added to a series of TSA plate containing 5% sheep blood seeded with two 
fold increments of antimicrobial agent.  Purity of the bacterial suspension was 
confirmed by plating each sample onto a fresh TSA plate containing 5% sheep blood.  
Plates were incubated in ambient air at 35-to-37˚C for 16-to-20 hr.  The MIC was 
recorded as the lowest antimicrobial concentration that inhibited growth.    
2.3 Mutant-Prevention Concentration (MPC) 
The MPC measurements for clinical isolates of C. freundi, E. cloacae, E. coli, 
K. pneumoniae, P. aeruginosa and S. pneumoniae (41, 144, 145, 149) were developed 
in the laboratory of Dr. J. Blondeau, Royal Univerisity Hospital, Saskatoon, SK. 
2.3.1 Inoculum Preparation and MPC Testing Procedure 
Strains of C. freundii, E.coli, E. cloacae, K. pneumoniae, and P. aeruginosa, 
were subcultured from thawed skim milk onto TSA plates containing 5% sheep blood 
using a sterile wooden applicator stick and incubated in ambient air at 35-to-37˚C for 
approximately 24 hr.  After overnight incubation, a sterile swab was used to create 
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heavy lawns of bacterial growth on three TSA plates (containing 5% sheep blood) for 
each isolate.  Plates were incubated in ambient air at 35-to-37˚C for approximately 24 
hr.  An initial absorbance reading of > 1.00 at a wavelength of 600 nm was used to 
estimate a cellular density >1010 cells.  Cells were collected via centrifugation in an 
Avanti J-E centrifuge (Beckman Coulter, Fullerton, CA, USA) at 5000 x g for 30 min 
at 4oC and resuspended in a total of 4 ml of cold, fresh MHB broth.  Viable counts 
were performed on the high-density bacterial cultures to confirm the presence of > 1010 
CFU/ml.  Three 100 μl aliquots of >1010 CFU/ml cultures were applied to TSA plates 
containing 5% sheep red blood cells. For each experiment, agar dilution plates were 
prepared by incorporating fluoroquinolones at seven concentrations into the TSA agar-
sheep red blood cell plates (plates were stored at 4°C and used within 7 days of 
preparation). Each experiment included the fully susceptible control strain S. 
pneumoniae ATCC 27853 grown to a standardized inoculum of 1.1 x1010 CFU/0.1 ml.  
Inoculated plates were incubated for 24 hr at 35-to-37°C in ambient air (or 5% CO2 for 
S. pneumoniae) and then screened for growth. All plates were reincubated for an 
additional 24 hr and re-examined. The MPC was recorded as the lowest antibiotic 
concentration that allowed no growth. 
 For S. pneumoniae, starter cultures were spread on blood agar plates (six plates 
per isolate) (PML, Richmond, ON) and incubated overnight (18-to-24 hr) at 35-to- 
37°C in 5% CO2. Bacterial cells were then transferred from the plates to 500 ml of 
THB (Difco Laboratories, Detroit, MI) followed by overnight incubation at 35-to-37°C 
in 5% CO2. After incubation, cultures were estimated to have concentrations of 3 × 108 
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CFU/ml by absorbency ( >0.4 at 600 nm). Cultures were concentrated by 
centrifugation at 5,000 × g for 30 min at 4°C and re-suspended in 3 ml of THB.  
Aliquots of 200 µl, containing >109 CFU, were applied to TSA plates containing 5% 
sheep red blood cells.  For each experiment, agar dilution plates were prepared by 
incorporating fluoroquinolones at seven concentrations into the TSA plates containing 
5% sheep red blood cells and plates were stored at 4°C and used within 7 days of 
preparation.  Each experiment included the fully susceptible control strain S. 
pneumoniae ATCC 49619 grown to a standardized inoculum of 5x109.   Inoculated 
plates were incubated for 24 h at 35-to- 37°C in 5% CO2 and then screened for growth.  
All plates were re-incubated for an additional 24 hr and re-examined. The MPC was 
recorded as the lowest antibiotic concentration that allowed no growth. 
Gram-negative organisms readily achieve high bacterial titres, in excess of 1010 
CFU/ml, which allows MPC measurements to be preformed using small (between 100-
to-300 μl) inoculums and relatively few MPC plates.  For fastidious organisms, such as 
S. pneumoniae and organisms which do not easily achieve high bacterial 
concentrations, higher volumes of organism (300-to-400 μl) or additional plates for 
each concentration tested were required to ensure that 109-to-1010 cells were tested.  
Mutant selection curves should be performed to ensure that a high enough number of 
cells are tested in order to capture representative first-step mutants which can be 
visualized by a characteristic two-stage decline in CFU that occurs in cultures 
containing in excess of 107-to-108 cells.      
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In some instances, a lack of visible growth could not be accurately ascertained 
after 48 hr and a faint haze caused by the inoculum may obscure growth.  A sterile 
cotton swab was used to collect potential bacterial growth and was inoculated into a 
test tube containing 200 μl of fresh THB.  The tube was briefly vortexed and the entire 
concents of the tube were applied to TSA plates containing 5% sheep red blood cells 
and the fluoroquinolone concentration in question.  Plates were incubated under 
appropriate conditions for an additional 18-to-24 hr period to confirm the absence of 
growth.  For most strains tested, a lack of visual growth after 48 hr correlates with a 
confirmed lack of growth after the additional 24 hr incubation.  The concentrations 
tested in the MPC method include one doubling dilution below the MIC of the isolate 
and a minimum of five doubling dilutions above the MIC. Upon repeat testing, the 
range of drug concentrations varied depending on the behavior of the organism (if the 
organism did not grow on any antimicrobial plates, the MIC was repeated and the 
MPC range was lowered; if the organism grew at the highest drug concentration plate, 
the MPC range was extended and the experiment was repeated at a higher drug 
concentration range).  For instances in which absolute growth could not be accurately 
determined by 48 hr, a swab of the plate was transferred to a 1-to-2 ml test tube 
containing fresh media and the contents of the tube were applied to fresh agar seeded 
with the corresponding drug concentration from which the swab was taken.  The plate 
was incubated for an additional 18-to-24 hr (72 hr total) and the lowest concentration 
producing a lack of visible growth was recorded as the MPC. 
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2.3.2 Mutant Selection Curves 
Overnight cultures of bacteria (typically 3-to-6 plates/isolate), grown under 
appropriate conditions for the organism, were inoculated in liquid media and incubated 
for an 18-to-24 hr period. After incubation, cells were collected via centrifugation at 
5,000 × g and 4oC for 30 min and then re-suspended in 6 ml (or calculated volume 
required) of fresh MHB/culture.  The contents of the two high-density cultures were 
pooled and a viable count of the culture was performed to ensure the presence of >1010 
CFU/ml.  Dilution sets consisting of 1/10 to 1/108 were created and 100 μl aliquots of 
various dilutions and pure culture were applied in triplicate to TSA plates seeded with 
fluoroquinolone concentrations spanning small concentration intervals (i.e., <1 
doubling dilution).  The decline in colony recovery was measured at each 
concentration and used to create the overall mutant selection curve(s).  For fastidious 
organisms such as S. pneumoniae, a total of 1 ml was sampled in 200 μl aliquots, 
containing approximately 1010 cells) over 5 different plates to ensure that 1010 cells 
were tested.  The concentration intervals tested should be designed to illustrate a 
distinct plateau region, followed by a second decline in colony recovery.  Thus, 
concentrations tested varied from organism to organism and strain-to-strain depending 
on the MPC of the strain tested.        
2.3.3 Viable Counts 
Viable counts were performed on selected organisms for each round of MPC 
testing.  Dilutions of 10-7, 10-8 and 10-9 were made from the bacterial suspension and 
100 µl of each dilution were plated onto triplicate TSA plates containing 5% sheep 
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blood.  The plates were incubated for 24 hr at 35-to-37°C in ambient air.  Colony 
counts were performed on each plate.  Calculations were then performed to determine 
CFU/ml.  
2.4 Characterization of First-step Mutants 
2.4.1 DNA Isolation, Amplification and Nucleotide Sequence 
 Determination for S. pneumoniae 
 
 Selected isolates of S. pneumoniae were grown on brain heart infusion (BHI) agar 
(Difco) containing 10% defibrinated sheep blood (Hemostat Laboratories, Dixon, CA.) 
following high-density inoculation.  Incubation was overnight at 35-to-37°C in 5% CO2.  
Bacteria grown as confluent lawns were recovered from agar plates by washing with 2 
ml of THB per plate. Cells were concentrated by centrifugation (as previously 
described), washed once with lysis buffer (50 mM Tris-HCl [pH 8.0] and 5 mM EDTA) 
and resuspended in 400 µl of lysis buffer per plate. Then, 50 µl of 10% sodium dodecyl 
sulfate and 20 µl of proteinase K (10 mg/ml) were added and the mixture was incubated, 
first at 55°C for 30 min and then at 37°C for 1.5 hr.  Cell lysates were extracted with 
phenol.  An equal volume of TE-saturated phenol (10 mM Tris-HCl [pH 8.0] and 1 mM 
EDTA) was added to 100 to 200 μl of DNA sample contained in a 1.5 ml 
microcentrifuge tube and vortexed for 15-to-30 sec.  The sample was centrifuged at 
10,000 rpm for for 5 min at room temperature to separate the phases.  The upper 
aqueous layer was aspirated, and placed in a clean tube, and was extracted a second 
time.   DNA was precipitated with ethanol and recovered by centrifugation. DNA was 
then dissolved in TE buffer and treated with a final concentration of 100 µg of RNase A 
per ml for 1 hr at 37°C.  DNA was reprecipitated with 2 volumes of ethanol and 
 49
dissolved in TE buffer.  
 The nucleotide sequences of the quinolone-resistance-determining regions of parC 
and gyrA were determined with an automated DNA sequencer (Applied Biosystems, 
Foster City, CA) using primer SP-parC sequence (5' TCA GCG CCG TAT TCT TTA 
TTC TAT G 3') and primer SP-gyrA sequence (5' TCG AGA TGG CTT AAA ACC 
TGT TCA C 3') after PCR amplification of DNA fragments using primers SP-parCfwd 
(5' GTC TAA CAT TCA AAA CAT GTC CCT G 3'), SP-parCrev (5' TCT TTC TCC 
GTA TCG TCA AAG TTC 3') for parC and SP-gyrAfwd (5' TGT CAA TCT GAC AAA 
GGA GAT GAA G 3') and SP-gyrArev (5' CCA GTT GCT CCA TTA ACC AAA AG 
3') for gyrA.  
PCR reactions were performed in 100 μl volumes containing 0.1 μM of each 
nucleotide primer, 0.2 μM each 2’-deoxynucleoside 5’-triphosphate (Pharmacia, 
Montreal, QC), 10 μl of reaction buffer (Sigma-Aldrich), 4 μl of template DNA sample 
and 1U of platinum Pfx polymerase (Gibco BRL, St. Louis, MO).  All reactions were 
performed in a DNA thermocycler (MJ research, Waltham, MA) and cycled 25 times 
following a 6-min denaturation step at 94oC.  Each cycle consisted of a 30 sec 
denaturation step at 94oC, a 30 sec annealing step at 55oC and 2 min at 72oC for primer 
extension.  PCR products were purified using a QIAquick PCR purification kit (Qiagen 
Inc., Mississauga, ON) according to the manufacturers’ recommendations.  DNA 
sequencing was performed using an automated gene sequencer (Natural Research 
Council, Saskatoon, SK). 
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2.4.2    DNA Isolation, Amplification and Nucleotide Sequence 
 Determination for Recovered Mutants of P. aeruginosa 
 
Selected mutants of P. aeruginosa were recovered from MPC plates seeded 
with ciprofloxacin and levofloxacin.  Two colonies were selected and suspended in 
100 μl of insta-gene matrix (Sigma-Aldrich).  Cells were centrifuged for 15 sec and 
boiled for 10 min.  Following a second centrifugation step, 4 μl of the supernatant was 
used for PCR reactions. 
 Two primers GYRA1 (5’ CCAAAGAAATTCTCCGGTCA 3’) and GYRA2 
(5’ GGTTGGGAATCTTGGTCGGCA 3’) were constructed based on the nucleotide 
sequence of P. aeruginosa gyrA subunit reported by Kureishi et al (196).  Primers for 
DNA gyrA were designed to amplify a 484 base pair region spanning nucleotides 256-
740.  This region includes the QRDR encompassing codons 67-to-106.  One 22-mer 
primer and one 21-mer primer (PARC1 5' ATGAGCGCCTCCCTCGATCTGA 3’and 
PARC2 5’ GCCGRCGAAGRRCGGRACCCA 3’) were constructed based on the 
sequence of the P. aeruginosa Topoisomerase IV gene reported by Akaska et al (2).  
The PCR reaction amplified a 424 base pair region including the QRDR associated 
with Topoisomerase IV. 
 PCR reactions were perfomed as previously described for S. pneumoniae.  PCR 
reactions cycled 36-to-41 times following a 6-minute denaturation step at 95oC.  Each 
cycle consisted of a 35 second denaturation step at 94oC, a 40 second annealing step at 
57o C and a 35 second polymerization at 72oC.  PCR products were purified and 
sequenced as previously described for S. pneumoniae.   
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2.4.3   Primer Preparation and Storage 
Each primer set was made at a stock 100 mmolar concentration using TE 
buffer.  Primers were stored in aliquots at –20oC.   
2.4.4    Analysis of PCR Products 
PCR products were analyzed on 1% agarose gels prepared as described in 
Appendix A.  Six µl of tracking dye were added to each PCR reaction tube.  For the 
marker, 2 µl of a 123 bp ladder (Sigma, St. Louis, MO.) were added to 12 µl of sterile 
distilled water and 4 µl of tracking dye.  Each tube was gently mixed.  A sample 
volume of 20 µl was loaded into designated lanes and a current of 117 volts was 
applied to the gel for approximately 20-to-30 min.  Gels were analyzed under 
ultraviolet light. 
2.5 Pulsed-Field Gel Electrophoresis (PFGE) for Clinical Isolates of P. 
 aeruginosa  
 
2.5.1    DNA Extraction 
P. aeruginosa isolates were thawed and plated out on TSA supplemented with 
5% sheep red blood cells.  Plates were incubated at 35-to-37oC for 18-to-24 hr in 
ambient air.   
2.5.2    Cell Disruption 
An overnight culture was used to create a bacterial suspension in TE buffer. An 
inoculum equal to a 5.0 McFarland standard (~15 x108 CFU/ml) was created.  A 1.5 ml 
aliquot of the bacterial suspension was then mixed with an equal volume of a 1.2% low 
melting point agrose solution.  The mixture was vortexed for 20 sec and aspirated into 
a 3cc monoject Luer lock syringe with a 1.5 gauge needle (Fisher Scientific, Napean, 
 52
ON).  The syringes were incubated at 4oC for 30 min.  The solid agarose cylinder was 
removed from the syringe and placed in a sterile plastic petri dish. Using a sterile 
scalpel blade, the cylinder was cut into 10-to-15 (approximately 3 mm in thickness) 
agarose plugs.  The plugs were added to sterile test tubes containing 4 ml of proteinase 
K lysis buffer and incubated at 50oC with constant agitation.    
2.5.3     Proteinase K Treatment 
Most standard protocols for DNA extractions from Gram-negative bacteria for 
PFGE require 4-to-6 hr Proteinase K incubation.  However, for P. aeruginosa, an 
incubation of this length is often insufficient to obtain the required cell lysis.  
Increasing the amount of time the Proteinase K was able to react from 6 hr to overnight 
(16-to-18 hr) increased lysis efficiency (Hansen and Blondeau-unpublished 
observations).  The Proteinase K lysis buffer was removed and replaced with 4 ml of 
lysis buffer and incubated for a further 24 hr at 50oC 
2.5.4    Inactivation of Proteinase K  
 Lysis buffer was removed and replaced with 4 ml of phenylmethyl-sulfonyl 
fluoride (PMSF) rinse solution.  This rinse step was performed at least twice with 
continuous agitation at room temperature for 1 hr each time.  The PMSF rinse solution 
was replaced with 4 ml of TE buffer and agitated for 30 min at room temperature.  This 
rinse step was repeated three times. 
 2.5.5     Storage of Plugs 
The TE buffer rinse solution was removed from the plugs and the plugs were 
stored in 3 ml of fresh TE buffer in tissue culture plates (Fisher Scientific Nepean, ON) 
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at 4oC.  The level of TE buffer was monitored and replenished frequently to prevent 
the plugs from drying.   
2.5.6     Restriction Endonuclease Digestion 
Plugs were removed from storage plates using a sterilized spatula and placed in 
a sterile plastic petri dish.  Individual plugs were cut into quarters, with one quarter 
being transferred to a sterile 1.5 ml microcentrifuge tube.  A 1 ml mixture of the 
manufacture’s 1x restriction endonuclease buffer, bovine serum albumin and 14 μl 
(between 30 and 270 units) of the enzyme SpeI was added. 
2.5.7     Preparation of the Gels  
 A 1% pulsed-field certified agarose gel was prepared in a 250 ml flask.  The 
molten agarose was cooled to 50-to-55oC and the gel was cast in a BioRad 
Laboratories pulsed-field gel casting apparatus.  The agarose was allowed to set for 30 
min after which the molten plugs were transferred to the wells in the gel.  The last well 
was reserved for the λ ladder molecular weight marker.  The gel was submerged in 
PFGE running buffer (Appendix A) in the electrophoresis cell of a BioRad CHEF DR 
III system.  The gel was subjected to pulsed orthoganol fields ramping from 2-to-15 
sec, opposing each other by 120o at a field strength of 6 V/cm.  The buffer was held at 
a constant temperature of 14oC by a cooling unit.  The electrophoresis was carried out 
over 18 hr.   
 2.5.8     Staining Procedure 
A 1 mg/ml solution of ethidium bromide solution was placed in a plastic 
tupperware container containing distilled water, the gel was then removed from the 
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electrophoresis cell and placed in solution.  The gel was protected from direct light and 
agitated for 30 min.  The stain solution was decanted and the gel destained for 30 min 
in sterile distilled water with agitation.  The gel was analyzed on the Gel Doc 1000 
Illuminator (BioRad Laboratories, Mississauga, ON).  A difference of three or more 
bands is typically used to distinguish between different clones (137, 138) and was used 
as the criteria for distinguishing between different strains. 
 2.6 Killing of S. pneumoniae by Fluoroquinolones Assessed with  
  Conventional Kill Curves 
 
Powdered forms of each fluoroquinolone were dissolved according to the 
manufacturer’s instructions.  Stock solutions were prepared from fresh preparations or 
samples stored at –70oC.  Clinical isolates of S. pneumoniae used in kill curve 
experiments were grown overnight on blood agar plates.  The following day, an 
inoculum was transferred to THB and incubated for 2 hr at 35-to-37oC in 5% CO2.  
After incubation, spectrophotometer readings of > 1.5 (at 600 nm) were used to verify 
cell densities of > 109 cells/ml as previously determined.  To achieve cell densities 
ranging from 106 to 109 cells/ml, further dilutions in THB were taken.  The 
antimicrobial agent was then added.  Drug concentrations used for kill experiments 
were based on the MIC, MPC and Cmax drug concentrations.  The measurement of kill 
(log reduction in viable cells) was recorded at 0, 0.16, 0.5, 1, 2, 3, 4, and 24 hr after the 
addition of the drug.  Three 100 μl aliquots were taken at each time interval and 
cultured on drug-free agar plates that were subsequently incubated overnight at 35-to-
37oC in 5% CO2.  The three results obtained at each time interval were averaged and 
the log10 reductions and percent killing of viable cells were calculated and recorded.  
 55
Significant bactericidal activity was recorded as > –3 log reduction in viable cells, as 
previously established in the literature (34, 245).   
 2.7 Killing of P. aeruginosa by Ciprofloxacin and Levofloxacin  
  Assessed with MPC-based Kill Curve Experiments   
 
Kill curve experiments designed to compare the effects of MPC and MIC 
based-killing were performed with clinical isolates of P. aeruginosa.  MIC and MPC 
measurements were preformed as previously described (Section 2.3).  Preparation of 
high-density P. aeruginosa cultures were prepared as outlined in MPC testing (see 
Section 2.2).   Viable counts were performed on the high-density culture to determine 
the number of cells present per ml of culture.  Cultures were re-suspended in 4 ml of 
fresh cold MHB and divided equally into four flasks containing 500 ml each of fresh 
MHB broth.  For ciprofloxacin and levofloxacin, two separate flaskes containing the 
contents of the initial 1010 CFU/ml were used for each agent and tested for killing at 
either the MIC of MPC, respectively.   This procedure distributed the contents of the 
>1010 CFU/ml culture into 4 cultures, each containing approximately 107 cells.  Two 
flasks (culture 1 and culture 2) were dedicated for use with either ciprofloxacin or 
levofloxacin at the measured MIC or MPC drug concentration.  Three aliquots 
containing 300 μl were sampled from each flask at 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 
and 24 hr and applied to TSA supplemented with 5% sheep red blood cells and 
incubated for 24 hr while shaking at 35o C in ambient air.  A dilution series was 
created for each flask at each time interval sampled to ensure that individual colonies 
could be counted.  An additional 300 μl sample was taken from each flask and applied 
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to TSA supplemented with 5% sheep red blood cells and seeded with ciprofloxacin or 
levofloxacin at concentrations one dilution below the MPC value of the strain tested.   
Bacterial growth at each time interval for each flask was recorded and the log 
growth was subtracted from the initial cell density of starting culture before the 
addition of drug.  Mutant growth, as assessed by growth on plates seeded with 
fluoroquinolone concentrations 2-fold below the measured MPC, was recorded.   After 
24 hr, cells were collected from each culture via centrifugation at 5000 x g for 30 min 
at 4°C and re-suspended in a volume of 5 ml of fresh MHB.  The contents of the entire 
cultures were sampled in 0.3 ml aliquots on TSA plates supplemented with 5% sheep 
red blood cells and seeded with the fluoroquinolone concentration that corresponded to 
one dilution below the MPC value of the strain.  This final process was used to 
determine the viability of mutant cultures. 
 2.8 Ciprofloxacin and Levofloxacin Efficacy in a Rat Abscess Model of  
 P. aeruginosa  Infection  
 
 Individual strains of P. aeruginosa were plated on three TSA plates 
supplemented with 5% sheep red blood cells and grown overnight (18-to-24 hr) at 35-
to-37oC in ambient air.  After 24 hr, cells were collected via centrifugation at 5000 x g 
at 4oC for 30 min and re-suspended in a total of 4 ml of cold, fresh MHB broth.  Viable 
counts were preformed on the high-density bacterial cultures to confirm the presence 
of > 1010 CFU/ml.  Three sterile sections of open-ended dialysis tubing (~1.5 cm in 
length) were inoculated with 50-125 μl of concentrated P. aeruginosa culture using a 
sterile pipette.  Each implant contained between 5 x109 to 4.3 x1010 CFU/ml as 
determined by viable counts.       
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2.8.1 Animal Model of Infection 
 Male Sprague Dawley white rats (Charles River, Wilmington, MA) weighing 
between 300 and 350 g were used.  Sixteen rats were used per experiment set, which 
included 4 control animals (2 animals did not receive drug, 2 animals were implanted 
with saline- filled implants), 6 ciprofloxacin-treated animals and 6 levofloxacin-treated 
animals.  Rats were weighed and anaesthetized with an intra-peritoneal (I.P.) injection 
using a 1cc syringe with a 25 GA needle containing a 90 mg/kg:5 mg/kg 
ketamine:zylazine dose (Warner-Lambert and Co., Bellevelle, ON) (Bayer, Toronto, 
ON).  Animals were placed on a warm protected surface for approximately 5-10 min.  
A drop of eyelube (Sabex, Boucherville, QC) was administered to each eye.  A 5 cm x 
5 cm long section of the dorsal flank of each rat was shaved, scrubbed with hibitane 
(Fisher scientific, Nepean, ON) and washed with 95% alcohol.  Under anaesthetic, an 
elastic band was tied around the base of the tail and a rat tail vein catheter (22 GA x 
2.5 cm I.V. catheter, Becton Dickinson Infusion Therapy System Inc., Sandy, UT,) was 
inserted.  A protective gauze wrap was inserted over the catheter to prevent the rat 
from removing it.  In each rat, three 1.5 cm long incisions were made in a triangular 
fashion (beneath each scapula and on the midline of the lower back) using a size 10 
sterile disposable scalpel (Fisher Scientific, Nepean, ON).  The skin was separated 
from the fascia by blunt dissection using sterilized forceps (Fisher scientific, Nepean, 
ON).  The implants were positioned in a triangular pattern behind the shoulders.  The 
overlying incision was sealed with a combination of individual 00 Vicryl silk sutures 
(Ethicon, Sommerville, NJ) and/or Vetbond tissue adhesive (3M Animal Care 
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Products, St. Paul, MN). A 0.05mg/kg injection of buprenorphine (Reckitt and Colman 
Pharmaceuticals Inc. Richmond, VG) was given by (I.P.) injection for pain control.  
Animals recovered on a clean, soft surface under a heat lamp for 15-to-30 min.   
2.8.2 Administration of Fluoroquinolones 
Antimicrobials were administered I.V. in 1 cc syringes with a 25 GA needle via 
the tail vein catheter as 400 mg ciprofloxacin (q24h and qh8) and 750 mg levofloxacin 
(q24h, q8h) doses.  Doses were started 3-to-4 hr after the implantation of implants.  
 2.8.3 Recovery of Blood Samples  
Blood samples were collected in 10-to-15 μl amounts, taken every 18-to-24 hr 
from a tail vien catheter and were followed by a 100-to-150 μl infusion of sterile saline 
solution to replenish fluid volume and flush residual antimicrobial from the site.     
    2.8.4 Recovery of Infected Tissue and Blood Samples   
In an attempt to ensure that the majority of an animal’s blood volume was 
recovered, a 20 cc syringe with a 20 GA needle filled with saline was introduced into 
the inferior section of the heart, inserted into the aorta and clamped with a 15.9 cm 
hemostat (Fisher Scientific, Neapon ON).  The right ventricle was cut and sterile saline 
was infused throughout the circulatory system and collected in a tube attached beneath 
the left ventricle.  Blood samples were injected into pediatric Bactec resin bottles 
(Becton Dickson, Sparks, MD) (which coagulates any remaining antibiotic) using a 20 
GA syringe and incubated for 12t-to-24 hr at 35-to-37oC in ambient air.  Inoculated 
bottles were incubated in the Bactec 9000 blood culture system (Becton Dickson, 
Sparks, MD) and incubated with agitation for 5 days.  Bottles flagging positive were 
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removed from the instrument and an aliquot of the contents were removed with a 
sterile needle and inoculated to agar plates and incubated for 18-to-24 hr at 35-to-37oC 
in ambient air.  The next day, culture plates were inspected for growth and recovered 
organisms were identified by the Vitek system.  Culture-positive blood samples were 
streaked onto MaConkey and blood agar plates and incubated for 18-to-24 hr at 35-to-
37oC in ambient air.   Bacterial growth was identified as P. aeruginosa on the based on 
colonial morphology, Gram stain, and a positive oxidase test.    Infected tissues were 
recovered and homogenized with the use of a high-speed homogenizer (Labcor, 
Concord, ON).  The resulting suspension was streaked for growth and any growth was 
identified as P. aeruginosa by Gram stain and a positive oxidase test.  Recovered 
organisms were stocked, and frozen at –70o C in sterile cryovials as previously 
described. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60
3.0 MUTANT-PREVENTION CONCENTRATIONS OF  
 FLUOROQUINOLONES FOR CLINICAL ISOLATES OF  
 S. PNEUMONIAE  
  
 3.1 Abstract 
   
Antibiotic resistance among human pathogens now occurs in almost every 
bacterial species for which antibiotic therapies exist.  In the case of S. pneumoniae, 
resistance to penicillin and macrolides (i.e., azithromycin, clarithromycin, 
erythromycin) has become so widespread that clinicians have started to use the 
fluoroquinolones for the treatment of community-acquired respiratory tract infections.  
Fluoroquinolones with increased anti-pneumococal activities are becoming available, 
but new treatment strategies must accompany use of these agents in order to halt the 
selection of resistant mutants.   The MPC represents a concentration threshold above 
which the selective proliferation of resistant mutants is expected to rarely occur.  MPCs 
were defined and measured for six fluoroquinolones with clinical isolates of S.  
pneumoniae.  Based on their potential for restricting the selection of resistant mutants, 
the six fluoroquinolones, in descending order of potency, were found to be: 
gemifloxacin > moxifloxacin >  trovafloxacin  >  gatifloxacin  >  grepafloxacin 
> levofloxacin.  For several compounds, clinical isolates that lacked a known resistance 
mutation had an MPC value that was close to or below the serum levels that could be 
attained using current dosing strategies.  These data identify moxifloxacin, gatifloxacin 
and gemifloxacin as good candidates for determining whether MPC can be used as a 
guide for choosing and eventually administering fluoroquinolones in a way that would 
significantly reduce the development of resistance.  High MPC results for levofloxacin 
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suggest that more than once daily dosing may be required in order to ensure that drug 
concentrations remain in excess of the MPC for a sufficient amount of the 24 hr dosing 
period.  Killing experiments based on the MPC and performed using conventional kill 
curve methodology require further examination but suggest that killing based on the 
MPC may be essential for rapid bacterial eradication and shorter durations of therapy. 
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3.2 Introduction  
S. pneumoniae is the most common bacterial pathogen associated with (lower) 
respiratory tract infections and accounts for approximately 50% of all cases of 
community-acquired pneumonia, 35% of cases of acute sinusitis and acute otitis media 
and 20% of acute exacerbations of chronic bronchitis in patients with chronic lung 
disease (113, 199).  Of growing concern is the increasing level of resistance to S. 
pneumoniae among commonly used antimicrobials, namely, the penicillins and other ß-
lactams as well as the macrolides.  Although geographically dependent, the frequencies 
of penicillin and macrolide resistance among strains of S. pneumoniae are estimated to 
be 40 and 30%, respectively (79, 348).  Of perhaps greater concern is the rapid rate at 
which resistance has developed within clinical strains of S. pneumoniae (353).  The 
incidence of penicillin-resistant S. pneumoniae increased from between 3-to-6% before 
1991 to 39-to-46 % by 2000 and 2001 (31, 35, 79, 102, 348).  In several studies, isolates 
with high-level resistance represented 13-to-20% of all strains and isolates with 
intermediate-level resistance represented 23-to-28% (79, 80).  More recent data suggest 
that >70% of high-level penicillin-resistant pneumococci demonstrate cross-resistance 
to the macrolide class of antimicrobials (32, 79, 80).   
The relatively low incidence of fluoroquinolone resistance among clinical 
strains of S. pneumoniae (< 2% overall in Canada and the US) (337, 348, 363) has led to 
the use of fluoroquinolones as first-line agents for the treatment of pneumonia and 
lower respiratory infections both in inpatient and the outpatient settings, and particularly 
when antimicrobial resistance is suspected (15, 16, 154).  However, fluoroquinolone-
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resistance associated with clinical failures is now being reported, raising concerns over 
the continued use of quinolones with border-line (near breakpoint) activity against S. 
pneumoniae (32, 89, 315, 318).  In Canada, Chen et al (53) found that the prevalence of 
ciprofloxacin-resistant pneumococci increased from 0% in 1993 to 1.7% in 1997-1998 
(p=0.01).  In adults, the prevalence increased from 0% in 1993 to 3.7% in 1998.  In 
addition to the increase in prevalence, increases in the overall degree of fluoroquinolone 
resistance were also noted (53).  Similar results have also been reported in Spain (211), 
Japan (159), Eastern Europe (254) and the United States (80).  The rapid global 
dissemination of penicillin-resistant strains of S. pneumoniae (220) demonstrates the 
threat that antimicrobial resistance poses in the clinical setting.  For the fluoroquinolone 
class of antimicrobials, rates of resistance to S. pneumoniae remain relatively low 
(<2%) (46), and clinicians, laboratorians, and the scientific community are faced with 
the daunting task of minimizing resistance while  maintaining the clinical lifespan of the 
fluoroquinolone class of antimicrobials.  This task requires a proactive approach to 
dealing with resistance.  Unfortunately, fluoroquinolone-resistant S. pneumoniae are 
emerging (53) and, since 1999, there have been over 30 case reports of levofloxacin 
treatment failures in the United States and Canada (7, 70, 75, 97, 114, 186, 194, 305, 
340, 351, 358).   
Among the most well known and well characterized cases were those reported 
by Davidson et al (70) who documented the development of resistance mutations in 
strains of S. pneumoniae for patients receiving quinolone therapies.  A report by Davies 
et al (71) involving a subset of  levofloxacin-susceptible pneumococcal isolates from 
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the 1999-2000 respiratory season, evaluated as part of the TRUST (Tracking Resistance 
in the United States) study, indicated that 6.6 and 7.1% of the S. pneumoniae isolates for 
which the levofloxacin MICs are 1.0 and 2.0 µg/ml, respectively, contain a first-step 
parC mutation.  Recent experiments conducted on clinical strains of S. pneumoniae 
demonstrated that of 164 unique patient isolates of S. pneumoniae, 29.9% harboured a 
mutation in either the parC or the gyrA gene, with the majority of isolates (67.3%) 
having a mutation in the parC locus only (46).  An additional Canadian study which 
examined clinical isolates between 1993-to-1998 revealed that 59% of the isolates with 
a levofloxacin MIC of 2 μg/ml, a level considered susceptible by NCCLS criteria, had a 
first-step parC mutation (210).  Thus, the state of fluoroquinolone efficacy for the 
current and future treatment of S. pneumoniae is clear.  In order to preserve this 
important group of antimicrobial agents and prevent the rapid emergence of resistance, 
inappropriate use needs to be controlled and it is paramount that we learn which 
fluoroquinolones and which dosing regimes will help to minimize selection of resistant 
bacteria (32, 53, 164). 
 The MPC describes the minimal antibiotic concentration required to inhibit the 
most resistant first-step mutant present in large (>109 CFU/ml) susceptible cultures (41, 
87, 149, 367).  For example, bacterial populations may reach 1010 cells in human 
infections (100, 116, 220, 241), but at a mutation frequency of 10 7, more than 1014 
bacteria (107 × 107) would be required to detect two concurrent fluoroquinolone-
resistant mutations (41, 367).  When we examined the effect of fluoroquinolone 
concentration on the selection of resistant mutants of S. pneumoniae, we found drug 
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concentrations that prevented the growth of mutant colonies when 109-to-1010 cells 
were applied to agar plates containing antibiotic.  This drug concentration, designated 
the MPC, would require a bacterial cell to develop more than one resistance mutation 
for growth in the presence of the antibiotic. Thus, at concentrations above the MPC, a 
bacterial population size greater than that normally present during infection would be 
necessary for mutant growth.  Since fluoroquinolone structure affects the value of the 
MPC (83), we hypothesized that the MPC might serve as a simple measure of antibiotic 
potency that incorporates the ability of a compound to restrict selection of resistant 
mutants.  The application of the MPC in current dosing regimes would add 
consideration of the development of resistance to the traditional goal of clearing 
infection. 
Examination of large numbers of clinical isolates generally involves 
measurement of antibiotic potency that is typically defined by the MIC.  With the agar 
dilution method, approximately 105 CFU/ml are applied to a series of agar or microtiter 
plates containing various antibiotic concentrations (258) and the concentration that 
prevents colony formation is recorded as the MIC.  Measurement of MPC is carried out 
using the same strategy, except that more cells (approximately 1010 cells) are applied to 
agar plates containing varying drug concentrations.  Consequently, it should be possible 
to define MPC measurements for large numbers of clinical isolates against a panel of 
different fluoroqouinolone agents.  In the following work, I define MPC values for 
clinical isolates of S. pneumoniae against gatifloxacin, gemifloxacin, grepafloxacin, 
levofloxacin, moxiflxoaicn, and trovafloxacin.  MPC measurements were compared 
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with published PK/PD parameters and bacterial killing studies were conducted to 
determine if, and for how long, serum/tissue drug concentrations were expected to 
remain in excess of the MPC for a given drug.  The relationship between 
fluoroquinolone PK/PD and the MIC90/ MPC90 measurements were used to empirically 
define the potential for a given fluoroquinolone to select for resistance.   
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 3.3  RESULTS 
 3.3.1 MPC Distributions for Clinical Isolates of S. pneumoniae  
When 109-to-1010 cells of S. pneumoniae were applied per plate, a sharp drop in 
growth was seen over a range of one-four dilutions above the MIC.  When the minimal 
concentration which prevented the growth of mutant colonies (MPCpr) was plotted 
against the number of isolates, distinct peaks were seen in the distribution (Figure 
4.3.1).  The MPCpr represents a provisional value because the initial 72 hr screening 
process, preformed on non-drug containing media, overestimates the MPC90 result by  
2-fold  (see Materials and Methods).  When the average of MPCpr results for 
approximately 100 clinical isolates of S. pneumoniae were determined, the five 
fluoroquinolones could be ranked in terms of potency, in descending order, with 
moxifloxacin, > gatifloxacin = trovafloxacin >grepafloxacin > levofloxacin (Table 
3.3.1).  Since working with large numbers of S. pneumoniae isolates is cumbersome, I 
determined an empirical relationship between MPC and the MIC so that the MPC of a 
drug can be calculated from the MIC of the drug. When the MIC of a drug was 
measured by the agar dilution method, most of the isolates exhibited a two- to four-fold 
difference between the MIC and MPCpr (one to three dilutions).  The ratio was slightly 
higher for trovafloxacin and grepafloxacin.  The ratio of the MPC to the MIC of a drug 
was calculated using values that exceeded those for 90% of the isolates (MPC90 and 
MIC90).  The ratio was found to be 8 for moxifloxacin, levofloxacin, and gatifloxacin, 
and 16 for trovafloxacin and grepafloxacin.  Similar ratios were obtained for the MPC 
and the MIC of these drugs with the laboratory strain ATCC 49619.    
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White bars represent isolates containing parC mutations known to confer resistance; 
shaded regions represent isolates containing parC mutations that have not been 
demonstrated by genetic tests to confer quinolone resistance; solid regions represent 
unsequenced isolates.   
MPCpr  (μg/ml) 
Figure 3.3.1 Distribution of MPCpr Results for 5 Fluoroquinolones Against 100  
  Clinical Isolates of S. pneumoniae  
moxifloxacin 
gatifloxacin 
trovafloxacin 
grepafloxacin 
levofloxacin 
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Table 3.3.1 Fluoroquinolone Potency Based on MPCpr Resultsa 
 
 
  a From data presented in Figure 3.3.1 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fluoroquinolone MPCpr50   
(μg/ml) 
MPCpr90  
(μg/ml) 
MIC90  (μg/ml) MPCpr90 / 
MIC90 
Moxifloxacin 0.5 2 0.25 8 
Trovafloxacin 1 4 0.25 16 
Gatifloxacin 1 4 0. 5 8 
Grepafloxacin 2 8 0.5 16 
Levofloxacin 4 8 1 8 
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Figure 3.3.2 depicts MPC results obtained using drug-containing plates for the 
72 hr screening process (described in Materials and Methods).  Development of  
trovafloxacin and grepafloxacin has stopped since our initial publication on MPC (41);  
thus, Figure 3.3.2 illustrates MPC results for 220 clinical isolates against the currently 
available fluoroquinolones, (moxifloxacin, gatifloxacin, gemifloxacin, and 
levofloxacin) used in the treatment of infections caused by S. pneumoniae.  
Fluoroquinolone-resistant isolates, based on a moxifloxacin MIC > 2 μg/ml, were 
excluded from MPC testing.  Gemifloxacin had the lowest modal MPC (0.125 µg/ml), 
followed by moxifloxacin (0.5 µg/ml), gatifloxacin (1 µg/ml) and levofloxacin (2 
µg/ml). The same rank order was observed when MPC was determined for 90% of the 
isolates. These data are consistent with gemifloxacin having greater in vitro activity than 
the other fluoroquinolones against resistant mutants (149, 254).  When the MIC at 
which 90% of the susceptible isolates were inhibited (MIC90) was determined, 
gemifloxacin was also more active than moxifloxacin, gatifloxacin and levofloxacin in 
these comparisons by 2, 3 and 4 doubling dilutions, respectively.   Detailed descriptions 
of MPC results for the 220 clinical isolates are illustrated in Table 3.3.2.  For 
moxifloxacin, 52.3% (115/220) of the isolates tested had MPC results of < 0.5 μg/ml 
compared to 7.7% for gatifloxacin and 0% for levofloxacin.  For gemifloxacin, 97% had 
a MPC of < 0.5 μg/ml and only 1 isolate tested had a MPC result of > 2 μg/ml.  For 
moxifloxacin, gatifloxacin, and levofloxacin, 9%, 25.5 %, and 93% of the isolates tested  
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Figure 3.3.2 Distribution of MPC Results for Moxifloxacin, Levofloxacin,  
  Gatifloxacin, and Gemifloxacin Against 220 Clinical Isolates of S. 
  pneumoniae  
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Table 3.3.2  Distribution of MPC Results and the Relationship Between MIC and MPC for Clinical Isolates of  
S. pneumoniae and Fluoroquinolones
                                       No. of isolates at various MPC drug concentrations Fluoroquinolone 
<0.031 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64   
Trovafloxacina 
(n=100) 
   5 28 36 14 7 6 4     
Grepafloxacinb 
(n=98) 
   2 23 37 25 9 2      
Moxifloxacin 
(n=220) 
  1 11 103 85 18 2       
Gatifloxacin 
(n=220) 
    17 145 51 3 1 1     
Levofloxacin 
(n=220) 
     15 151 46 7 1     
Gemifloxacin 
(n=220) 
3 34 86 70 14 5  1       
                                       No. of isolates having ratios of MPC/MICc Fluoroquinolone 
0.06 0.13 0.25 0.5 1 2 4 8 16 32 64 128 256 512 
Trovafloxacina 
(n=100) 
    1 1 28 33 22 9 4 2   
Grepafloxacinb 
(n=100) 
     5 18 27 31 15 3 1   
Moxifloxacin 
(n=220) 
    5 17 101 62 34  1    
Gatifloxacin 
(n=220) 
    4 68 116 29 3  4    
Levofloxacin 
(n=220) 
     118 72 8 1 1     
Gemifloxacin 
(n=220) 
    16 49 77 54 17 6 1    
a ,b Trovafloxacin and grepafloxacin have been withdrawn from the market.  Trovafloxacin and grepafloxacin results represent provisional (MPCpr) 
values, which overestimate the actual MPC result 2-fold.   
c Ratio of MPC/MIC was determined for each isolate and the number of isolates having the indicated values of the ratio were tabulated.  This data set 
includes strains that have a known resistance mutation(s).  MPC and MIC values were determined by either plating >109 (MPC) or 105 (MIC) 
respectively on agar containing two-fold dilutions of fluoroquinolones. 
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had a MPC of > 2 μg/ml.  On average, MPC results for the six fluoroquinolones 
tested were 4-fold higher than MIC measurements.     
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3.3.2 Relationship of MPC Results to Fluoroquinolone PK/PD Properties  
             Since the effectiveness of an antibacterial agent is likely to be a function of both 
activity (MPC) and pathogen exposure, I was interested in examining the relationship 
between MPC results and the recommended fluoroquinolone doses and drug PK/PD 
parameters (Table 3.3.3) to see if compounds could be differentiated based on their 
potential to select for resistance during therapy.  Gemifloxacin, the most potent of the 
compounds tested, has a Cmax of 1.6 μg/ml with a half-life of 7-to-8 hrs.  Concentrations 
of gemifloxacin are expected to exceed the MPC for approximately 12 hr of the dosing 
interval.  Moxifloxacin has a maximum serum drug concentration of 4.5 µg/ml and the 
half-life is 12 hr.  Therefore, once daily dosing should keep concentrations of 
moxifloxacin in serum above the MPC90 for the entire length of the dosing interval (i.e., 
24 hr).  Gatifloxacin is expected to maintain serum concentrations above the MPC90 for 
six hours and may require twice-daily dosing.  Levofloxacin concentrations are expected 
to exceed to the MPC90 for 3 hr, thus, restricting the selection of resistant mutants with 
levofloxacin may require higher or more frequent doses.   
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Table 3.3.3  Fluoroquinolone Potency Based on MIC and MPCa Results for Clinical Isolates of S. pneumoniae  
 
 
 
 
aFQ= Fluoroquinolone: Trova = trovafloxacin; Grepa = grepafloxacin; Moxi = moxifloxacin; Gati = gatifloxacin; Levo = levofloxacin; 
Gemi = gemifloxacin.  bMPC results were confirmed using a 72-hour drug screen. Trovafloxacin and grepafloxacin represent MPC90 
adjusted values.  Of the total 220 isolates tested, 58 were non susceptible to penicillin.  Fluoroquinolone susceptibility was unaffected by 
loss of susceptibility to penicillin.  c, d Trovafloxacin and grepafloxacin are not in clinical use and have been withdrawn from the market.  
Trovafloxacin and grepafloxacin represent MPC90 adjusted values.  e,f,g,h,I,j Cmax determinations based on published 200 (trova), 800 
(grepa), 400 (moxi), 500, 400 (gati), 500 (levo) and 320 (gemi) mg doses (5, 44, 69, 95, 135, 197, 222, 333, 343). 
FQa MIC90  
μg/ml 
MPC50b 
μg/ml 
MPC90 b 
μg/ml 
MPC90 b / 
MIC90  
Cmax 
 e,f,g,h,I, j 
(μg/ml) 
Half-life 
(hr) 
T>MPC50 b 
(h) 
T>MPC90 b 
(h) 
AUC0-24/ MIC90 AUC0-24/ 
MPC90 b 
Cmax/ 
MPC90 
b 
Cmax/ 
MIC90 
Trovac 
(n=100) 
 
  0.25     0.5      2    8 3.1    12    20      8       104     13    2   12 
Grepad 
(n=98) 
 
   0.5     1     4    8 2.7    14    10      0        25     2    2   5 
Moxi 
(n=220) 
 
  0.25   0.25    1    4 4.5   12-14   >24    >24       190     48    5   18 
Gati 
(n=220) 
 
  0.5  0.5    2    4 4.2   8-10   21.75     6       103     26   2   8 
Levo 
(n=220) 
 
  1   1    4    4 5.7   12-14    18     3.1       48     12   1   5 
Gemi 
(n=220) 
 
 0.06  0.125   0.5    8 1.6   7-8    16     12     140-280    16-34   3  27-53 
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 Some of the isolates examined at high inoculum concentrations required 
exceptionally high concentrations of fluoroquinolone to prevent colony formation 
(shaded bars Figure 3.3.1).  Since ciprofloxacin and levofloxacin have been used 
extensively in Canada as therapy for respiratory tract infections including those caused 
by S. pneumoniae and since many fluoroquinolone-resistant isolates have emerged, I 
suspected that at least some of the isolates in the present study contained mutations in 
the target genes, parC (topoisomerase IV) and/or gyrA (gyrase). To test this idea, DNA 
was obtained from 22 isolates and the nucleotide sequences of the QRDRs of the two 
genes were determined.  As shown in Table 3.3.4, 17 isolates were parC mutants, 7 of 
which also contained a gyrA mutation. Six of the parC mutants (isolate numbers 
10, 12, 13, 15, 16 and 18) contained alleles known from genetic studies (117) to confer 
resistance (predicted amino acid changes of  Ser-79 to Phe and Asp-83 to Asn). Of 
these, three also contained a GyrA alteration (Ser-81 changed to Phe or Tyr) known to 
confer resistance.  Since MPC is based on the recovery of colonies grown from wild-
type populations, the six resistant mutants (white portions of bars in Figure 3.3.1) were 
excluded from determination of MPC90 results.  For 11 other isolates, the nucleotide 
sequence predicted changes of Ser-52 to Gly, Asn-91 to Asp, or Lys-137 to Asn in the 
ParC protein (shaded portion of bars in Figure 3.3.1).  To my knowledge, genetic 
studies have not been performed that attribute resistance to these alleles. Consequently, 
I did not exclude these strains or those lacking a parC or gyrA mutation from the 
determination of the MPC90.  
 77
Table 3.3.4 Fluoroquinolone-Resistance Alleles Associated With High MPC 
Values 
 
 
 
  
 
 
 
 
                        MPC (μg/ml)a 
 
                      Changes in QRDRc Isolate no. 
Gati Grepab Levo Moxi Trovab Gemi parC gyrA 
wtd 2 4 4 1 1    
10 8 256 16 4 16  D83N (GAT to AAT) S81F (TCC to TTC) 
12 4 >256 32 4 16 2 S79F (TCT to TTT) S81Y (TCC to TAC) 
13 16 64 64  8 4 S79F (TCT to TTT) 
S52G (AGC to GGA) 
N91D (AAC to GAC) 
S114G (AGT to GGT) 
15 16 8 32 8 1 1 S79F (TCT to TTT) None 
16  256   16  S79F (TCT to TTT) S81F (TCC to TTC) 
18  >256   8  S79F (TCT to TTT) None 
27 8 >256 8 2 4 1 S52G (AGC to GGC) 
N91D (AAC to GAC) 
S114G (AGT to GGT) 
33 1 1 4 0.25 2 0.125 K137N (AAG to 
AAT) 
None 
35 2 4 8 0.5 4 0.5 K137N (AAG to 
AAT) 
None 
36 1 1 2 0.5 1 0.06 K137N (AAG to 
AAT) 
None 
37 1 2 2 0.5 1 0.125 K137N (AAG to 
AAT) 
None 
42 1 4 4 0.5 >16 0.125 K137N (AAG to 
AAT) 
None 
43 0.5 1 8  8 0.5 None None 
48 1 2 2 0.5 1 0.125 K137N (AAG to 
AAT) 
None 
51 0.5 2 2  1 0.06 K137N (AAG to 
AAT) 
None 
64 4 4 4 1 1 1 None None 
74 1 16 4 0.5 >8 0.25 S52G (AGC to GGC) None 
78 1 1 2 0.5 1 0.125 None None 
87 2 1 2  0.5 0.125 None None 
89 4 8 4 1 1 0.5 S52G (AGC to GGC) S114G (AGT to GGT) 
91 0.5 2 4 0.5 0.5  S52G (AGC to GGC) 
N91D (AAC to GAC) 
S114G (AGT to GGT) 
103 0.5 4 1 0.5 2 1 None None 
Gati = gatifloxacin; Grepa = grepafloxacin; Levo = levofloxacin; Moxi = moxifloxacin; Trova = 
trovafloxacin; and Gemi = gemifloxacin.  a All MPC values were determined using a 72h screening 
process on drug containing plates, b MPC results obtained for grepafloxacin and trovafloxacin represent 
provisional values which are a two-fold overestimation of the actual MPC value. c QRDR, quinolone 
resistance determining region.  Amino acid in wild-type protein is indicated before its number in the 
protein, followed by the amino acid change. D = aspartic acid; F = phenylalanine; G= glycine; K = Lysine; 
S = serine; Y = tyrosine.  d  wild type strain ATTC 49619. 
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3.3.3 Killing of S. pneumoniae by Fluoroquinolones at the MIC, MPC and 
 Cmax Drug Concentrations 
 
 Like traditional measures of drug susceptibility, the MPC measurement is not 
reflective of bacterial killing.  I was interested in examining the killing of S. 
pneumoniae by gemifloxacin, levofloxacin and moxifloxacin (by conventional kill 
curve methods) for four clinical strains of S. pneumoniae (SP-9, SP-26, SP-69, SP-73).  
All isolates tested were fluoroquinolone susceptible and were tested using inocula of 
105 and 108 CFU/ml against the MIC, MPC, and Cmax drug concentrations.  Table 
3.3.5 summarizes the MICs and MPCs of the pneumococcal isolates tested in the killing 
experiments.  Panel A in Figure 3.3.3 represents the killing of four strains exposed to 
MIC drug concentration for gemifloxacin, moxifloxacin, and levofloxacin using 
inoculums of 105 CFU/ml cultures.   Re-growth was observed with all fluoroquinolones 
tested during the initial 10 min of exposure and up two one hr following exposure to 
levofloxacin and moxifloxacin.  By 4 hr, –1.37, and - 1.0 log reductions in viable counts 
were measured for gemifloxacin and moxifloxacin, and a - 0.06 log reduction in viable 
counts was measured for levofloxacin (table 3.3.6).  After 24 hr, - 5.13, - 2.87, and - 
0.58 log reductions in viable counts were measured for gemifloxacin, moxifloxacin, and 
levofloxacin respectively.  A 73% reduction in viable cells was calculated for 
levofloxacin after 24 hr compared to > 99% for gemifloxacin and moxifloxacin.  When 
108 CFU/ml cultures were tested against the MIC drug concentrations, the log 
reductions in viable counts for gemifloxacin, moxifloxacin and levofloxacin over 4 hr 
were - 0.34, - 0.48, and - 3.62.  
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Table 3.3.5  MIC and MPC Results for Moxifloxacin, Gemifloxacin, and Levofloxacin Against 4 Isolates of S.  
  pneumoniae 
 
 
                                                                          Susceptibility Test 
Moxifloxacin Gemifloxacin Levofloxacin 
Isolate ID 
MIC (μg/ml) MPC (μg/ml) MIC (μg/ml) MPC (μg/ml) MIC (μg/ml) MPC (μg/ml) 
Sp9 0.125 0.5 0.03 0.125 0.5 2 
Sp26 0.125 0.5 0.06 0.25 1 4 
Sp69 0.125 0.5 0.03 0.125 1 2 
Sp73 0.125 1 0.03 0.25 0.5 2 
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Figure 3.3.3  Killing of S. pneumoniae (n=4) by Gemifloxacin, Moxifloxacin, and Levofloxacin at the MIC, 
  MPC and Cmax Drug Concentrations 
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 Four strains of S. pneumoniae were tested by gemifloxacin (triangles), moxifloxacin (circles) and levofloxacin (squares).  The S. 
pneumoniae ATTC 46919 growth control (incubated in the absence of drug) is represented by a blank line.  Graphs depict the average 
inocula tested and the average killing for the four strains tested.  Panels A, C, and E represent killing of 105 CFU/ml cultures.  Panels B, D, 
and F depict killing of 108 CFU/ml cultures.    
D
CBA
FE
MIC MIC CmaxMIC MPC Cmax
Time (hr) 
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Table 3.3.6 Killing of S. pneumoniae (n=4) at Varying Concentrations and Inocula for Clinical Isolates of S. 
  pneumoniae   
                                               Drug Concentration Tested in Kill Experiments 
                                                           (inoculums tested (CFU/ml) 
Time 
(hr) 
 
Measurement 
                                MIC                              MPC                          Cmax 
     Gemi 
(3.89x105) 
   Levo 
(7.81x105) 
    Moxi 
(6.17x105) 
    Gemi 
(3.89x105) 
    Levo 
(7.81x105) 
    Moxi 
(6.17x105) 
    Gemi 
(3.89x105) 
   Levo 
(7.81x105) 
      Moxi 
(6.17x105) 
1 -30.80 +26.60 +2.30 -56.60 -12.90 -58.30 -85.10 -76.40 -90.20 
3 -95.70 -12.90 -80.40 -98.30 -95.60 -96.70 -99.90 -99.64 -99.60 
4 -95.70 -36.90 -90.20 -99.35 -98.64 -99.44 -99.94 -99.82 -99.61 
24 
% reduction/re-
growth 
in viable cells 
>-99.99 -73.89 -99.80 >-99.99 -100 -100 -100 >-99.99 -100 
1 -0.16 +0.10 +0.14 0.00 -0.06 -0.43 -0.86 -0.63 -1.01 
3 -0.76 -0.13 -0.38 -1.77 -1.36 -1.80 -3.19 -2.38 -2.41 
4 -1.37 -0.06 -1.01 -2.19 -1.87 -2.25 -3.68 -2.75 -3.30 
24 
Log reduction/re-
growth 
-5.13 -0.58 -2.87 -5.24 -5.65 -5.49 -5.59 -5.50 -5.78 
                 MIC           MPC Cmax Time 
(hr) 
 
Measurement 
Gemi 
(2.51x108) 
Levo 
(8.81x108 
Moxi 
(6.57x108) 
Gemi 
(2.51x108) 
Levo 
(8.81x108) 
Moxi 
(6.57x108) 
    Gemi 
(2.51x108) 
Levo 
(8.81x108) 
Moxi 
(6.57x108) 
1 -20.1 -17.8 -50.7 +2.9 -32.4 -84.5 -41.49 -52.29 -84.59 
3 -63.5 -13.9 -66.8 -67.4 -48.7 -81.9 -62.89 -70.19 -81.99 
4 -59.50 -99.97 -76.01 -78.62 97.31 -49.30 -92.76 -75.59 -93.65 
24 
% reduction/re-
growth 
in viable cells 
>-99.99 -99.89 >-99.99 >-99.99 >-99.99 >-99.99 -99.77 -99.99 >-99.99 
1 +0.01 -0.09 -0.82 -0.01 -0.17 0.00 -0.76 -0.33 -0.81 
3 -0.24 -3.55 -0.61 -0.49 -0.35 -0.18 -1.08 -0.53 -0.74 
4 -0.34 -3.62 -0.48 -0.67 -1.57 -0.30 -1.14 -0.63 -1.20 
24 
Log reduction/re-
growth 
-4.34 -4.00 -6.03 -2.81 -8.25 -6.92 -2.97 -3.73 -5.03 
 
aMIC=minimum inhibitory concentration; MPC=mutant prevention concentration; Cmax=maximum serum concentration; 
Gemi-gemifloxacin; levo=levofloxacin; moxi=moxifloxacin.
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respectively.  By 24 hr, - 4.34, - 6.03, and - 4.00 log reductions in viable counts were 
measured for gemifloxacin, moxifloxacin, and levofloxacin, respectively, which 
represented > 99% killing for all three fluoroquinolones tested.  At the MPC drug 
concentrations (panel C), - 2.19, - 2.25, and - 1.87 log reductions in viable counts were 
measured after 4 hrs and killing of > 98% was observed for all three fluoroquinolones 
tested.  After 24 hr, > - 5 log reductions in viable counts were measured for all three 
fluoroquinolones tested.  When 108 CFU/ml cultures were exposed to the MPC drug 
concentrations (panel D) log reductions in viable cells were measured at - 0.67, - 0.30, 
and - 1.57 for gemifloxacin, moxifloxacin, and levofloxacin, respectively.  These values 
increased to - 2.9, - 6.9 and - 8.25 respectively after 24 hr and resulted in  > 99.99% 
killing for all three fluoroquinolones.   
When 105 CFU/ml cultures were exposed to the Cmax drug concentration, a >-3 
.0 log reduction was observed after 4 hr for gemifloxacin, levofloxacin and 
moxifloxacin.  After 24 hrs of exposure, - 5.6, - 5.5 and – 5.6 log reductions in viable 
counts were observed for gemifloxacin, levofloxacin and moxifloxacin, respectively.  
No growth was observed for gemifloxacin and moxifloxacin when 105 CFU/ml cultures 
of S. pneumoniae were exposed to the Cmax.  The killing of 108 cultures at the Cmax was 
less than that observed with 106 CFU/ml cultures.  After 4 hours, - 1.1, - 0.6 and - 1.1 
log reductions in growth were seen for gemifloxacin, levofloxacin and moxifloxacin, 
respectively.  By 24 hr, killing of > 2.0 log was observed for all agents tested;  - 2.0, - 
3.1 and - 3.8 log reductions in viable counts were observed for gemifloxacin, 
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levofloxacin and moxifloxacin, respectively, which resulted in > 99.78% killing for all 
three fluoroquinolones. 
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3.4 DISCUSSION   
  Preliminary MPC work with S. pneumoniae (40) revealed a narrow drug 
concentration range for mutant selection and led me to expect that agar plates used in a 
standard two-fold dilution analysis with clinical isolates would exhibit either confluent 
growth or no colonies, at least for the C-8-methoxy compounds.  When 109-to-1010 cells 
were applied per plate, a sharp drop in growth was seen over a concentration range of 
one to four dilutions above the MIC.  When the minimal concentration at which no 
colonies were recovered (MPCpr) was plotted against the number of isolates, distinct 
peaks were seen in the distribution (Figure 3.3.1).  The peak for moxifloxacin appeared 
at the lowest drug concentration; therefore, moxifloxacin was the most potent 
fluoroquinolone by this assay.  I consider the values of MPCpr shown in Figure 3.3.1 to 
be provisional because initial 72 hr screens used to confirm the absence of growth, were 
preformed on non-drug containing plates.  When plates with antibiotic concentrations at 
the MPC were used to confirm the absence of growth, it was determined that MPCpr 
results were a 2-fold overestimation of the MPC.  The observed difference between 
MPCpr and the actual MPC results appear to be due to differences in bacteriostatic 
versus bactericidal activity.  A heavy bacterial suspension containing a mixture of cells 
and capsular polysaccharides may have resulted in a thin “film” on some of the plates 
which in turn may have provided a “protective effect” when the contents of the plate 
were transferred to non-drug containing media and re-incubated for an additional 24 hr.  
These data also argue against complications due to autolysis occurring at high cell 
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density, since that would have made MPCpr an underestimation of MPC.  In a separate 
experiment using a laboratory isolate of S. pneumoniae (ATCC 49619), various 
fluoroquinolone concentrations were tested with dilute bacterial cultures and many agar 
plates so that mutants were recovered as single colonies (41).  The MPC for the ATTC 
49619 strain was 0.5 µg/ml for moxifloxacin and 2.6 µg/ml for levofloxacin.  The 
MPCpr was 1 µg/ml for moxifloxacin and 4 µg/ml for levofloxacin using the 2-fold agar 
dilution assay described in Materials and Methods.  Consequently, MPCpr overestimates 
MPC by an average of 2- fold for both the most active and the least active compounds in 
the present study.  
 When the average of MPCpr results for approximately 100 clinical isolates of S. 
pneumoniae were determined, the five fluoroquinolones could be ranked in terms of 
potency, in descending order, with moxifloxacin, > gatifloxacin = trovafloxacin 
>grepafloxacin > levofloxacin (Table 3.3.1).  Based on MPC results, intrinsic 
differences in the anti-pneumococcal activity for the agents tested were observed and in 
many cases, these differences were not reflected in the MIC measurements of 
susceptibility.  When the MICs and MPCs were determined using the same set of 
isolates for each compound, I found that gemifloxacin had the lowest modal MPC 
(0.125 µg/ml), followed by moxifloxacin (0.5 µg/ml), gatifloxacin (1 µg/ml) and 
levofloxacin (2 µg/ml).  The same rank order was observed when MPCs were 
determined for 90% of the isolates. These data are consistent with gemifloxacin having 
superior in vitro activity when compared to other quinolones (254, 340).  When the 
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MIC at which 90% of the susceptible isolates are inhibited (MIC90) was determined, 
gemifloxacin was also more active than moxifloxacin, gatifloxacin and levofloxacin in 
these comparisons by 2, 3 and 4 doubling dilutions, respectively.  
Since working with large numbers of S. pneumoniae isolates is cumbersome, I 
determined an empirical relationship between MPC and MIC so that the MPC of a drug 
can be calculated from the MIC of the drug.  When the MIC of a drug was measured by 
the agar dilution method, most of the isolates exhibited a 2- to 4-fold difference 
between the MIC and MPCpr for five fluoroquinolones tested. The ratio was slightly 
higher for trovafloxacin and grepafloxacin.  The ratio of the MPC to the MIC of a drug 
was calculated using values that exceeded those for 90% of the isolates (MPC90 and 
MIC90); this ratio was 8 for three of the compounds and 16 for trovafloxacin and 
grepafloxacin.  Similar ratios were obtained for the MPC and the MIC of these drugs 
with the laboratory strain ATCC 49619.  Large numbers of isolates tested against six 
different quinolone agents provides support for the extrapolation of MPC value from the 
MIC for strains of S. pneumoniae, provided few strains with MICs > 2 μg/ml to 
moxifloxacin are present in the population.  Ideally, a small MPC/MIC ratio should be 
targeted and would correlate with a narrow mutant selection window, since the time 
drug concentrations are in above the MIC and below the MPC is expected to be small.  
Increased incidence of fluoroquinolone-resistant S. pneumoniae have been associated 
with treatment of penicillin-resistant cases of pneumonia (53).  However, for the newer 
fluoroquinolones (such as moxifloxacin and gemifloxacin), the value of MIC90 is 
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unaffected by pneumococcal resistance to penicillin and/or other agents (27, 31, 33).  
Likewise, no increase in MPC was associated with the presence of penicillin resistance 
in the present data set.  Thus, potential cross-resistance between the two classes of 
compounds does not appear to be factor in quinolone-resistance. 
Sequence analysis of the QRDR of S. pneumoniae isolates with high MPCs 
revealed the presence of first-step parC mutations and double parC + gyrA mutations.  
While susceptible isolates that harbour a parC mutation lead to higher MPC results, the 
significance of these isolates in the general population remains unknown, in part 
because we are currently unable to detect them.  Apart from DNA sequencing, no 
accurate test can reliably identify isolates with first-step mutations (210).  In the context 
of isolates with pre-existing parC mutations, the value of the MPC measurement will 
become important, because it will be able to identify isolates which are difficult to treat 
isolates.  Recent fluoroquinolone-treatment failures in S. pneumoniae have been 
associated with strains that harboured first-step parC mutations prior to receiving 
treatment (7, 70).  In vitro studies have shown that upon acquisition of a first-step 
mutation, the likelihood of developing a subsequent mutation is enhanced in 
comparison to the development of the first-step mutation itself (128, 207, 282).  Studies 
preformed with E. coli  have shown that a parC resistance allele, which has no effect on 
the MIC of the drugs, can increase by orders of magnitude the frequency at which 
resistant mutants are selected by C-8-methoxy fluoroquinolones (369).  Therefore, 
minimizing the number of strains in the population which contain first-step mutations 
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and restricting their growth are key factors in helping to minimize fluoroquinolone 
resistance. 
A central question surrounding fluoroquinolone resistance is whether the choice 
of fluoroquinolone will influence the selection of first-step mutations and the 
development of resistance.  Less active compounds based on higher MPCs are more 
likely to select for resistant mutants during therapy if MPC concentrations are not 
maintained throughout dosing.  Thus, I expect continued use of ciprofloxacin and 
levofloxacin to seriously shorten the useful lifespan of moxifloxacin, gatifloxacin, and 
gemifloxacin.  Although the latter two compounds may be potent enough to treat 
infection caused by parC mutants (selected by ciprofloxacin and levofloxacin), parC 
gyrA double mutants would be readily selected by newer generation fluoroquinolones if 
the pathogens already contain a parC resistance allele. Thus, slowing the development 
of resistance may necessitate careful management of compounds within the same 
general class (41).      
The endpoint of antibiotic dosing strategies, such as those based on area under 
the inhibitory concentration curve, has often employed clearance of infection measured 
either as survival in animal models or loss of symptoms in humans. Widespread 
development of resistance suggests that consideration should also be given to restricting 
the selection of resistant mutants.  One approach has utilized the ratio of maximum 
concentration of drug in serum to the MIC of the drugs andsubsequent values have been 
found that restrict mutant outgrowth in vitro (25) and correlate with animal survival 
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(93).  However, this ratio does not take into account the time for which drug 
concentrations remain high and which may be important for preventing development of 
resistance.  Consequently, I have examined the relationship of the MPC to 
fluoroquinolone pharmacokinetic properties.   
Compounds and dosing protocols can readily be compared for the time that drug 
concentrations in tissue/serum exceed the MPC.  I have previously suggested that for 
the MPC to be a therapeutically useful parameter, its value must be below serum and 
tissue drug concentrations attained following administration of drug doses that are safe 
for patients (41, 149).  Gemifloxacin, the most potent of the compounds tested, has a 
Cmax of 1.6 μg/ml with a half-life of 7-to-8 hr.  Concentrations of gemifloxacin are 
expected to exceed the MPC for approximately 12 hr of the dosing interval.  
Moxifloxacin has a maximum serum drug concentration of 4.5 µg/ml and the half-life is 
12 hr.  As such, once daily dosing should keep concentrations of moxifloxacin in serum 
above the MPC90 for the entire length of the dosing interval (i.e., 24 hr) and minimize 
the potential that resistant mutant will be selected during therapy.  Gatifloxacin may 
also restrict the selection of resistant mutants, especially if administered twice daily.  
Levofloxacin may require higher doses, perhaps administered two to three times daily, 
to attain the same potency with respect to restricting selection of resistant mutants. 
Examination of the concentrations present at sites of infection and in infected 
tissues will help to further define drug concentrations which inhibit first-step mutants 
and since quinolone concentrations in relevant tissue may be higher than in serum (23, 
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162), dosing based on the MPC may serve as a realistic approach for minimizing 
resistance and maximizing therapeutic outcome.  Animal experiments and clinical trials 
are now required to test these hypotheses.  The serum drug concentrations listed in 
Table 3.4.1 represent total concentrations.  Fluoroquinolones bind to serum proteins, so 
additional corrections may be necessary when particular compounds are compared.  
Protein binding varies among the compounds, but in general less than half of the total 
drug that is present is bound and consequently, protein binding probably has little effect 
on the conclusions reached above.  The time serum/tissue concentrations exceed the 
MPC (T > MPC) will directly correlate with reduced likelihood of selecting resistant 
mutants because concentrations required to inhibit their growth (and possibly kill) will 
be maintained throughout dosing.  For fluoroquinolones, the Cmax/MIC (or 
Cmax/MPC) ratio has been suggested as the most important PK property associated 
with bacterial eradication (94).  Thus, it could be perceived that that time above the 
MIC/MPC is not the most useful PK parameter used to assess fluoroquinolone potency.  
Recently, Shenteg et al  (316, 319) summarized PK/PD data relating to clinical trials, 
animal studies, and in vitro models with fluoroquinolones and concluded that AUIC 
values of  >100 are  predictive of clinical and microbiologic outcomes and reduced 
incidence of resistance for fluoroquinolones.  Like the T > MPC relationship, the AUIC 
takes into account the length of time a pathogen is exposed to inhibitory concentrations 
throughout a pharmacokinetic profile.  Therefore, like the AUC, the T > MPC 
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Table 3.4.1 PK/PD Properties for Fluoroquinolones 
 
Agent Dose  
(mg) 
Cmax  
(μg/ml) 
Tmax 
(hr) 
 
t1/2 
(hr) 
AUC 
(mg x hr/l) 
 
Cmax/MPC % Protein 
 binding 
Ref 
500  5.2-6.2 47.7 1.3-1.55 
750  7.13-11 82 1.8-2.8 
500 (I.V) 6.4 48.3 1.6 
Levofloxacin 
750 (I.V) 12.1 
1.7 6.3-7.4 
110 3 
26-31 (8, 55-57, 68, 
111, 135, 364) 
200  1.71  0.9 Gatifloxacin 
400  3.4-4.2 
1.5 8.4 31.7-33 
 1.7-2.1 
20 
 
 (28, 91, 257, 
355, 364) 
Gemifloxacin 320  1.19-1.5 1-2 8 9.3 2.38-3 58 (5, 364) 
Moxifloxacin 400 4.5 0.8-2 12 48-200 4.5 37 (33, 68, 333, 364)
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relationship does not contradict concentration dependent killing by fluoroquinolones, 
but may in fact complement it (32).  Fluoroquinolones (such as moxifloxacin) that 
maintain serum/tissue concentrations in excess of the MPC throughout the dosing 
interval are expected to restrict the selection of resistant mutants.   
Direct comparisons of fluoroquinolones based on the MPC requires examination 
of the MPC result in relation to resistance breakpoints, drug PK, the type(s) of mutants 
selected, and the clinical history.  For example, comparison of moxifloxacin and 
levofloxacin revealed that 9% of the isolates tested with moxifloxacin had a MPC value 
at or above an intermediate breakpoint (i.e., > 2 μg/ml), compared to 25% of the isolates 
tested against levofloxacin, which had MPC values at or above an intermediate 
breakpoint (> 4 μg/ml) for resistance.  Thus despite the fact that a larger fraction of 
isolates tested against levofloxacin had a lower MPC/MIC ratio than was seen for 
moxifloxacin, a larger number of isolates tested against levofloxacin had a MPC value 
that would be considered intermediate or above by conventional susceptibility 
guidelines.  The resistance breakpoints established by the NCCLS serve as a surrogate 
marker of whether therapy is likely to be successful, and strains displaying intermediate 
and/or resistant phenotypes have typically been associated with clinical failures and the 
development of resistance (7, 70, 75, 351).  The larger numbers of levofloxacin MPCs 
that fell within an intermediate breakpoint are of particular concern in light of recent 
evidence demonstrating that over half of the S. pneumoniae population with a 
levofloxacin MIC of 2 µg/ml, may contain a first-step mutation in parC.   The 
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requirement of first-step mutations in the subsequent development of high-level 
fluoroquinolone resistance has been well documented (164, 207, 210, 275, 370) and 
supports the hypothesis that inhibiting first-step resistant mutants with MPC drug 
concentrations will severely restrict the selection of fluoroquinolone resistant strains.  
Thus, the significance of the MPC results should be interpreted in relation to:  1.) The 
pharmacokinetics dose-response profile of the drug.  2.) The relationship between the 
MPC and the susceptibility breakpoint for resistance.  3.) The types of mutants selected, 
and, 4.) the overall potency of the agent.  These factors are likely to differ among agents 
within the fluoroquinolone class of antimicrobials.   
 Overall, the MPC measurement is a useful tool in determining appropriate 
quinolone therapy for the treatment of infections caused by S. pneumoniae.  First-step 
resistant mutants of S. pneumoniae were selected from susceptible cultures when > 109 
cells were applied to agar-containing plates seeded with increasing concentrations of 
quinolones. In all cases, the MPC measurement was in excess of the MICs of the wild-
type cultures.  Fluoroquinolones that possess low MPC values, maintain serum/tissue 
concentrations above the MPC90 for the entire length of a dosing interval, maintain a 
narrow MPC/MIC relationship and possess bactericidal activity against first-step 
resistant mutants are good candidates for restricting the selection of fluoroquinolone-
resistant S. pneumoniae.  Based on this criterion, moxifloxacin and gemifloxacin are 
likely to severely restrict the development of resistant mutants if the principles of MPC 
are applied during dosing.  Gatifloxacin may require twice daily dosing in order to 
 94
restrict the development of resistant mutants.  Levofloxacin had the highest MPCs of all 
the fluoroquinolones tested, and may require additional and/or higher doses to restrict 
the selection of resistant mutants of S. pneumoniae.   
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4.0 ENRICHMENT OF FLUOROQUINOLONE-RESISTANT 
 MUTANT SUBPOPULATIONS OF P. AERUGINOSA 
 
4.1 Abstract 
 Ciprofloxacin and levofloxacin are potent first-line fluoroquinolones which are 
often used in combination with anti-pseudomonal cephalosporins and/or 
aminoglycosides, for the treatment of infections caused by P. aeruginosa.   However, 
microbiological factors (MIC, MBC, killing) and PK considerations such as the 
Cmax/MIC and AUC, have not always correlated with the clinical outcome and 
development of resistance in cases of infections caused by P. aeruginosa.  In an attempt 
to examine unresolved issues related to selection of resistant mutants of P. aeruginosa,   
I measured MPC values for 155 clinical isolates of P. aeruginosa for ciprofloxacin and 
levofloxacin.  The MPC90 values for ciprofloxacin and levofloxacin were 4 and 16 
μg/ml, respectively, suggesting that neither ciprofloxacin nor levofloxacin is suitable as 
monotherapy.  Based on currently administered I.V. doses, ciprofloxacin is projected to 
remain in excess of the MPC90 for 5.5 hr while no currently recommended dose of 
levofloxacin is expected to exceed the MPC90 value.  Levofloxacin was > 2-fold less 
active against first-step resistant mutants of P. aeruginosa compared to ciprofloxacin, 
and for strains over expressing four different efflux mechanisms, levofloxacin was an 
average of 3 times less active than ciprofloxacin.  When mutant selection was examined 
for six susceptible strains of P. aeruginosa, a larger proportion of the mutant population 
was recovered when tested against levofloxacin.  DNA sequence analysis of selected 
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mutants revealed alterations in the gyrA and parC genes.   Killing experiments 
preformed at the MPC and MIC drug concentrations for 106 and 1010 CFU/ml cultures 
demonstrated that maintaining MPC drug concentrations severely restricts the selection 
of resistant mutants.  Preliminary results from a rat abscess model of infection revealed 
that resistant mutants are readily selected when ciprofloxacin and levofloxacin were 
dosed once a day.  Collectively, MPC experiments conducted with ciprofloxaicn and 
levofloxacin against clinical isolates of P. aeruginosa provide a microbiological basis 
for observed clinical differences between ciprofloxacin and levofloxacin against P. 
aeruginosa and support the hypothesis that superior clinical performance of 
ciprofloxacin correlates with activity against resistant mutant subpopulations measured 
in vitro.      
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4.2 INTRODUCTION 
Opportunistic infections caused by P. aeruginosa are a major cause of 
morbidity and mortality in nosocomial settings as well as in patients with significant 
underlying disease (150).  Such infections may occur at any anatomical site, but 
frequently they are located in the respiratory and urinary tracts (125).   The frequency 
with which P. aeruginosa causes disease is reliably estimated from annual surveillance 
data.  P. aeruginosa was the second most common cause of nosocomial pneumonia 
(14% of cases), the third most common cause of urinary tract infection (7%), the fourth 
most common cause of surgical site infection (8%), the seventh most frequently isolated 
pathogen from the bloodstream (2%) and the fifth most common isolate (9%) overall 
from all sites (1, 50, 174, 178).  Intrinsic resistance of P. aeruginosa to a wide variety of 
antibiotics has made treatment of these infections difficult, often requiring combination 
therapies and only a limited number of antibiotic agents retain reliable activity against 
this patahogen, including aminoglycosides, anti-pseudomonal penicillins, carbapenems, 
cephalosporins, and fluoroquinolones (124, 125, 127).  Fluoroquinolones are among the 
more useful agents because they possess good antibacterial activity, oral bioavailabity, 
tissue penetration and sustainable drug concentrations (9, 28, 132, 364).  However, in 
some instances, clinical success has sometimes been only modest and failure is often 
associated with the presence of resistant organisms (108, 228, 238, 280) .   
 Recent reports have documented declining susceptibility of ciprofloxacin and 
other contemporary fluoroquinolones when tested by commercial or reference methods 
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against clinical isolates of P. aeruginosa (183).  For example, among 404 P. 
aeruginosa strains isolated in 2000, resistance rates were 20.5, 20.3 and 23.0% for 
ciprofloxacin, levofloxacin and gatifloxacin, respectively, (183) and were higher  than 
those observed for ceftazidime, gentamicin, imipenem and piperacillin/tazobactam 
(susceptibility range, 82.9-to-89.9%).  Sahm et al  (310) reported 21.6-to-24.9% 
resistance  to ciprofloxacin and levofloxacin, respectively, against isolates of  P. 
aeruginosa collected by two surveillance networks during 1999-to-2000.  An 
additional study reported a 10% decrease in fluoroquinolone susceptibility among 
isolates of P. aeruginosa from 1994-to-2000 (259).  Globally, fluoroquinolone 
resistance rates to P. aeruginosa range from 12-to-75% (76, 339, 344), however, 
because of a lack of effective alternative agents, fluoroquinolones remain first-line 
agents for the treatment of severe pseudomonal infections (106, 124-127, 178, 262).  
Therefore, retaining and protecting fluoroquinolone activity against P. aeruginosa 
remains important.   
 Fluoroquinolone treatment of infection caused by P. aeruginosa may represent a 
situation in which clinical resistance reflects activity mutant sub-populations.  Two 
commonly used compounds, ciprofloxacin and levofloxacin, are not readily 
distinguished by traditional measures: ciprofloxacin has greater intrinsic activity and is 
better able to block pathogen growth as indicated by a 2-fold lower MIC, while 
levofloxacin is more lethal at equivalent concentrations and achieves higher 
serum/tissue concentrations (225, 323).  The debate over fluoroquinolone potency 
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against P. aeruginosa is exemplified in a recent report by Jones et al  (177) who 
documented the contemporary equality in fluoroquinolone activity against P. 
aeruginosa based on overall rates of fluoroquinolone resistance (177).  Conventional 
wisdom suggests that differences in intrinsic activities, bacterial killing, and drug PK, 
serve to normalize anti-pseudomonal activities of ciprofloxacin and levofloxacin, 
however, several clinical observations suggest that preferential use of specific agents 
may escalate the rate of quinolone-resistant P. aeruginosa (22, 283, 303).   
Historically, ciprofloxacin has been the fluoroquinolone of choice for treating 
pseudomonal infections because it has the highest intrinsic activity (36), but pricing 
differences between ciprofloxacin and ofloxacin/levofloxacin prompted some hospital 
centres to switch to ofloxacin and, subsequently levofloxacin for the treatment of 
infections caused by P. aeruginosa.  Peterson et al  (283) discovered that a change from 
ciprofloxacin to ofloxacin use correlated with a 20% increase in fluoroquinolone 
resistance that was partially reversed when ciprofloxacin use was reinstated.  Rifenberg 
et al  (303) investigated the influence of fluoroquinolone purchasing patterns on 
antimicrobial expenditures and P. aeruginosa susceptibility.  As part of this study, 109 
hospitals were followed over a 4-year period.  P. aeruginosa susceptibilities were 
compared between hospitals that had ciprofloxacin or ofloxacin on their formularies and 
did not change to another quinolone as compared to those institutions that switched 
from ciprofloxacin to ofloxacin.  A 5.4% decrease in overall fluoroquinolone 
susceptibility correlated with a $300.00 (US dollars) increase in ofloxacin expenditure 
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per occupied bed.  No associations were found between increased ciprofloxacin 
expenditures and subsequent changes in P. aeruginosa susceptibility to quinolones 
(303).  A subsequent follow up study, which included data collected for levofloxacin, 
confirmed a 5% increase in quinolone resistance which occurred for every $300 (US 
dollars) increase in levofloxacin expenditure per occupied bed which was not observed 
for ciprofloxacin (22).  The question of whether a change in quinolone use could 
influence class resistance was again raised by Pangrazzi et al  (279) who observed  
decreased activity of fluoroquinolones to P. aeruginosa (78% to70%) in one hospital 
following an eight month  conversion from ciprofloxacin to levofloxacin.  While this 
data suggests the switch to levofloxacin may have impacted P. aeruginosa susceptibility 
to fluoroquinolones, this study is limited by the fact that observations occurred over a 
relatively short time frame (8 months) and no statistical significance was identified.  
Polk et al  (289, 290) reported on trends in fluoroquinolone prescribing from 35 US 
hospitals in relation to fluoroquinolone resistance in P. aeruginosa.  Total 
fluoroquinolone use remained stable over two years, however, levofloxacin use 
increased significantly while ciprofloxacin use decreased slightly.  Resistance of P. 
aeruginosa to quinolones increased in 22 of the 35 hospitals and a significant positive 
relationship between total fluoroquinolone use and resistance to P. aeruginosa was seen 
(r=0.54, p=0.01).  Mohr et al  (243) studied the impact of antimicrobial usage on 
susceptibility of P. aeruginosa over an eight year period at a community-based 700 bed 
teaching hospital.  The study period ranged from 1995-to-2002 and a statistically 
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significant correlation was seen between 4th generation cephalosporin (r2=0.782, 
p=0.004) or levofloxacin use (r2=0.726, p=0.007) and the development of quinolone- 
resistant P. aeruginosa.  No such relationship existed for other antimicrobial agents 
investigated which included ciprofloxacin, suggesting that the development of 
fluoroquinolone resistance is associated with the use of individual agents rather than 
overall antibiotic consumption.   
These findings raise the question of whether differences in fluoroquinolone 
resistance could be attributed to undefined microbiological properties of ciprofloxacin 
and levofloxacin.  The MPC is a measure of the selection potential for resistance for any 
given fluoroquinolone-pathogen combination and is defined by the lowest antimicrobial 
concentration required to inhibit the most resistant first-step resistant mutant present in 
large, overall susceptible bacterial populations.  Threshold conditions for restricting 
mutant growth have been defined in vitro (86) and in mice (179), however, few clear 
relationships have been established between clinical performance and in vitro, anti-
mutant activity.  MPC results for ciprofloxacin and levofloxacin for clinical isolates of 
P. aeruginosa were examined and compared in an attempt to identify possible 
differences between the ability of the antimicrobial agents to prevent emergence of 
antimicrobial resistance.   
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4.3       RESULTS 
  
 4.3.1 Effect of Fluoroquinolone Concentration on Mutant Recovery  
  for Fluoroquinolone-Susceptible Clinical Isolates of P. aeruginosa. 
 
 The recovery of colonies from 1010 CFU/ml cultures of fluoroquinolone-
susceptible clinical isolates of P. aeruginosa (n=6) tested against increasing 
concentrations of ciprofloxacin or levofloxacin resulted in a two-stage decline in CFUs 
(Figure 4.3.1).  Low to moderate fluoroquinolone concentrations (< 0.5 μg/ml) produced 
a gradual decline in CFUs of P. aeruginosa when tested against ciprofloxacin and 
levofloxacin, respectively.  The MPC measurement can be characterized as a 
characteristic two-stage decline in CFUs when 1010 cells/ml were applied to agar plates 
containing increasing concentrations of fluoroquinolones.  The initial MIC, MPC, and 
numbers of cells tested in each experiment are listed in Table 4.3.1.  The first stage in 
colony decline results from the decline of susceptible cells and occurred at 
fluoroquinolone concentrations that approximated the MIC of the wild-type strains 
(ciprofloxacin MIC = 0.21 μg/ml, levofloxacin MIC = 0.7 μg/ml).  At fluoroquinolone 
concentrations above the MIC of the wild-type strains, mutant growth could be 
measured via a generalized plateau region in colony recovery.  Increasing 
fluoroquinolone concentrations resulted in a second decline in CFUs until a 
concentration of ciprofloxacin and levofloxacin was reached which prevented the 
growth of the most-resistant cell present in 1010 CFU/ml cultures.  This concentration 
defined the MPC for each fluoroquinolone and occurred at 3 and 9 μg/ml for 
ciprofloxacin and levofloxacin, respectively.  Comparison of the anti-mutant  
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Figure 4.3.1 Effect of Fluoroquinolone Concentration on Recovery of  
  P. aeruginosa Colonies from Six Fluoroquinolone-Susceptible  
  Isolates  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.1.  Effect of fluoroquinolone concentration on recovery of P. aeruginosa 
colonies.  Clinical isolates were applied to tTSA plates containing the indicated 
concentrations of ciprofloxacin (filled circle) or levofloxacin (open triangle).  The  
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 Clinical isolates were applied to TSA plates containing the indicated concentrations of ciprofloxacin (filled 
circle) or levofloxacin (open triangle).  The fraction of input cells recovered as mutants was determined after re-
growth of colonies on drug-free agar followed by regrowth on agar containing the fluoroquinolone at the initial 
drug selection concentration.  Each data point reflects the average decline in CFUs from six susceptible isolates 
of P. aeruginosa when 1010 cells/ml were tested aginst defined ciprofloxacin and levofloxacin concentrations.  
Panel A.  Average values for seven susceptible clinical isolates (ciprofloxacin MIC = 0.21 μg/ml; levofloxacin 
MIC = 0.7 μg/ml).   Panel B represents the recovery of resistant mutants as a linear function of fluoroquinolone 
concentration. Differences in mutant recovery between ciprofloxacin and levofloxacin were determined based on 
the area for which mutant selection occurred which is expressed in a ciprofloxacin:levofloxacin ratio of 1:1500.  
Error bars represent the standard deviation in the measurements for the six strains testd 
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 Table 4.3.1 MIC and MPC Results for Clinical Isolates of P. aeruginosa Used in Mutant Selection Curves  
 
a MIC results obtained using microbroth dilution method.  bSusceptibility based on NCCLS guidelines for susceptible (S), 
intermediate (I), resistant (R) (258).  Ciprofloxacin S, I, R = < 1, 2, > 4 μg/ml.  Levofloxacin S, I, R = < 2, 4, > 8 μg/ml.    
 
                            MICa measurement                       MPC measurement 
Ciprofloxacin Levofloxacin Ciprofloxacin Levofloxacin 
Isolate Source 
# of cells 
 Tested 
(CFU) 
MIC  
(μg/ml)
# of cells 
 tested 
MIC  
(μg/ml)
Susceptibility 
Resultb # of cells 
 Tested 
(CFU/0.3ml)
MPC  
(μg/ml)
# of cells 
 tested 
MPC  
(μg/ml) 
PA – 25 Skin and  
Soft  tissue 
2.1 x106 <0.125 2.1 x106 0.5 Susceptible 5.0 x 1010 1.75 5.0 x 1010 9 
RV – 85431 Sputum 5.8 x 105 0.25 5.8 x 105 
 
1 Susceptible 4.4 x 1010 3.25 4.4 x 1010 12 
RV – 77900 Abdominal  
fluid 
8.0 x 105 <0.125 8.0 x 105 0.5 Susceptible 4.8 x 1010 2 4.8 x 1010 8 
Mt.S – 7 Urine 8.7 x105 <0.125 8.7 x105 
 
0.5 Susceptible 4.6 x 1010 2.5 4.6 x 1010 8 
OGH – 4  Skin and  
Soft tissue 
1.1 x106  <0.125 1.1 x106 0.5 Susceptible 4.1 x 1010 1.125 4.1 x 1010 4 
St.C – 14344 Sputum 3.2 x 105 0.5 3.2 x 105 
 
1 Susceptible 2.1 x 1010  2.5 2.1 x 1010 11 
Ave of 6  
Susceptible 
 Isolates 
 9.6 x 105 0.21 9.6 x 105 0.7 Susceptible 4.2 x 1010 2.2 4.2 x 1010 8.7 
CBRH – 25138 Urine 
 
1.0 x 106 2 1.0 x 106 
 
4 Intermediate 5.7 x 1010 8 5.7 x 1010 16 
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activities for ciprofloxacin and levofloxacin could be quantitatively assessed by 
examining the numbers of mutants selected with respective ciprofloxacin and 
levofloxacin MSWs.  Thus, the frequency with which mutants are selected by each drug 
could be quantitatively described in the relative area created during mutant selection.  
Levofloxacin was 1500 times (a > 3 log difference in CFU) more efficient at selecting 
mutant colonies of P. aeruginosa at comparable concentrations.   
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 4.3.2 Effect of Fluoroquinolone Concentration on Mutant Recovery  
  for a Clinical Isolate of P. aeruginosa  
 
 The effect of fluoroquinolone concentration of mutant recovery from a clinical 
isolate (CBRH 25138) with intermediate susceptibility to ciprofloxacin (MIC=2 μg/ml) 
and levofloxacin (MIC=4 μg/ml) was examined in reference to susceptible strains 
(Figure 4.3.2).  As expected, the recovery of CFU that occurred for a strain with 
intermediate susceptibility resulted in a shift in the mutant selection curve toward higher 
concentrations (ciprofloxacin MPC= 8 μg/ml, levofloxacin MPC =16 μg/ml).  At 
fluoroquinolone concentrations which approximated the MIC for ciprofloxacin (MIC= 2 
μg/ml) and levofloxacin (MIC= 4 μg/ml), a sharp decline in colony recovery was seen 
which occurred for approximately half of the cells present in the inoculums tested (i.e., 
105 CFU).  In comparison with mutants recovered from susceptible strains, the plateau 
in mutant recovery for a strain with intermediate fluoroquinolone susceptible occurred 
over a broad concentration range for ciprofloxacin and levofloxacin, respectively.  
Mutant growth was observed at ciprofloxacin concentrations encompassing 2-to-7 
μg/ml.  Thus, the plateau in colony recovery seen with ciprofloxacin concentrations was 
shifted an average of 4-fold, in the direction of higher ciprofloxacin concentrations 
when compared to colony recovery in susceptible strains.  For levofloxacin, mutant 
growth occurred over drug concentrations ranging from 3-to-15 μg/ml, which shifted 
the mutant selection curve by an average of 3-fold in the direction of higher 
levofloxacin concentrations.   The MPC for ciprofloxacin and levofloxacin were   
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Figure 4.3.2 Effect of Fluoroquinolone Concentration on Mutant Recovery for  
  Clinical Isolates of P. aeruginosa  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical isolates were applied to tTSA plates containing the indicated concentrations of ciprofloxacin 
(filled circle) or levofloxacin (open triangle).  The fraction of input cells recovered as mutants were 
determined after re-growth of colonies on drug-free agar followed by regrowth on agar containing the 
fluoroquinolone at the initial drug selection concentration.  Each data point reflects the average decline in 
CFUs from six susceptible isolates of P. aeruginosa when 1010 CFU/ml inoculums when tested against a 
defined ciprofloxacin or levofloxacin concentration Panel A. represents the recovery of colonies P. 
aeruginosa colonies from six fluoroquinolone susceptible isolates of P. aeruginosa.  Panel B.  represents 
colony recovery from a 1010 CFU/ml culture of P. aeruginosa (isolate CBRH 25138) with intermediate 
susceptibility, ciprofloxacin MIC=2 μg/ml; levofloxacin MIC=4 μg/ml).  Arrows indicate drug 
concentrations from which colonies were examined for gyrA and parC QRDR resistance mutations.  A 
gyrA mutation was observed only at the point indicated.         
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measured at 3 and 8.5 μg/ml, respectively.  Thus, the preferential ability of 
ciprofloxacin to restrict mutant growth was also evident with an isolate having 
intermediate susceptibility.  Sequence analysis of 14 mutants (see arrows figure 4.3.2B) 
revealed that QRDR mutants (dashed arrow gyrA T83I) were selected at a levofloxacin 
concentration of 14 μg/ml (n=3 mutants).  No QRDR mutants were recovered from 
selected mutants (n=6) recovered from agar plates containing ciprofloxacin 
concentrations.   
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4.3.3 Distribution of MIC and MPC Results for 155 Clinical Isolates of  
 P. aeruginosa 
 
To obtain a more general view of fluoroquinolone susceptibility, I measured 
MIC and MPC values with 155 clinical isolates of P. aeruginosa using conventional  
2-fold dilutional increments of ciprofloxacin and levofloxacin concentrations in agar 
plates (Figure 4.3.3).  By traditional susceptibility measures the compounds were 
similar.  MICs for ciprofloxacin ranged from 0.06-4 μg/ml, MIC50 and MIC90 values 
were <0.125 and 1μg/ml, respectively.  Based on NCCLS breakpoints (258), 95%, 3% 
and 2% of the isolates, respectively, were susceptible, intermediate and resistant, to 
ciprofloxacin.  MICs for levofloxacin ranged from 0.125-8 μg/ml, MIC50 and MIC90 
values were 0.5 and μg/ml, with 96%, 1% and 3% considered susceptible, intermediate 
and resistant, respectively.  MPC results for ciprofloxacin and levofloxacin were 4- to 
32-fold higher than MIC results.  As expected from data in Figure 4.3.1, the MPC for 
ciprofloxacin was lower than for levofloxacin (Figure 4.3.3; modal values were 2 and 8 
μg/ml, respectively; values of MPC90 were 4 μg/ml and 16 μg/ml, respectively).  Thus, 
the upper boundary of the mutant selection window (i.e., the MPC) was 4 times higher 
for levofloxacin.  Ciprofloxacin was 2- to 8-fold more active than levofloxacin as 
determined by comparison of MPC results.  The relative distributions of MPC results 
were affected only slightly by restricting the analysis to highly susceptible isolates 
(Figure 4.3.4) or in most cases by considering the anatomical site from which the 
isolates were obtained (Figures 4.3.4C-E).  Urinary tract isolates displayed a shift in the  
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 Figure 4.3.3 MIC and MPC Distributions for 155 Clinical Isolates of 
P. aeruginosa Against Ciprofloxacin and Levofloxacin 
 
 
 
 
 
 
 
Panel A. depicts MIC (shaded bars) and MPC results (open bars) for 155 clinical 
isolates of P. aeruginosa against ciprofloxacin.  Modal MIC and MPC values for 
ciprofloxacin were 0.125 and 0.5 μg/ml, respectively.  Ciprofloxacin MIC90 and MPC90 
values were 0.5 and 2  μg/ml, respectively.  Panel B. depicts MIC (open bars) and MPC 
results (filled bars) for 155 clinical isolates of P. aeruginosa against levofloxacin.  
Modal MIC and MPC values were 0.5 and 8 μg/ml, respectively, and MIC90 and MPC90 
were 1 and 16 μg/ml, respectively.   
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Figure 4.3.4 MPC results for 155 Clinical Isolates of P. aeruginosa Against 
Ciprofloxacin and Levofloxacin 
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Distribution of MPC for clinical isolates of P. aeruginosa. Panel A. All isolates tested (n = 155).  Panel B. 
Isolates having low values of MIC (≤ 0.5 μg/ml) to both ciprofloxacin and levofloxacin (n = 105).  Panel 
C.  Respiratory isolates (n = 55).  Panel D. Skin and soft tissue isolates (n = 24), Panel E.  Urinary tract 
isolates (n = 72).  Four blood isolates are not shown.  Similar results were obtained in a replicate 
experiment; solid bars indicate MPC for ciprofloxacin, open bars indicate levofloxacin.  The modal MPC 
and MPC90 results for ciprofloxacin against respiratory, skin and soft tissue and urinary tract isolates of P. 
aeruginosa were 2 and 4 μg/ml, respectively; for levofloxacin these values were 8 and 16 μg/ml.  The 
MPC distributions were largely unaffected by the source of isolation although a noticeable shift in the 
MPC  distributions for urinary tract isolates was observed which is consistent with a history of 
ciprofloxacin use in UTIs. 
MPC (μg/ml) 
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distribution to higher drug concentrations; however, the shift in MPC 
distributions observed in the urinary subset of isolates did not change the overall 
MPC90 distribution.    
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4.3.4 Effect of Individual MIC Results on Ciprofloxacin and Levofloxacin 
 MPC Distributions 
 
 Analysis of highly susceptible isolates of P. aeruginosa (MIC = < 0.5 μg/ml) 
had little effect on the distribution of MPC results relative to the total population tested.  
I was interested in examining the effect of the initial degree of susceptibility (as 
assessed by the MIC) on the MPC distributions for ciprofloxacin and levofloxacin 
against clinical isolates of P. aeruginosa.  Figure 4.3.5 shows the MPC distributions as 
they related to initial MIC results.  As expected, isolates with low MIC tended to 
correlate with low MPC results.  However, MIC results could not directly predict MPC 
results in some isolates and different MPC results were observed with isolates with 
identical MIC values.  For example, 92/155 isolates of P. aeruginosa had a 
ciprofloxacin MPC of 2 μg/ml.  Of the 92 isolates, 71% (65/92), 14% (13/92), 12% 
(11/92), and 3% (1/92), had ciprofloxacin MICs of < 0.125, 0.25, 0.5, and 1, μg/ml, 
respectively.      
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Figure 4.3.5 Initial MIC Results and MPC Distributions for Ciprofloxacin and 
  Levofloxacin for 155 Clinical Isolates of P. aeruginosa  
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The number of isolates with corresponding MIC results to ciprofloxacin (panel A.) and 
levofloxacin (panel B.) are shown.  The effect of MIC results on fluoroquinolone MPC 
distributions are depicted in shaded bars (see legend)  
A
B
Fluoroquinolone MIC (μg/ml) 
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4.3.5 Relationship Between MPC Results and Susceptibility Breakpoints 
MPC values can also be related to susceptibility breakpoints, which serve as 
empirical thresholds below which clinical success is expected to occur.   NCCLS 
breakpoints for ciprofloxacin and levofloxacin were applied to MPC results for the 155 
clinical isolates of P. aeruginosa (Figure 4.3.6).  Breakpoints were determined based on 
NCCLS guidelines for ciprofloxacin and levofloxacin against P. aeruginosa (258).  
Briefly, results are reported as susceptible (S), intermediate (I), or resistant (R) 
(ciprofloxacin S, I, R = < 1, 2, > 4μg/ml and levofloxacin S, I, R = < 2, 4, > 8 μg/ml).  
Based on MIC results, both ciprofloxacin and levofloxacin had comparable 
susceptibility against clinical isolates of P. aeruginosa.  For ciprofloxacin, the 
percentage of isolates conferring an S, I and R phenotype were 95%, 3% and 2%, 
respectively.  For levofloxacin 96%, 1% and 3% of the isolates were classified as S, R, 
or I based on MIC results.  Comparison of MPC results to NCCLS breakpoints for 
resistance revealed that 36% and 67% of the isolates tested against ciprofloxacin and 
levofloxacin would now be considered resistant.  This finding suggests that neither 
antimicrobial agent would be appropriate for use as monotherapy in the treatment of P. 
aeruginosa.  Based on MPC results, the percentage of isolates with an S, I, or R 
phenotype were 5%, 59% and 36% for ciprofloxacin and 3%, 30% and 67% for 
levofloxacin.   
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Figure 4.3.6 Relationship of MIC and MPC Results to NCCLS Susceptibility 
  Breakpoints with P. aeruginosa 
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 NCCLS breakpoints for resistance were applied to 155 clinical isolates of P. aeruingosa based 
on MIC and MPC results.  Results are reported in percentage of total isolates.  Susceptible 
(open areas), intermediate (shaded areas) or resistant (filled areas).  Figures A and B illustrate 
MIC distributions for ciprofloxacin and levofloxacin, respectively.  C and D illustrate MPC 
results for ciprofloxacin and levofloxacin, respectively.   
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 4.3.6 Characterization of First-Step Mutants 
4.3.6.1  Phenotypic Demonstration of Resistance in Recovered      
  Mutants  
 
I screened 204 mutants recovered from ciprofloxacin and levofloxacin 
containing plates using standardized microbroth dilution methods in order to examine 
the stability and susceptibility of recovered mutant colonies.  The MICs of selected 
mutants were recorded as “MICrecovered “ values and compared to the MIC of the parental 
strains (Table 4.3.2).  For ciprofloxacin, the modal MIC of the original susceptible 
population was < 0.125 μg/ml, and the MIC90 was 0.5 μg/ml.  Of the original parental 
population, 90% (139/155) were inhibited by ciprofloxacin concentrations of < 0.5 
μg/ml.  The modal MICrecovered and MIC90  recovered results for ciprofloxacin were 2 and 4 
μg/ml, respectively, which represented an 8-fold decrease in ciprofloxacin susceptibility 
relative to parental isolates.  Of the recovered mutant population, only 3% (5/204) were 
inhibited by ciprofloxacin concentrations < 0.5 μg/ml, compared to the MIC for 90% of 
the parental isolates.  The levofloxacin modal MIC and MIC90 values for parental 
isolates of P. aeruginosa were 0.5 and 1 μg/ml, respectively, and 92% (142/155) of the 
parental isolates were inhibited by levofloxacin concentrations of < 1 μg/ml.  In 
comparison, the modal levofloxacin MICrecovered and MIC90  recovered  values for recovered 
mutant colonies were 4 and 16 μg/ml, and 3% (5/155) of the recovered mutants were 
inhibited by a levofloxacin concentration of < 1 μg/ml.  MIC90 recovered  results for mutant 
colonies possessed stable phenotypes, which were in 90% agreement with the MPC of 
the parental isolates.  Overall, 81% (165/204) of the recovered mutants demonstrated a  
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Table 4.3.2   MIC and MICrecovered Results for Selected Mutants and Parental Strains of P. aeruginosa 
FQ Fluoroquinolone Susceptibility (μg/ml) summarized by MIC or MPC distributions Susceptibility  
Result (μg/ml) <0.125 0.25 0.5 1 2 4 8 16 32 >64 
MIC50 
 (μg/ml) 
MIC90 
 (μg/ml)
MPC50 
 (μg/ml)
MPC90 
 (μg/ml) 
MIC  
(parental strains)
(n=155) 
95 
(61%) 
20 
(74%) 
23 
(90%) 
9 
(95%)
4 
(98%) 
3 
(100%)
    <0.125 0.5 --- --- 
MIC 
(Recovered) 
(n=204) 
 1 
(0.5%) 
5 
(3%) 
18 
(12%)
89 
(55%) 
72 
(91%) 
6 
(94%) 
5 
(96%)
5 
(99%)
3 
(100%)
2 4 ---- ---- 
MIC –CCCP 
(n=65) 
 2 
(3%) 
 4 
(9%) 
25 
(23%) 
20 
(75%) 
13 
(95%) 
1 
(97%)
1 
(99%)
1 
(100%)
4 8 ---- ---- 
MIC +CCCP 
(n=65) 
 2 
(3%) 
 7 
(14%)
30 
(60%) 
16 
(85%) 
8 
(97%) 
1 
(99%)
0 1 
(100%)
2 8 ---- ---- 
Cipro 
MPC  
(n=155) 
  3 
(3%) 
5 
(5%) 
92 
(65%) 
43 
(92%) 
6 
(96%) 
2 
(97%)
4 
(100%)
   2 4 
MIC  
(parental strain) 
(n=155) 
7 
(5%) 
24 
(20%) 
91 
(79%) 
20 
(92%)
6 
(96%) 
2 
(97%) 
2 
(99%) 
 3 
(100%)
 0.5 1 8 16 
MIC 
(Recovered) 
(n=204) 
 1 
(0.5%) 
 4 
(3%) 
9 
(7%) 
63 
(38%) 
106 
(90%) 
6 
(93%)
9 
(97%)
6 
(100%)
8 16 ---- ---- 
MIC –CCCP 
(n= 64) 
   1 
(0.5%)
3 
(6%) 
4 
(13%) 
33 
(64%) 
20 
(95%)
2 
(99%)
1 
(100%)
8 16 ---- ---- 
MIC +CCCP 
(n= 64) 
   1 
(0.5%)
3 
(6%) 
10 
(22%) 
30 
(69%) 
19 
(98%)
0 1 
(100%)
8 16 ---- ---- 
Levo 
MPC  
(n=155) 
    5 
(3%) 
47 
(34%) 
84 
(88%) 
13 
(96%)
4 
(97%)
1 
(100%)
  8 16 
FQ= fluoroquinolone; Cipro = ciprofloxacin, Levo = levofloxacin.  MIC results for the paretnal populations and recovered mutants were analyzed.  Recovered mutants demonstrated elevated 
MIC results with respect to the parental organisms when re-tested by conventional microbroth dilution.  MICrecovered  results were in 90% agreement with previously measeured MPC results.  A 
50 mM amount of CCCP was added to the wells of microtitre tray containing increasing concentrations of ciprofloxacin and levofloxacin.  The distributions of MIC results are shown. 
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> 2-fold change in the MIC to either ciprofloxacin or levofloxacin when tested by the 
conventional microbroth dilution.   
The addition of a 50 mM solution of CCCP, to the wells of the susceptibility panels 
has been documented as a method for implicating possible efflux mechanisms which 
contribute to fluoroquinolone resistance by inhibting proton motive force (287, 365).  
Generally, a > 2-fold change in the MIC upon the addition of CCCP to the wells of the 
microtitre tray is required to implicate the possible involvement of efflux as contributing of 
fluoroquinolone resistance (365).  By this system, active efflux dose not appear to be a 
major mechanism of fluoroquinolone resistance in recovered mutants (Table 4.3.2).  For 
ciprofloxacin, 9% (6/65) of the recovered mutants demonstrated a > 2-fold change in the 
MIC when CCCP was added.  For levofloxacin, 11% (7/64) of the recovered mutant 
population demonstrated a > 2-fold change in the MIC when CCCP was added to wells 
containing levofloxacin drug concentrations.  Recovered mutants were tested for altered 
susceptibility patterns relative to parental organism by a semi-automated laboratory 
identification system know as Vitek.  No differences between the ciprofloxacin and 
levofloxacin susceptibilities for parental organisms and recovered colonies were seen (data 
not shown).    
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4.3.6.2   DNA Sequence Analysis of gyrA and parC Targets in Recovered  
   Mutants of P. aeruginosa 
 
Some of the isolates required high fluoroquinolone concentrations (> 8 μg/ml) to 
prevent colony formation.   Analysis of the MIC results for the recovered mutants 
confirmed elevated susceptibility patterns with respect to parental organism in the 
presence of fluoroquinolones and CCCP.  Thus, I suspected that these some of these 
organisms contained mutations in the target genes, gyrA (DNA gyrase) and/or parC 
(topoisomerase IV).  To test this idea, I sequenced a 484 base-pair region of the gyrA 
gene and a 424 base-pair region of the parC which included the QRDR of each gene (see 
Materials and Methods).   Twenty-five different mutants, from 11 different isolates were 
analyzed along with the original parental colony and mutations were reported in reference 
to target sequences in the parental isolate (Table 4.3.3).  Low concentrations of 
fluoroquinolones selected only non-GyrA mutants; at slightly higher concentrations, 
distinct gyrA and parC variants were obtained.  A number of mutations which have not 
been associated with quinolone resistance (non-characterized mutations) were identified 
in mutant colonies.  To my knowledge, genetic studies have not been preformed that 
attribute resistance to these alleles, but they represent mutations which are not seen in 
parental organisms, consequently, I did not exclude these mutations from my analysis.  
Five mutants (isolate numbers 13, 27, 77, 105, and 126) contained a gyrA mutation 
(T83I) known from genetic studies to confer resistance (4).   A number of 
uncharacterized silent mutations were identified which were not present in the sequences  
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Table 4.3.3    Sequence Analysis of GyraseA and TopoisomeraseIV Target Genes of Recovered Mutants of P. aeruginosa 
 
Wild type MIC 
(μg/ml) 
MPC 
(μg/ml) 
QRDR Amino Acid Sequence Isolate (source) 
Cipro Levo Cipro Levo gyrA parC 
13  (LEVO-
8μg/ml) 
 
0.5 2 2 16 T83I ACC to ATC) 
H132H (CAC to CAT) 
N27N (AAT to AAC) 
A115A (GCT to GCG) 
27  (LEVO-
4μg/ml) 
 
1 2 8 16 Wild type Wild type 
27 (LEVO-5μg/ml)
   
1 2 8 16 Wild type Wild type 
27  (LEVO-
7μg/ml)  
1 2 8 16 Wild type Wild type 
27  (LEVO-10-a 
μg/ml) 
1 2 8 16 Wild type Wild type 
27  (LEVO-10-b 
μg/ml) 
1 2 8 16 T83I ACC to ATC) 
A84A (GCG to GCA) 
Wild type 
27  (LEVO-12 
μg/ml) 
1 2 8 16 T83I ACC to ATC) 
A84A (GCG to GCA) 
Wild type 
27  (LEVO-16 
μg/ml) 
1 2 8 16 T83I ACC to ATC) 
A84A (GCG to GCA) 
Wild type 
27  (CIPRO -2 
μg/ml) 
1 2 8 16 Wild type Wild type 
27  (CIPRO –
3.μg/ml) 
1 2 8 16 Wild type Wild type 
27  (CIPRO –3.5 
μg/ml) 
1 2 8 16 Wild type Wild type 
40 (LEVO-16μg/ml <0.125    1 8 32  H132H (CAC to CAT)  N27N (AAT to AAC) 
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A115A (GCT to GCG) 
40 (CIPRO 4μg/ml <0.125    1 8 32  H132H (CAC to CAT)  N27N (AAT to AAC) 
A115A (GCT to GCG) 
76 (LEVO 4 μg/ml) 
 
0.5 1 2 8 A67A (GCC to GCG) 
H132H (CAC to CAT) 
A115A (GCT to GCG) 
76 (CIPRO 1 
μg/ml) 
 
0.5 1 2 8 Wild type Wild type 
77a (CIPRO-
32μg/ml) 
1 2 >32 >32 T83I ACC to ATC) A115A (GCT to GCG) 
*#77a (LEVO-32μg/m
 
1 2 >32 >32 T83I ACC to ATC) 
H132H (CAC to CAT) 
N27N (AAT to AAC) 
A115A (GCT to GCG) 
81 (LEVO-
16μg/ml)  
<0.125    0.5  8 32 H132H (CAC to CAT) 
85 (LEVO-
16μg/ml) 
<0.125 0.125  8 32 H132H (CAC to CAT)  N27N (AAT to AAC) 
A115A (GCT to GCG) 
#92 (LEVO-
8μg/ml) 
 <0.125  1    4 16 G105G (GGC to GGT);  
H132H (CAC to CAT) 
N27N (AAT to AAC) 
A115A (GCT to GCG) 
#105 (LEVO-
32μg/ml)  
1         2 >32     >32     T83I ACC to ATC N27N (AAT to AAC) 
A115A (GCT to GCG) 
#103    (LEVO-
8μg/ml                       
0.25        1      4 16 V103V (GTA to GTC) 
A118A (GCA to GCG) 
A136A (GCG to GCC) 
D144D (GAC to GAT) 
D150D (GAT to GAC) 
N27N (AAT to AAC);   
H40H (CAT to CAC) 
R50R (CGA to CGG) 
D62D (GAT to GAC) 
Y107Y (TAT to TAC) 
G114G (GGG to GGC) 
Y135Y (TAT to TAC)   
103 (CIPRO - 
1μg/ml) 
0.25        1   2 16 Wild type Wild type 
126 (LEVO- 1 2 2 16 T83I ACC to ATC;   N27N (AAT to AAC) 
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8μg/ml) 
  
A115A (GCT to GCG) 
126 (CIPRO-
1μg/ml) 
 
1 2 2 16 H132H (CAC to CAT) N27N (AAT to AAC) 
A115A (GCT to GCG) 
 
Nucleotide sequences were determined for the QRDRs of P. aeruginosa gyrA and parC genes (3, 195) using PCR and 
automated DNA sequencing.  a Cipro = ciprofloxacin; Levo =levofloxacin.  b QRDR, quinolone-resistance-determining 
region. Amino acid in wild-type protein is indicated before its number in the protein,  followed by the amino acid 
change. A, alanine; D, aspartic acid;  H, histadine; G, glycine;  I, Isoleucine;  N, asparagine;  R, arginine;  T, threonine  
Y, tyrosine;  V, valine.  All mutations are reported in reference to changes from the orginal parental sequence.
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of the parental organisms.  For example, a gyrA H132H (CAC-CAT) and a parC 
mutation N27N (AAT- AAC) where identified in mutant colonies.  The type of gyrA 
and parC mutation selected also differed for mutants recovered from ciprofloxacin 
and levofloxacin plates.  For isolate 126, a T83I gyrA mutation was identified in a 
mutant recovered from an agar plate containing 8 μg/ml of levofloxacin.  This mutant 
was not recovered from colonies selected from any plates containing ciprofloxacin.   
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4.3.6.3   PFGE Analysis of Recovered Mutants of P. aeruginosa 
 
MIC testing confirmed the presence of stable phenotypes in mutant colonies 
and DNA sequence analysis of the QRDR for the gyrA and parC genes revealed target 
mutations.  I used PFGE to test the hypothesis that mutant colonies represented 
different clones of P. aeruginosa compared to parental isolates.  PFGE DNA banding 
patterns for 4 mutants recovered from agar plates containing levofloxacin 
concentrations were examined and compared to the PFGE fingerprint of the parental 
isolates.  For all mutants tested, no differences in the PFGE pattern were observed 
between mutant and parental colonies selected from 1010 CFU/ml cultures of P. 
aeruginosa (Figure 4.3.7).      
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Figure 4.3.7   PFGE Analysis of Recovered Mutants of P. aeruginosa 
 
     MWM        1             2           3            4        MWM       5           6            7            8             
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane #      Recovered mutant           MIC (μg/ml)             MPC (μg/ml ) 
                                                                                                                               Cpx Lfx   Cpx Lfx        
(MWM) = 123 base pair molecular weight marker      
1 = PA- CMH 32 (parental strain)   levo-4 μg/ml  1 2    4           8 
2 = PA- CMH 32 (recovered mutant)    
3 = PA-OGH 22  (parental strain)     levo-16 μg/ml  4 8    32        >32 
4= PA- OGH 22  (recovered mutant)      
5= PA- HMR 24 (parental strain)    levo-4 μg/ml  1 4    2         8 
6= PA- HMR 22  (recovered mutant)     
7= PA –OGH 17 (parental strain)     levo-16 μg/ml  2 4    8        32 
8= PA- OGH 17 (recovered mutant)
PFGE was preformed on four clinical strains of P. aeruginosa.  Cpx = ciprofloxacin. Lfx = 
levofloxacin.    
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4.3.7 Enrichment of Mutant Subpopulations from nalB, nfxB, nfxC, and 
 oprD Mutants of P. aeruginosa 
 
 
 Some of the recovered mutants demonstrated elevated susceptibility in the 
absence of alterations in sequenced regions of the gyrA and parC genes.   Phenotypic 
analysis of mutants recoved at low and moderate fluoroquinolone concentrations using 
mutant selection curves suggest that the nature of the low-concentration mutant slection 
may be efflux mediated.  Why the non-gyrase mutants were so abundant has not been 
established.  I examined the possibility that differences in mutant selection between 
ciprofloxacin and levofloxacin may be partially attributed to the ability to inhibit cells 
containing efflux mechanisms.  Mutant selection curves were performed on nalB, nfxB, 
nfxC, and oprD efflux mutants of P. aeruginosa (Figure 4.3.8).   For each strain tested, a 
two-stage decline in growth was observed.  The first stage in colony decline occurred at 
fluoroquinolone concentrations that approximated the ciprofloxacin and levofloxacin 
MIC, and resulted in the inhibition of growth of approximately 105 cells (see arrows, 
Figure 4.3.8).  At concentrations above the ciprofloxacin and levofloxacin MIC of the 
strain tested, growth of mutants occurred.  Eventually, a concentration which inhibited 
the most-resistant mutant present in 1010 CFU/ml populations was obtained, defining the 
MPC for the fluoroquinolones tested.  For the nalB mutant (MexAB-OprM), the MPC 
for ciprofloxacin and levofloxacin was 1.125 and 3.5 μg/ml,  
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Figure 4.3.8    Effect of Fluoroquinolone Drug Concentration on Colony Recovery  
  from nalB, nfxB ,nfxC, and oprD efflux Mutants of P. aeruginosa  
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P. aeruginosa cultures containing 1010 CFU/ml were applied to agar plates containing increasing concentrations of 
fluoroquinolones.  PAO1 isogenic strain for the nalB, nfxB and oprD efflux mutants.  K372 isogenic strain for the 
nfxC mutant.  NalB (MexAB-OprM) efflux mutant.   NfxB (MexCD-OprN) efflux mutant.  NfxC (MexEF-OprJ) 
efflux mutant.  OprD efflux mutant.  Ciprofloxacin is represented by filled circles; levofloxacin is represented by 
open triangles.  Arrows represent the MIC for each strain tested.   
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A 
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respectively, which represents a 2- to 3-fold decrease in susceptibility relative to the 
MIC of the wild type strain (ciprofloxacin MIC= 0.25 μg/ml, levofloxacin MIC = 0.75 
μg/ml) (Table 4.3.4).  Based on the MPC result, ciprofloxacin was 3.1-fold more active 
against mutants selected from 1010 CFU/ml cultures of a nalB mutant of P. aeruginosa.  
Differences between the numbers of mutants selected by ciprofloxacin and levofloxacin, 
above the MIC of the wild-type strain, were not remarkable.   However, the 
concentrations of levofloxacin required to inhibit mutant colonies were 2-to 4.5-fold 
higher than for ciprofloxacin, resulting in a higher levofloxacin MPC, and a lower 
AUC/MPC ratio (levofloxacin AUC/MPC = 23, ciprofloxacin AUC/MPC = 35)     
 The highest fluoroquinolone MPCs were measured against the nfxB mutant 
(MexCD-OprJ) which corresponded to ciprofloxacin and levofloxacin MPCs of 2.5 and 
9 μg/ml, respectively, and represented a 5- to 4-fold decrease in susceptibility to 
ciprofloxacin and levofloxacin relative to the MIC of the parental strain (ciprofloxacin 
MIC = 0.5 μg/ml, levofloxacin MIC = 2.25 μg/ml) (Table 4.3.4).  AUC/MPC values of 
ciprofloxacin and levofloxacin for an nfxB mutant were the lowest among all the efflux 
mutants tested and corresponded to a ciprofloxacin value of 18 and levofloxacin value 
of 9.  Analysis of mutant selection, based on the MSW, for ciprofloxacin and 
levofloxacin revealed that levofloxacin selected 12.6 times the number of mutant  
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Table 4.3.4 MIC and MPC Results for nalB, nfxB, nfxC and oprD  
 Efflux Mutants of P. aeruginosa  
 
 
Strain Fluoroquinolone MIC 
(μg/ml) 
MPC 
(μg/ml)
Change in  
Susceptibility 
 (fold increase) 
AUC/MPC 
Ciprofloxacin 0.25 1.125 4.5 35  
nalB Levofloxacin 0.75 3.5 4.6 23 
Ciprofloxacin 0.5 2.5 5 18  
nfxB Levofloxacin 2.25 9 4 9 
Ciprofloxacin 0.4 2 5 22  
nfxC Levofloxacin 1.75 6 3.4 14 
Ciprofloxacin 0.5 1.125 2.25 35  
oprD Levofloxacin 1.25 2.5 2 47 
Ciprofloxacin 0.125 0.75 6 59 PAO1a 
Levofloxacin 0.75 3.125 4.2 26 
Ciprofloxacin 0.175 1 5.7 44 K372b 
Levofloxacin 0.75 3 4 27 
 
 
aPAO1 is the isogenic strain for the nalB, nfxB, and oprD mutants 
bK372 is the isogenic strain for the nfxC mutant
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colonies when compared to selction of mutants with ciprofloxacin drug concentrations.  
Fluoroquinolone concentrations at which mutant selection occurred were 3.6- to 5-fold  
higher for levofloxacin.   Thus, levofloxacin continued to select mutants over a resistant 
breakpoint for the drug. In contrast, mutants selected by ciprofloxacin concentrations 
were below the breakpoint for resistance.  Comparisons between the nfxB mutant and 
the isogenic strain (PAO1), revealed no differences in the frequency of mutant selection.  
Comparison of MPC results revealed a 3-fold increase between the nfxB mutant and the 
respective isogenic strain.  Ciprofloxacin and levofloxacin MPC results for the nfxC  
mutant (MexEF-OprN), were 2 and 6 μg/ml, respectively.  MexEF-OprN efflux 
expression caused a 5- and 3.4-fold decrease in the susceptibility to ciprofloxacin and 
levofloxacin.   A fourth efflux mutant, oprD, which confers resistance to carbapenem 
antibiotics via reductions in porin channels, resulted in small changes to fluoroquinolone 
susceptibility when MIC and MPC results were compared (2.2-fold difference for 
ciprofloxacin, 1.8-fold difference for levofloxacin).   The MPC results for ciprofloxacin 
and levofloxacin were 1.25 and 3.125 μg/ml, respectively (Table 4.3.4). 
 Selection of first-step resistant mutants from isolates of P. aeruginosa 
expressing efflux mechanisms resulted in higher ciprofloxacin and levofloxacin MPC 
results when compared to the MPC of the respective isogenic strains.  Two mutants 
which overexpressed the MexCD-OprJ (nfxB) and MexEF-OprN (nfxC) operons 
resulted in high MPC values which were above the breakpoints for resistance for 
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ciprofloxacin and levofloxacin, respectively.  Sequence analysis for regions of the gyrA 
and parC genes in selected mutants have not been performed, but selection of resistant 
mutants which co-express efflux plus target mutations are likely to have high MPCs.  
Ciprofloxaicn had lower MPCs than levofloxacin against strains of P. aeruginosa which 
express drug efflux systems, suggesting that the ability to restrict the selection of 
fluoroquinolone-resistant mutants may be linked to the ability to inhibit efflux 
expression in clinical isolates of P. aeruginosa.         
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4.3.8 Bacterial Killing and MPCs for Clinical Isolates of P. aeruginosa  
 
Like other susceptibility measurements, the MPC is not reflective of bacterial 
killing and the time that fluoroquinolones are required to exceed the MPC during dosing 
is a factor which is currently unknown.  It is expected that first-step mutants selected at 
sub-MPC drug concentrations may be selectively amplified under dosing which allows 
drug concentrations to fluctuate within the MSW.  I examined the effect of the MPC 
drug concentration on the killing of 1010 CFU/ml cultures of P. aeruginosa and the 
killing/enrichment of mutant populations.  Killing experiments for P. aeruginosa were 
preformed as outline in Materials and Methods.  Briefly, the contents of 1010 CFU/ml 
cultures were evenly divided among two 500 ml flasks containing the specified MPC or 
MIC drug concentrations.  Mutant growth was assessed via growth on agar plates 
containing concentrations of ciprofloxacin and levofloxacin that were an average of 4- 
fold above the MICs of the wild-type strains.  Experiments were preformed in duplicate 
and conducted over 24 hr.  The rates of killing at the MIC and MPC drug concentrations 
for two strains of P. aeruginosa (CBRH- 25138 and PA-25) are shown in Figures 4.3.9 
and 4.3.10.   For each experiment the detection limit was +1.00 log growth.  The MPC 
for ciprofloxacin and levofloxacin against P. aeruginosa isolates CBRH 25138 and PA-
25 were 4 and 16, and 2 and 4 μg/ml, respectively.  Figure 4.3.9 and Table 4.3.5 depict 
results obtained for the P. aeruginosa strain CBRH-25138.  At the MIC, -1.32 and -1.33 
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Figure 4.3.9  Killing of P. aeruginosa CBRH 25138 by Ciprofloxacin and 
Levofloxacin at the MIC and MPC 
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The killing of P. aeruginosa CBRH-25138 at the MIC and MPC are represented in panels A and B.  The 
killing of mutants at the MIC and MPC drug concentrations are represented in panels C and D. Open 
triangles represent the growth/reduction in viablility for levofloxacin-treated cultures.  Filled circles 
represent the growth/reduction in viablility for ciprofloxacn-treated cultures.   
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Figure 4.3.10  Killing of P. aeruginosa PA-25 by Ciprofloxacin and Levofloxacin    
at the MIC and MPC   
The killing of P. aeruginosa PA-25 at the MIC and MPC are represented in panels A and B.  The killing of 
mutants at the MIC and MPC are represented in panels C and D. Open triangles represent the growth/reduction 
in viablility for levofloxacin-treated cultures.  Filled circles represent the growth/reduction in viablility for 
ciprofloxacin-treated cultures.   
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Table 4.3.5  Killing of P. aeruginosa CBRH 25138 by Ciprofloxacin and Levofloxacin at the MIC and MPC 
Original 
 Strain 
Killing at the  
MIC  (μg/ml) 
 
Fluoroquinolone Time (h) Original broth concentration  
(CFU/ml) 
Log Reduction/growth 
of entire culture (CFU/ml) 
Log Reduction/ growth of  
mutant growth 
(CFU/ml) 
CBRH 25138 MPCcipro =2  
MPClevo =4 
Ciprofloxacin 
Levofloxacin 
0 3.06 x107 
1.53 x107 
------- a 
----------- b 
+1.01 c 
+1.58 d 
  Ciprofloxacin 
Levofloxacin 
4 1.45 x106 
7.23 x105 
-1.32 
-1.33 
+1.18 
+1.15 
  Ciprofloxacin 
Levofloxacin 
8 3.56 x105 
1.78 x105 
-1.93 
-1.93 
+2.29 
+2.93 
  Ciprofloxacin 
Levofloxacin 
12 4.2 x105 
2.1 x105 
-1.86 
-1.87 
+3.75 
+4.22 
  Ciprofloxacin 
Levofloxacin 
18 4.44 x105 
2.22 x106 
-1.84 
-1.83 
+>6.00  
+>6.00 
  Ciprofloxacin 
Levofloxacin 
24 4.58 x106 
2.29 x106 
-0.82 
-0.83 
+>6.00  
+>6.00 
Original 
 Strain 
Killing at the  
MPC  (μg/ml) 
 
Fluoroquinolone Time (h) Original broth  
concentration  
(CFU/ml) 
Log Reduction/growth 
of entire culture (CFU/ml) 
Log Reduction/ growth of  
mutant growth 
(CFU/ml) 
CBRH 25138 MPCcipro =8  
MPClevo  =16 
Ciprofloxacin 
Levofloxacin 
0 3.41 x107 
3.41 x107 
------- e 
----------- f 
+1.00 c 
+1.40 d 
  Ciprofloxacin 
Levofloxacin 
4 1.76 x105 
1.37 x105 
-2.28 
-2.40 
+1.00 
+1.00 
  Ciprofloxacin 
Levofloxacin 
8 2.71 x104 
4.12 x103 
-3.10 
-3.92 
+1.00 
+1.00 
  Ciprofloxacin 
Levofloxacin 
12 1.68 x104 
9.25x102 
-3.31 
-4.57 
 
+1.00 
+1.00 
  Ciprofloxacin 
Levofloxacin 
18 1.20 x103 
1.58 x102 
-4.45 
-5.33 
+1.00 
+1.00 
  Ciprofloxacin 
Levofloxacin 
24 3.02 x102 
4.00 x101 
-5.05 
-5.93 
+1.00 
+1.00 
Maximum log reduction; a-7.49, b- 7.18.  e-7.53, f-7.53.    
Maximum log growth;  c+ >6.0, d+ >6.0. 
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log reductions in growth were measured for the strain CBRH 25138 for ciprofloxacin 
and levofloxacin by 4 hr.  Maximum killing for both ciprofloxacin and levofloxacin 
occurred by 8 hr.  Neither ciprofloxacin nor levofloxacin treated cultures achieved >3 
log reductions in viable cells at any time tested at the MIC drug concentration.  By 24 
hr, a -0.82 and -0.83 log reduction in viable counts were observed for ciprofloxacn and 
levofloxacin, respectively.  As expected, an increase in killing occurred when the MPC 
drug concentration was tested.  By 4 hr, a -2.28 and -2.4 log reduction in growth was 
observed for ciprofloxacin and levofloxacin.  Significant killing, as assessed by > -3.0-
log reduction, was measured at 8 hr and corresponded to -3.10 and -3.90 log reductions 
in growth for ciprofloxacin and levofloxacin, respectively.  Maximal killing was 
observed by 24 hr which resulted in -5.05 and -5.93 log reduction in viable cells when 
ciprofloxacn and levofloxacin were tested.   
For the P. aeruginosa strain CBRH-25138, mutant growth was determined via 
conoly formation on agar plates containing 4 and 8 μg/ml of ciprofloxaicn and 
levofloxacin, respectively.  At time 0 hr, mutatnt colonies were detected in three of four 
cultures tested and demonstrated that mutant growth was present prior to introduction of 
a fluoroquinolone.  Mutant colonies were recovered from both ciprofloxaicn and 
levofloxacin-treated cultures at every time interval tested.  By 8 hr, a 2.29 and 2.93 log 
increase in mutant growth was observed, and by 18 hr, mutant growth reached the 
detection limit (> +6.00 log) of the assay.  At the MPC drug concentration, mutant 
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growth was initially detected at time 0 hr in 3 of 4 culutres.  However, no mutants were 
recovered at time points beyond 2 hr for either ciprofoxaicn or levofloxacin treated 
cultures (Figure 4.3.9).   
For the P. aeruginosa strain PA-25 (Figure 4.3.10), killing by 24 hr at the MIC 
drug concentration for ciprofloxacin and levofloxacin was -1.25 and -1.83 log, 
respectively (Table 4.3.6).  A > -3 log reduction in growth for ciprofloxaicn or 
levofloxacin was not obtained at any point sampled during 24 hr and relativly small 
differences in killing were observed for both ciprofloxaicn and levofloxacin from 8-to-
24 hr.  At the MPC, a -3.00 and -3.31 log killing occurred by 4 hr for ciprofloxaicn and 
levofloxacin, respectively.  Significant killing, represented by > -3.00 log reductions in 
viability, was measured from 2-to-24 hr for both ciprofloxaicn and levofloxacin.   
Mutant growth for the P. aeruigonsa strain PA-25 was defined by growth on 
agar plates containing 1 and 8 μg/ml of ciprofloxaicn and levofloxacin, respectively.  At 
the MIC and MPC drug concentrations, mutant growth was detected in all culutres 
tested at time 0 hr.  At the MIC drug concentration, mutant growth increased over 24 hr, 
accounting for the majority of cells present in culture, and reached the detection limit (> 
+ 6.00 log) of the assay by 10 and 16 hr for ciprofloxaicn and levofloxacin, respectively 
(Table 4.3.6).  Increased killing of mutant colonies was observed for cultures treated  
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Table 4.3.6.  Killing of P. aeruginosa Strain PA-25 by Ciprofloxacin and Levofloxacin at the MIC and MPC   
Original 
 Strain 
Killing at the  
MIC  (μg/ml) 
 
Fluoroquinolone Time (h) Original broth concentration  
(CFU/ml) 
Log Reduction/growth 
of entire culture (CFU/ml) 
Log Reduction/ growth of  
mutant growth (CFU/ml) 
PA-25 MICcipro = 0.125 
MIClevo   = 0.5 
Ciprofloxacin 
Levofloxacin 
 
0 1.22 x108 
3.92 x107 
--------a 
-------- b 
+1.23c 
+2.8d 
  Ciprofloxacin 
Levofloxacin 
4 1.2 x108 
1.94 x107 
-0.007  
-0.31  
+1.23 
+2.8 
  Ciprofloxacin 
Levofloxacin 
8 3.1 x106 
6.8 x105 
-1.59 
-1.16 
+2.28 
+3.00 
  Ciprofloxacin 
Levofloxacin 
12 1.64 x106 
8.87 x105 
-1.87 
-1.65 
+2.73 
+>6.00 
  Ciprofloxacin 
Levofloxacin 
18 6.58 x106 
5.53x105 
-1.27 
-1.85 
+>6.00 
+>6.00 
  Ciprofloxacin 
Levofloxacin 
24 6.94 x106 
5.79 x105 
-1.25 
-1.83 
+>6.00 
+>6.00 
 Killing at the  
MPC  (μg/ml) 
 
Fluoroquinolone Time (h) Original broth concentration  
(CFU/ml) 
Log Reduction/growth 
of entire culture (CFU/ml) 
Log Reduction/ growth of  
mutant growth (CFU/ml) 
PA-25 MICcipro = 2 
MIClevo  = 16 
 
Ciprofloxacin 
Levofloxacin 
0 3.41 x107 
4.23 x107 
------- c 
------------ d 
+1.07c 
+1.21d 
  Ciprofloxacin 
Levofloxacin 
4 3.38 x104 
2.06 x104 
-3.00 
-3.31 
+1.10 
+1.29 
  Ciprofloxacin 
Levofloxacin 
8 2.38 x104 
1.7 x104 
-3.16 
-3.39 
+1.00 
+1.32 
  Ciprofloxacin 
Levofloxacin 
12 7.65 x104 
1.03 x104 
-3.65 
-4.61 
+1.00 
+1.00 
  Ciprofloxacin 
Levofloxacin 
 
18 6.2 x103 
1.84 x102 
-3.74 
-5.36 
+1.00 
+1.00 
  Ciprofloxacin 
Levofloxacin 
 
24 2.85 x102 
3.44 x101 
-5.07 
-6.08 
+1.00 
+1.00 
Maximum log reduction; a-8.08, b- 7.52.  e-7.53, f-7.63.   
Maximum log growth;  c+ >6.0, d+ >6.0. 
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 with the MPC drug concentrations at every time point sampled.  For ciprofloxaicn 
treated cultures, mutant colonies were recovered at 0, 2, and 4 hr (+ 1.1, 1.08, and 1.1 
log growth), however, no mutants could be recoverd beyond 4 hr.  For levofloxacin, 
mutants were recovered from 0-to-20 hr (+ 1.00 to 1.49 log growth).  By 24 hr, no 
mutants were recoverd from ciprofloxacin- or levofloxacin-treated cultures, which 
represented a 5 log difference in mutant recovery when mutant growth at the MIC drug 
concentration was compared.                              
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4.3.9 Ceftazidime plus Ciprofloxacin/Levofloxacin Combination MPC 
 Results for Clinical Isolates of P. aeruginosa  
 
Many of the clinical isolates tested had a levofloxacin and/or ciprofloxacin MPC 
value above a breakpoint for resistance, and in some cases, above a clinically achievable 
concentration (based on recommended doses).  Synergistic activity between 
antimicrobial combinations, including fluoroquinolones and cephalosporins against 
strains of P. aeruginosa, have been documented in vitro and in vivo (110, 309).  Fish et 
al (110) documented the successful clinical utility of fluoroquinolones used in 
combination with anti-pseudomonal cephalosporins for treatment of P. aeruginosa that 
demonstrated high MICs to the antimicrobial agents when tested as a single agent.  I 
suspected that combination MPC testing could be used to restrict the selection of 
resistant mutants in isolates that had high fluoroquinolone MPCs.  In an effort to 
identify antimicrobials that could be used in combination testing, I measured individual 
MPC results for four different classes of antimicrobials used to treat P. aeruginosa 
(Table 4.3.7).  With the exception of ciprofloxacin (400 mg I.V. q8h) and possibly 
ceftazidime (2 g I.V.), the MPC results for all isolates tested (n=7) exceeded the peak 
serum concentrations for all antimicrobials tested.  The MPC90 for clinical isolates of P. 
aeruginosa against imipenem (n=10) and ceftazidime (n=14) were > 64 μg/ml, in both 
cases.  For the aminoglycosides gentamicin, and tobramycin, the MPC90 results (n=25) 
were 64 and > 64 μg/ml, respectively.  MPC90 results for ciprofloxacin (n=155), 
levofloxacin (n=155) and ofloxacin (n=10) were 4, 16, and > 64 μg/ml, respectively. 
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Table 4.3.7 MPC Results for Antimicrobials Against Clinical Isolates of P. aeruginosa 
 
 
 
Antimicrobial  
Class 
Antimicrobial  
Agent 
N MPC50 
μg/ml 
MPC90 
μg/ml 
Peak Serum 
Concentration 
Cmax (μg/ml) 
Dose Serum 
(t ½ hr) 
Ref 
Carbapnenem Imipenem 10 >64 >64 40 500 mg IV 1 (98, 127, 357) 
Cephalosporin Ceftazidime 14 32 >64 60 1g IV 1.8 (74, 127) 
     144 2g IV TID 2 (21, 127) 
Tobramycin 25 8 64 4-8 1.2 mg/kg IV 2,5 (19, 127) Aminoglycoside 
Gentamicin 25 32 >64 4-8 1.2 mg/kg IV 2,5 (19, 127) 
Ofloxacin 10 16 >64 4.6 7.2 mg IV 7 (127) 
Ciprofloxacin 155 2 4 2.9 500 mg  1.2 
 155 2 4 4.6 400 mg IV 4 
 155 2 4 6.3 400 mg IV 
q8h 
2 
(23, 49, 68, 127, 212) 
Levofloxacin 155 8 16 5.2 500mg  1.7 
 155 8 16 6.2 500 mg IV 7 
Fluoroquinolone 
 155 8 16 12.1 750 mg IV 7.9 
(68, 111, 127, 274, 364) 
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The activities of ciprofloxacin, levofloxacin, and ceftazidime against six 
isolates of P. aeruginosa are summarized in Table 4.3.8.  Ciprofloxacin and 
levofloxacin had generally comparable MICs against the 6 isolates of P. aeruginosa 
(ciprofloxacin MIC90 = 0.5 μg/ml, levofloxacin MIC90 = 1 μg/ml) and all were 
considered susceptible by NCCLS criteria (Table 4.3.9).  Two isolates were resistant 
to ceftazidime by MIC testing (isolate numbers PA-96 MIC > 8 mg/L and PA-94 MIC 
> 16 mg/l).  Ceftazidime plus fluoroquinolone combinations yielded a reduction in the 
fluoroquinolone plus ceftazidme MPC in 75% (9/12) of the isolates tested and 83% 
(10/12) of the isolates demonstrated a reduction in the MPC value for one of the 
antimicrobials.   
In combination with ceftazidime, an average 1.4-fold (range 2- to 4-fold) 
reduction in the ciprofloxacin MPC was seen in 5/6 strains tested.  The average 
reduction in the levofloxacin MPC values upon combination of ceftazidime 
concentrations was one doubling dilution (range 2- to 4-fold).  For ciprofloxacin 
tested in combination with ceftazidime, a decrease in the ciprofloxacin MPC was seen 
in four strains and corresponded to an average increase in ciprofloxacin susceptibility 
of 1.3-fold.  One isolate (PA-90) did not show any decrease in the fluoroquinolone 
MPC when tested in combination with ceftazidime.  Isolate number 96 showed a 2-
fold decrease in the ciprofloxacin MPC when tested in combination with a 
ceftazidime concentration of 16 μg/ml.  No decrease in the levofloxacin or 
ceftazadime MPC was observed in this strain.     
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Table 4.3.8 Fluoroquinolone Ceftazidime Combination MPC Results for Clinical Isolates of  
P. aeruginosa 
 
 
Isolate             MIC μg/ml             MPC μg/ml Combination 
MPC μg/ml  
  T>MPC /24h dosing interval 
             (h)  
T>MPCcomboination /24ha,b, ,c 
 Cipro Levo Cftz Cipro Levo Cftz Cipro/ 
Cftz 
Levo/ 
Cftz 
T>cipro a T>levo,b T> Cftz ,c Cipro/ Cftz Levo/ Cftz 
PA-
101 
 
0.125 0.5 4 2 4 8 0.5/2 
 
 
2/ 2 8.5 9.4 19.1 23.25 
(ceftaz=24) 
18.1 
(ceftaz=24) 
PA-96 
 
0.5 1 8 4 8 32 2/ 16 
 
8/ 32 
 
5.5 2.3 5.8 8.5 
(ceftaz=12) 
2.3 
(ceftaz=8) 
PA-98 
 
0.125 1 4 2 4 8 1/ 2 
 
2/2 8.5 9.4 19.1 17.5 
(ceftaz=24) 
18.1 
(ceftaz=24) 
PA-90 0.125 0.5 4 2 4 32 2/ 16 
 
4/ 16 8.5 9.4 5.8 8.5 
(ceftaz=12) 
9.4 
(ceftaz=12) 
PA-94 0.125 0.5 16 2 4 >64 1/ 16 
 
 
4/ >64 8.5 9.4 0.5 12  
(cipro=17.5)
0.5 
(ceftaz=<6) 
ATTC 
27853 
 
0.5 1 2 2 4 16 1/ 2 
 
2/ 2 8.5 9.4 12 17.5 
(ceftaz=24) 
18.1 
(ceftaz=24) 
 
 
Cipro=ciprofloxacin, levo=levofloxacin, cftz=ceftazadime.  Estimated T>MPC based on a400 mg ciprofloxacin IV T.I.D 
(212) , b750 mg levofloxacin IV (203) and b1000mg ceftazadime IV q8h (74).      
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Table 4.3.9 NCCLS Breakpoints for Antimicrobials Against P. aeruginosa  
 
 
                             NCCLS Susceptibility breakpoints (μg/ml) Class of antimicrobial Antimicrobial agent 
Susceptible  Intermediate Resistant 
Carbapnenem Imipenem < 4 8 > 16 
3rd generation 
Cephalosporin 
Ceftazadime < 8 16 > 32 
Aminoglycoside Tobramycin < 4 8 > 16 
 Gentamicin < 4 8 > 16 
Fluoroquinolone Ofloxacin < 2 4 > 8 
 Ciprofloxacin < 1 2 > 4 
 Levofloxacin < 2 4 > 8 
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Ceftazidime plus fluoroquinolone combinations resulted in a reduction in the MPC, to at 
least one of the agents used in combination, for 6/6 strains tested by ceftazidime plus 
ciprofloxacin and 4/6 strains tested against ceftazidime plus levofloxacin concentrations.  
Susceptibility, as determined by a susceptible NCCLS breakpoints was restored in 4/6 
strains tested by ceftazidime plus ciprofloxacin.  Similarly, ceftazidime plus 
levofloxacin restored susceptibility in the same 3/6 strains tested.  Combination MPC 
results increased the length of time ceftazidime and ciprofloxacin combinations are 
projected to exceed the combination MPC result by 6.5 and 7.5 hr (based on 400 mg 
T.I.D. ciprofloxacin, 1 g ceftazidime).  Levofloxacin and ceftazidime combinations 
resulted in an average increase of 1.45 hr for levofloxacin and 3.48 hr for ceftazidime in 
the time MPC concentrations are expected to be maintained during dosing (based on 400 
mg T.I.D. ciprofloxacin, 1g ceftazidime).   Additionally, at least one of the antimicrobial 
agents tested was in excess of the MPC for 6 hr of a potential 24 hr dosing period (Table 
4.3.9).  Thus, combination MPC testing with a fluoroquinolone and Ceftazidime 
resulted in a lower fluoroquinolone MPC (when compared to initial MPC result) in at 
least half of the strains tested, and demonstrated that combination MPC testing can be 
used to minimize the potential for selecting resistant organisms with antimicrobials that 
have high individual fluoroquinolone MPCs.     
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 4.3.10 Recovery of Resistant Mutants in a Rat Abscess Model of  
  Infection with P. aeruginosa 
 
 The majority of data pertaining to the MPC measurement has been obtained 
using in vitro studies, and animal models are now required to examine the clinical utility 
of the MPC measurement and the concept of the MSW.  I used an absess rat model to 
create infections using 4.5x109 to 3.8x1010 CFU/ml cultures of P. aeruginosa (Figure 
4.3.11).  The ciprofloxacin and levofloxacin MIC for isolate CBRH 25138 used to 
create infection were 1 and 2 μg/ml, respectively.  The ciprofloxacin and levofloxacin 
MPC were 4 and 16 μg/ml.  Four experimental groups consisted of rats given, 400 mg 
I.V. once daily dose of ciprofloxacin (400 mg I.V. (n=2) and 400 mg I.V. qh8 (n=2) and 
750 mg I.V. once daily dose of levofloxacin (750 mg I.V. once daily (n=3) and 750 mg 
I.V. qh8 (n=2), results are summarized in Table 4.3.10.  P. aeruginosa was recovered 
from infected tissues and blood samples which were were analysed for changes in 
susceptibility based on the MIC.   Resistant mutants were defined by a > 2-fold change 
in the ciprofloxacin and levofloxacin MIC relative to the MIC of the wild-type strain.  
Resistant organisms were recovered in 33% (3/9) of the rats tested.  Of the 23 cultures 
recovered (total swabs plus tissues plus blood cultures), 22% (5/23) demonstrated 
elevated susceptibilities to both ciprofloxacin and levofloxacin.  Swabs of infected 
tissues and homogenized tissue samples collected from a rat given a 400 mg I.V. once 
daily ciprofloxacin (rat number 48), grew P. aeruginosa with a ciprofloxacin MIC of 8 
μg/ml  and a levofloxacin MIC of 16 μg/ml.  Swabs of infected tissues taken from rat 
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Figure 4.3.11 Administration of Fluoroquinolones and Collection of Clinical 
Samples in a Rat Abscess Model of P. aeruginosa Infection 
 
A
B
C
 
Collection of infected tissue and blood samples from infected rats.  
Antimicrobials were administered and blood samples taken via a rat tail vein 
catheter (panel A).  Swabs of infected tissues and infected tissues were 
recovered from infected rats (panel B).  The circulatory system was infused with 
sterile saline and blood samples were collected (panel C). 
 
 149
Table 4.3.10 Recovery of P. aeruginosa  from a Rat Abscess Model of Infection 
   
 
 
 
Fluoroquinolone dose I.V (mg) 
MICrecovered 
(μg/ml) 
MICparent 
(μg/ml 
MPCparent 
(μg//ml) 
Culture 
 ID 
Rat 
ID 
Cipro 
400 
Cipro 
400 
T.I.D 
Levo 
750 
Levo 
750 
T.I.D 
Infectious  
dose 
(CFU/.45ml) 
Source of 
isolation 
Cipro levo Cipro Levo Cipro Levo 
1 47   +  tissue  2 4 2 4 
 
4 
 
16 
2    +  swab 2 4     
3    +  swab 2 4     
4    +  blood 2 4     
5    +  blood 2 4     
6    +  tissue 2 4     
7 48 +    tissue  8 16     
8  +    swab 8 16     
9  +    swab 8 16     
10  +    blood 2 4     
11  +    blood 2 4     
12  +    tissue 2 4     
13 49   +  
3.9 x1010 
Tissue 2 4     
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Nine rats, divided into 4 experimental groups; 1.) ciprofloxacin dosed 400 mg I.V, 2.) Ciprofloxacin dosed 400 mg I.V T.I.D., 
3.) Levofloxacin dosed 750 mg I.V, and 4.) Levofloxacin dosed 750 mg I.V. T.I.D were tested.   Plus signs indicate s the 
recoverey of P. aeruginosa from treated animals  
Culture 
 ID 
Rat 
ID 
Fluoroquinolone dose I.V (mg) Infectious  
dose 
(CFU/.45ml) 
Source of 
isolation 
MICrecovered 
(μg/ml) 
MICparent 
(μg/ml 
MPCparent 
(μg//ml) 
  Cipro 
400   
Cipro 
400  
T.I.D 
Levo 
750 
Levo 
750 
T.I.D 
 tissue Cipro levo Cipro Levo Cipro Levo 
14 49   +  3.9 x1010 swab 2 4 2 4 4 16 
15 56  +   4.5 x109 swab 2 4     
16 50 +    swab 2 4     
17  +    swab 2 4     
18  +    blood 8 32     
19  +    blood 2 4     
20  +    
3.9 x1010 
tissue 2 4     
21   +  swab 8 16     
22 
51 
  +  
4.5 x109 
blood 2 4     
23 59 Control (no drug) 3.9 x1010 swab 2 4     
24 60 Control (no drug) swab 2 4     
25 53    + swab 2 4     
26 55    + swab 2 4     
27 58  +   
4.5 x109 
swab 2 4     
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number 51 (culture 21) which had been given a 750 mg I.V. once daily levofloxacin 
dose grew resistant P. aeruginosa with a ciprofloxacin and levofloxacin MIC of 8 and 
16 μg/ml, respectively, which correlated with the MPC of the original parental strain.  
Blood samples taken from a second rat (rat number 50, culture number 18) which had 
been given a 400 mg I.V once daily dose of ciprofloxacin grew resistant P.aeruginosa 
with a ciprofloxacin and levofloxacin MIC of 8 and 32 μg/ml, respectively.  The MIC of 
the recovered culture (culture # 18) showed a 4- and 6-fold increase in the MICs to 
ciprofloxacin and levofloxacin.  No mutants were recovered in rats, which had been 
given a three times daily dose.  Overall, mutants demonstrated a 4-fold decrease in 
fluoqouinolone susceptibility in 33% (3/9) of the rats tested which demonstrated that 
fluoroquinolone-resistant mutants could be readily selected and enriched under 
fluoroquinolone concentrations which fail to inhibit the most resistant mutant present in 
1010 CFU/ml cultures of P. aeruginosa.    
 
 
 
 
 
 
 
 
 152
4.4 DISCUSSION  
 Fluoroquinolone development has resulted in more potent agents such as 
moxifloxacin, gatifloxacin and gemifloxacin, however, these agents do not exhibit 
enhanced activity against P. aeruginosa.  Consequently, maintaining the efficacy of 
existing fluoroquinolone agents with activity against P. aeruginosa, such as 
ciprofloxacin and levofloxacin, is of paramount importance.  Conventional 
susceptibility considerations are inadequate for choosing between ciprofloxacin and 
levofloxacin for treatment of infections caused by P. aeruginosa: resistance develops 
frequently to both and neither compound demonstrates a clear advantage when 
surveillance data, in vitro activities, and drug PK are considered collectively (212, 225, 
323).  Nevertheless, clinical surveys indicate that increased prevalence of resistance is 
associated with a switch from ciprofloxacin to ofloxacin/levofloxacin (22, 283, 303).  
When ciprofloxacin and levofloxacin were compared for activities against cultures 
containing subpopulations of resistant mutants, ciprofloxacin was more active by two 
criteria.  First, MPC, a value that approximates the MIC of the least susceptible mutant, 
was three to four times higher for levofloxacin, both by population analysis (Figure 
4.3.1) and by survey of more than 150 clinical isolates (Figure 4.3.4).  Second, larger 
numbers of moderately susceptible and high level resistant mutants were more likely to 
be recovered following exposure to levofloxacin than ciprofloxacin (Figure 4.3.1), 
particularly with clinical isolates having intermediate fluoroquinolone susceptibility 
(Figure 4.3.2).    
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 When fluoroquinolone-susceptible clinical isolates of P. aeruginosa (n=6) were 
applied to agar plates containing various concentrations of ciprofloxacin or 
levofloxacin, recovery of colonies decreased as the fluoroquinolone concentration 
approximated the MIC (Figure 4.3.1).  In these experiments, each data point represented 
a 1010 CFU/ml culture exposed to defined ciprofloxacin or levofloxacin drug 
concentrations.  At higher concentration, both compounds exhibited a pronounced 
inflection in mutant recovery, visualized as a generalized plateau regions at 
concentrations above the MIC.  As fluoroquinolone concentrations increased, a second 
decline in CFU corresponding to the inhibition of first-step mutants was seen for both 
ciprofloxacin and levofloxacin, and eventually a concentration of ciprofloxacin and 
levofloxacin was reached which prevented the growth of the most-resistant first-step 
mutant present in a population of > 109 cells.  For ciprofloxacin and levofloxacin, MPC 
drug concentrations were measured at 3 and 9.5 μg/ml, respectively.  Comparison of the 
MSWs for ciprofloxacin and levofloxacin indicated that levofloxacin was 1500 times 
more efficient at selecting resistant mutants.  The quantitative differences in mutants 
selected by ciprofloxacin and levofloxacin extend beyond the conventional 
understanding of fluoroquinolone activity for P. aeruginosa.  For example, differences 
in the anti-pseudomonal activities between ciprofloxacin and levofloxacin manifest in 
an approximate 2-fold difference in the MIC.  If  differences in mutant selection 
between ciprofloxacin and levofloxacin parallel activity described by MIC 
measurements, then one should expect parallel activity against first-step resistant 
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mutants, albeit shifted by a factor of 2-fold toward higher levofloxacin drug 
concentrations.  As expected, this relationship holds true for 105 to 106 cells present in 
1010 CFU/ml cultures,  however, parallel fluoroquinolone activity was not seen when 
mutant recovery at concentrations above the MIC were examined.  Quantitative 
differences in mutant selection were determined by analyzing the area created under 
respective ciprofloxacin and levofloxacin MSWs.  Levofloxacin selected more mutants, 
at higher concentrations, and over wider concentration ranges when compared to 
ciprofloxacin which could be expressed in a ciprofloxacin: levofloxacin ratio of 1:1500 
(> 3 log difference in CFUs).  I also examined an isolate of P. aeruginosa that exhibited 
intermediate fluoroquinolone susceptibility (MIC = 2 and 4 μg/ml for ciprofloxacin and 
levofloxacin, respectively).  At moderate drug concentrations (0.5-to-8 μg/ml), resistant 
mutants were more frequently recovered from agar containing concentrations of 
levofloxacin (Figure 4.3.1)  Thus, the preferential ability of ciprofloxacin to restrict 
mutant growth is also evident with isolates having intermediate susceptibility.  
 Adapting MPC testing to incorporate conventional 2-fold dilution agar testing 
resulted in modal MPC values of 2 and 8 μg/ml for ciprofloxacin and levofloxacin and 
MPC90 of 4 μg/ml and 16 μg/ml, respectively, when 155 clinical isolates of P. 
aeruginosa were tested.  Thus, the upper boundary of the mutant selection window (i.e.,  
the MPC) was about 4 times higher for levofloxacin.  The significance of this finding 
can be reflected by examining the percentage of isolates whose MPC value fell at or 
above a fluoroquinolone resistant breakpoint.  When the MPC results for ciprofloxacin 
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and levofloxacin were analysed in relation to NCCLS described breakpoints for 
resistance, the number of isolates that showed resistance to levofloxacin (67%) were 
nearly twice the number that demonstrated resistance to ciprofloxacin (36%) (Figure 
4.3.6).  High-level resistance assessed by MPC values of >16 μg/ml, correlate with poor 
clinical success (124) and were selected by levofloxacin in 13% of the isolates 
compared to 5% for ciprofloxacin.   
 The significance between ciprofloxacin and levofloxacin MPC results remains 
an area of intense investigation.  A proposed model of infection suggests that higher 
numbers of mutants selected under levofloxacin dosing places the patient at increased 
risk for enriching mutant populations.  Comparison of the MSW for ciprofloxacin and 
levofloxacin revealed that the levofloxacin MSW was twice as large as the MSW for 
ciprofloxacin.  This difference is not reflected in current MIC testing for susceptibility.   
 Comparisons between compounds, based on the MPC, require consideration of 
drug PK.  I have suggested comparisons based on the time relevant drug concentrations 
are above the MPC (41, 149), since during this time mutant growth will be restricted.  
Levofloxacin concentrations  failed to exceed the MPC90 value for any portion of the 
dosing interval (based on 750 mg I.V. once daily), while concentrations of ciprofloxacin  
are projected to remain in excess of the MPC90 for approximately 5.5 of a 24 hr dosing 
interval (based on 400 mg T.I.D., I.V.) (57, 212, 274) (Figure 4.4.1).  For some 
antibiotic dosages, the drug-susceptible population may completely replaced with 
resistant mutants over time if the MPC is not targeted throughout dosing, or achieved 
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Figure 4.4.1 Relationship of MPC Results to Ciprofloxacin and Levofloxacin Dose  
  Response Profiles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
The relationship between MPC90 and MPC50 results for 155 clinical isolates of P. aeruginosa and the 
ciprofloxacin (400 mg I.V. T.I.D) dose response curve is shown in A. The ciprofloxacin dose-response 
curves were adapted from Lipman et al (212). B shows the relationship between MPC90 and MPC50 results 
for 155 clinical isolates of P. aeruginosa and the levofloxacin (750 mg I.V.) dose response curve.  Data for 
levofloxacin was adapted from product insert (274) ciprofloxacin (400 mg I.V. T.I.D) levaquin package 
insert (274). 
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for sufficient time to inhibit mutant growth.  Clinically, this may manifest in failure of an 
infection to respond to therapy or a relapse of infection with drug-resistant mutants shortly 
after a prescribed course of antibiotic therapy is completed.  Another approach is to 
consider the time that the two compounds are inside the mutant selection window, since 
longer times are expected to facilitate mutant enrichment (14, 86, 109).  Here the difference 
is not striking: 100% for levofloxacin and 80% for ciprofloxacin (Figure 4.4.1).  However, 
these numbers fail to consider differences in selection of low and moderately resistant 
mutants.  For ciprofloxacin, 65% of the isolates tested were inhibited at concentrations <2 
μg/ml compared to 30% which were inhibited at levofloxacin concentrations <4 μg/ml.  
Thus, for low-level resistant mutants, ciprofloxacin concentrations would remain in the 
window for 44% of each 24 hr-period (based on a T.I.D. dose), while levofloxacin 
concentrations would be in the window for 80% of the 24 hr period (based on once daily 
dosing).  
Fluoroquinolone resistance in P. aeruginosa has been described for strains 
demonstrating MICs of >8 μg/ml to both ciprofloxacin and levofloxacin and these 
strains frequently contain gyrA mutations at sites 83 and 87 (4).  Comparison of MPC 
values demonstrated that 8% of the mutants selected by ciproflxoaicn concentrations 
had a MPC value >8 μg/ml compared to 67% of the strains tested which had a   
levofloxacin MPC value of > 8 μg/ml (Figure 4.4.2).  In vitro studies have shown that 
acquisition of gyrA mutations in Gram-negative bacteria facilitate the step-wise 
selection of additional target mutations which confer higher degrees of fluoroquinolone 
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resistance (256, 267, 307, 342).  The selection of a first-step quinolone target mutation 
also increases the frequency with which additional mutations are selected relative to 
strains that do not harbour gyrase or topoisomerase mutations (207).  Sequence analysis 
of >400 base pair regions of the gyrA and parC genes demonstrated that selected 
mutants of P. aeruiginosa contain QRDR and as well as target mutations which map 
outside of the characterized QRDR regions of gyrA and parC.  Mutants selected from 11 
different strains of P. aeruiginosa were analyzed and five mutants contained a gyrA 
T83I mutation which has been proven to contribute to fluoroqouinolone resistance based 
on genetics studies (2).  Additional mutants contained uncharacterized mutations in 
regions of the gyrA and parC genes that were not present in the parental strains, 
suggesting a possible association between target mutations and phenotypic resistance.  
Examination of mutants recovered from mutant selection curves revealed that low 
concentrations of fluoroquinolone selected only non-gyrA mutants; at slightly higher 
concentrations, gyrA and parC variants were detected.  Failure to detect target mutants 
at low concentrations is likely due to the overwhelming numbers of susceptible cells 
relative to target mutants, or may be attributed to the presence of efflux mechanisms 
which are known to operate in clinical isolates of P. aeruginosa (176, 205, 219).   
However, overexpressions of different efflux proteins in the selected mutants were not 
analyzed in this study.  High fluoroquinolone concentrations selected T83I gyrA 
mutants, which were readily detected in isolates with intermediate fluoroquinolone 
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Figure 4.4.2.   Stratification of the Mutant Selection Window Based on  
  Ciprofloxacin and Levofloxacin MPC Distributions for 155 Clinical 
  Isolates of P. aeruginosa 
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susceptibilities, suggesting that isolates with intermediate phenotypes appear to select 
the T83I mutation as the “next-step” mutant in the progression of fluoroquinolone 
resistance.  This suggestion implies that the T83I mutant(s) should be present in >1010 
CFU/ml cultures of P. aeruginosa with intermediate susceptibility to both ciprofloxacin 
and levofloxacin, and should be selected by both ciprofloxacin and levofloxacin drug 
concentrations.  For some strains, no target mutants (i.e., gyrA/parC) could be detected 
in colonies selected from ciprofloxacin plates.  Two related factors may contribute to 
this finding.  1.) Sequence analysis was preformed on a limited number of mutants, thus, 
target mutants present in low numbers, may not have been detected in the limited 
numbers of colonies sampled.  2.)  Differences in mutant recovery may reflect 
differences in bactericidal activity which are not reflected in the MPC measurement.   
Thus, enhanced killing of mutant cells at low and moderate concentrations of 
ciprofloxacin may reduce, or eliminate the T83I mutant population, making it difficult 
to detect target mutants relative to levofloxacin.      
 Step-wise  acquisition of resistance may explain why some of the mutations 
identified in recovered mutants of P. aeruginosa have yet to be reported in the literature, 
because first-step mutants selected from susceptible strains produce small changes in 
susceptibility that are not detected as a 2-fold change in susceptibility (i.e., the MIC).  
Additionally, resistance is not an absolute term and many levels of resistance can be 
attained through acquisition of target mutations.  For example, over 30 different 
resistance alleles have been obtained with fluoroquinolones and M. tuberculosis (332, 
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334).  Analysis of P. aeruginosa mutants identified 10 different gyrA, and 8 parC 
mutations.  However, “resistance” is typically detected and acknowledged in a 2-fold 
change in the MIC and would not account for target mutations that may lead to the 
selection of mutants with higher degrees of resistance.  In this respect, the definition of 
the MPC should include the concentration which prevents the growth of the most 
resistant phenotype selected from within a given susceptible population.  This 
hypothesis may also help to explain detection of multiple target mutations in some of 
the recovered mutants.  Figure 4.4.3 represents a potential dose response curve and 
mutant selection window for a hypothetical fluoroquinolone antimicrobial.  For any 
given pathogen, different susceptible phenotypes are likely to exist, each conferring a 
relative degree of “resistance” which manifest through differences in susceptible MICs.  
Thus, a number of different susceptible strains can exist within a population of cells 
classified as susceptible.  Allelic diversity within the regions of the gyrA and parC 
genes coupled with efflux pump expression may influence the specific resistance 
determinant selected.  A given compound may only be able to inhibit the selection of a 
defined number of mutants.   
 Therefore, once a certain degree of “resistance” is achieved in a parental strain, 
the “next-step” mutant select may not be inhibited (or killed) by clinically relevant 
concentrations.  Differences between an agent’s propensity to select for resistance, as 
determined by the MPC, may reflect targeted activities against a defined number an/or 
variants of first-step resistant mutants selected from within genetically distinct 
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Figure 4.4.3 Relationship Between Selection of Resistant Mutants and Initial  
  Degree of Susceptibility   
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A proposed model for mutant selection suggests that differences in allelic variants selected in 
1010 CFU/ml cultures is dependent on the degree of susceptibility in initial susceptible 
populations.  Different susceptible isolates are represented as rectangles, all of which confer a 
different degree of susceptibility as determined by variance in susceptible MIC values.  
Mutants selected from 1010 CFU/ml cultures of susceptible isolates are illustrated by stars.  
For any given fluoroquinolone agent, the growth of a finite number of mutants can be 
inhibited at concentrations below a breakpoint for resistance for the drug.  Thus, differences 
in the MPC results between antimicrobials of the same class may relate to the preferential 
ability of an agent to inhibit a larger proportion of the mutants selected from within 
susceptible populations.    
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susceptible populations.  Therefore, differences between ciprofloxacin and levofloxacin 
MPC results may be due to the preferential ability of ciprofloxacin to inhibit the growth 
of a larger number of first-step mutant populations that are selected from within a larger 
array of susceptible isolates.  The gyrB and parE subunits of DNA gyrase and 
topoisomerase IV are secondary quinolone targets and resistance and gyrB and parE 
mutations have been found in strains of P. aeruginosa which already contain gyrA or 
gyrA + parC mutations (156, 200, 248).   
 Mutations in gyrB and parC regions were not examined in my analysis as it is 
well known that gyrA mutations are the first target mutations to be obtained in Gram-
negative bacteria and those parC mutations are secondary.  Since my study looked at 
first-step mutations, it was not necessary to look at parE and gyrB mutations because 
they are unlikely to be present, but I cannot exclude the possibility that mutations in 
regions of the parE and gyrB gene may have contributed to resistance in some of the 
recovered mutants.  The effect of target mutations on the subsequent development of 
resistance is still under investigation.  MPC measurements preformed on recovered 
mutants will help to identify if selected mutants increase the acquisition or frequency of 
additional resistance alleles relative to parental colonies.  MPC results for isolates with 
intermediate susceptibilities to ciprofloxacin and levofloxacin reproducibly selected 
T83I gyrA mutations (Table 4.3.3) suggesting that the  “next-step” mutant selected from 
strains with intermediate susceptibility is one which confers a level of resistance that is 
associated with poor clinical success (4, 124).   
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 MICs for recovered mutants (MICrecovered) were 6- to 10-fold higher when 
compared to parental MICs (Table 5.3.2).  Overall, 81% (165/204) of the recovered 
mutants demonstrated elevated MICs to ciprofloxacin and levofloxacin when compared 
to the MIC of the parental isolates and 69% (140/204) of the mutants tested had a 
resistant phenotype.  One hundred and eight mutant colonies were recovered from 
ciprofloxacin concentrations above the MPC during MPC testing and 91% (98/108) of 
the recovered mutants were within one doubling dilution of the MPC results when re-
tested by conventional MIC testing.  For levofloxacin, 94% (91/96) of mutants 
recovered from levofloxacin plates were with one doubling dilution of the MPC 
measurement.  Thus, mutant colonies represent stable phenotypes with decreased 
fluoroquinolone susceptibilities.  A 50 mM solution of CCCP was added to 
susceptibility panels to examine whether efflux mechanisms contribute to 
fluoroquinolone resistance in recovered mutants (287, 365).  For ciprofloxacin, 23% of 
the strains tested showed at least a 2-fold decrease in the MICrecovered in the presence of a 
50 mM solution of CCCP.  For levofloxacin, 16% of the strains demonstrated a >2-fold 
decrease in susceptibility upon the addition of CCCP.  Generally, a >2- fold change in 
the MIC with the addition of CCCP is required to identify active efflux as a mechanism 
of fluoroquinolone resistance in isolates of P. aeruginosa (365).  Thus, by this system, 
efflux mechanisms could not be identified as primary mechanisms of fluoroqouinolone 
resistance in recovered mutants of P. aeruignsoa, however, a lack of clear correlation 
between CCCP-promoted increases in fluoroquinolone accumulation and resulting 
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decreases in the MIC is known to exist in strains where efflux has been shown (119, 
266).  In addition, these studies did not account for cumulative differences in efflux 
expression between 105 and 1010 CFU/ml.   As such, demonstration of CCCP-enhanced 
MIC results cannot be the sole determinant used to support (or disprove) the role of 
efflux mechanisms in fluoroquinolone resistance.  PFGE of recovered mutants and 
parental isolates showed no differences in the DNA banding profiles (Figure 4.3.7) and 
indicated that recovered mutants did not represent distinct clones relative to parental 
organisms but rather were selected from within parental populations. 
 Concentration-dependent killing by fluoroquinolones suggests that targeting 
MPC in antibiotic dosing strategies may have a profound impact on minimizing 
resistance and the speed to clinical resolution (34, 146).  Thus, agents whose 
serum/tissue concentrations do not exceed the MPC for the entire length of the dosing 
interval may still be effective at minimizing the selection of resistant mutants if mutant 
killing occurs within a time interval during which fluoroquinolone concentrations 
exceeds the MPC (Figure 4.4.4).  Conventional kill-curves performed with 
fluoroquinolones do not reflect the killing of first-step resistant mutants because the  
inoculums used are too low to account for their presence.  Killing at the MIC drug 
concentrations resulted in < -2 log reductions in overall viability for both isolates tested.  
Mutant outgrowth was observed in both ciprofloxacin and levofloxacin treated cultures 
which accounted for the majority of the cells present in cultures by 12-24 hr.  Killing at 
the MPC drug concentration resulted in > -3 log killing between 4 and 8 hr and mutant 
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Figure 4.4.4  The Relationship Between Bacterial Killing and the MPC for 
          Fluoroquinolones  
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growth was restricted.  Thus, killing at the MPC drug concentration resulted in > 5 log 
difference in mutant killing compared to killing at the MIC drug concentration when the 
contents of 1010 CFU/ml cultures of P. aeruginosa were tested against ciprofloxacin and 
levofloxacin.  A difference of ~4 logs growth was observed between cultures treated 
with MIC and MPC fluoroquinolone concentrations indicating that killing at the MPC 
drug concentration resulted in rapid reductions in both susceptible and mutant cells 
which is hypothesized to decrease the potential for selecting resistant mutants and 
positively impact on clinical outcome since clinical performance is dependent on 
antibiotic-mediated bacterial eradication in a number of infections (67). 
 Recently, Firsov et al (109) demonstrated that fluoroquinolone concentrations 
which fluctuated within the MSW were associated with a decrease in the susceptibility 
of S. aureus to fluoroquinolones.  Killing experiments based on the MIC drug 
concentration failed to achieve significant bacterial killing and the outgrowth of mutant 
subpopulations paralled the decline in growth of the susceptible population.   
Killing experiments conducted at the MPC drug concentration using 1010 CFU/ml 
cultures provide preliminary insight into the relationship between drug PK and time 
required for mutant killing.  For ciprofloxacin, the projected time serum drug 
concentrations are expected to in excess of the MPC90 for P. aeruignsoa is estimated to 
be 5.5 hr for 90% of strains and 13 hr for organisms with ciprofloxaicn MPCs of <2 
µg/ml.  For levofloxacin, the MPC90 was 16 µg/ml and the modal MPC value was 8 
µg/ml.  As such, no current recommended dosage of levofloxacin would exceed 16 
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µg/ml and for organisms with MPCs of 8 µg/ml, serum drug concentrations would 
exceed this value for approximately 2 hr (144, 146, 148).  Serum drug concentrations 
for levofloxacin fall within the experimentally defined MSW for a greater time and 
correlate with decreased time above the MPC required to prevent the selection and 
enrichment of resistant subpopulations.  Using an in vitro PK/PD model to simulate 
fluoroquinolone doses that fluctuated within the MSW for S. aeurus, Firsov et al  (109) 
demonstrated that drug concentrations which remain within the MSW for >45% of the 
dosing interval could readily select for resistant organisms.  It can be further argued that 
the practical role of bacterial killing on enrichment of resistant mutants within the MSW 
serves to minimize the rounds of replication for mutant cells.  To date, the anti-infective 
community relates the concentrations of antimicrobial agents in plasma to the MICs for 
relevant pathogens and thereby makes recommendations on antibiotic dosages and 
dosing intervals. Thus, it may be argued that the relevant concentration used in in vitro 
kill kinetic experiments should include the relevant serum/tissue Cmax.  This argument 
has been the basis for debate in the literature regarding the bactericidal action of 
ciprofloxacin and levofloxacin against P. aeruginosa (323).  Levofloxacin is dosed 
based on tolerability and, as such, accumulates in the serum and infected tissues to a 
much greater degree than can be obtained for ciprofloxacin.  This allows levofloxacin to 
be dosed at much higher levels, thereby achieving a larger AUC/MIC for a single dose 
which may result in higher rates of bacterial killing, as the action of fluoroquinolones is 
concentration dependent.  Thus, recent reports citing superior killing by levofloxacin 
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against P. aeruginosa have fuelled the debate over appropriate quinolone use in 
infection caused by this agent (130, 225, 322, 323).  
 Gillespie et al  (130) examined the mutation rate for ciproflxoaicn and 
levofloxacin against strains of P. aeruignsoa, using large inocula.   In the 11 examples 
where the mutation rates could be directly compared, levofloxacin was less likely to 
select resistant mutants in five instances.  Mutants recovered from six strains were 
tested for killing by ciprofloxacin and levofloxacin at the expected pulmonary epithelial 
lining fluid drug concentration and no consistently significant differences in killing 
between the two agents was observed, despite the fact that levofloxacin concentrations 
represent a 2-fold higher epithelial lining fluid drug concentration than for 
ciprofloxacin.  In the context of my kill experiments, some notable observations in the 
Gillespie study require further explanation.  The inoculums used to select mutants 
ranged from 6.6x106 to 3 x109 CFU/ml  For levofloxacin, 1/7 stains tested utilized a test 
inoculum > 109 CFU/ml and only 2 of the strains tested were exposed to inoculums 
>108 CFU/ml.  Previous experiments have demonstrated that a minimum of 109 CFU/ml 
is required to consistently detect sub-populations of first step resistant cells (146), thus 
the absence of mutants selected by levofloxacin may be a result of using inoculums that 
do not contain mutants (or high enough numbers of mutants) to be detected.  In some 
cases, the authors failed to acknowledge that direct comparisons between the mutant 
selection potential for ciprofloxacin and levofloxacin were made using inocula that 
differed up to 1000-fold.  In addition, many of the strains used in the study represented 
 170
intermediate phenotypes.  For fluoroquinolones and P. aeruginosa, application of MPC 
may only be significant in the context of fully susceptible strains.  Therefore, their 
conclusion that levofloxacin is less likely than ciprofloxacin to select resistant mutants 
may not hold true when susceptible strains are used and when inocula of >109 CFU/ml 
are tested.     
Additional reports have also described equivalent killing of ciprofloxacin and 
levofloxacin against P. aeruginosa (271, 362).  MacGowan et al  (225) further qualified 
the differences in killing by suggesting that the bactericidal activities of levofloxacin 
and ciprofloxacin are equivalent provided similar AUC/MIC ratios can be obtained.  
Thus, apparent differences in the bacteristatic and bactericidal activities of ciprofloxacin 
and levofloxacin may relate to the initial degree of resistance present in the parental 
isolate.  As has been previously implied, it is possible that once a defined degree of 
resistance is achieved, the bacteristatic and bactericidal activity of ciprofloxacin and/or 
levofloxacin may be compromised to the point where clinically achievable 
concentrations are unable to control the mutant either through inhibition of growth or 
bacterial killing.  Although levofloxacin is able to achieve a high Cmax (12.1 μg/ml) 
(274), it is expected to remain in excess of the MPC90 and MPC50 for 0 and 3 hr, 
respectively, of the dosing interval for P. aeruginosa.  Some strains of P. aeruginosa 
possess MPCs which lie outside clinically achievable concentrations.  Enhanced killing 
related to a high Cmax may be offset by the fact that relevant killing concentrations are 
attained for short periods.  Serum concentrations of ciprofloxacin dosed three times 
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daily are projected to remain in excess of the MPC90 and MPC50 for 5.5 and 13 hr 
respectively, of the dosing interval for P. aeruginosa. Thus, relevant killing 
concentrations are also maintained for longer periods for ciprofloxacin.  In my 
preliminary experiments on the killing of P. aeruginosa by ciprofloxacin and 
levofloxacin, MIC concentrations failed to achieve > -3 log killing and mutant colonies 
could be readily recovered from cultures treated at the MIC drug concentration.  As 
expected, when cultures were treated at the MPC drug concentration, significant killing 
was observed and mutant growth was inhibited.  Mutant colonies were killed by 
ciprofloxacin and levofloxacin MPC drug concentrations within a 2-to-4 hr period, 
however, the entire contents of the cultures were not sampled and viable mutant 
colonies may have been missed as a result.  Nevertheless, these experiments 
demonstrate that increased killing is observed at the MPC drug concentration and 
mutant growth is prevented.  Killing of characterized target mutants and detailed 
analysis of the drug concentrations at the sites of infection will help to further define the 
length of time ciprofloxacin and levofloxacin MPC concentrations should be targeted in 
treatment of infection caused by P. aeruginosa. 
Antibiotic extrusion by efflux pumps is a major determinant of antimicrobial 
resistance in P. aeruginosa and four MDR efflux pumps with broad specificities have 
been identified in clinical isolates (264, 265, 291).  The four major efflux systems 
which contribute to apparent fluoroquinolone resistance in strains of P. aeruginosa, 
include MexAB-OprM (206, 208, 294), MexCD-OprJ (190, 292), MexEF-OprN (189), 
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and MexXY-OprM (161, 240, 352).  The selection of non-gyrase mutants at low and 
moderate fluoroquinolone concentrations raised the question of whether activity against 
efflux mutants of P. aeruginosa could be used to account for differences in mutant 
selection between ciprofloxacin and levofloxacin.   However, the relevance of efflux 
mechanisms in resistance of clinical strains pf P. aeruginosa has rarely been 
demonstrated, mainly because an experimental approach for accurate measurement of 
the rates of export of antibiotics into bacterial cells is lacking.  The selection of efflux 
mutants at low and moderate quinolone concentrations was demonstrated by Kohler et 
al  (190) who were able to detect spontaneously resistant colonies which expressed 
efflux pumps after incubation when 109-to- 1010 CFU/ml cultures were challenged with 
multiple concentrations of the fluoroquinolone MIC.  The authors were able to conclude 
that the preferred resistance mechanism selected by P. aeruginosa in response to a 
single exposure of quinolones at low concentrations (close to the MIC) is antibiotic 
efflux and not alteration of the gyrase gene (190).    
As expected, when mutants over-expressing four efflux systems were tested 
against increasing fluoroquinolone concentrations, a shift in the recovery of resistant 
colonies, toward higher drug concentrations, was observed.  For all strains tested, a 
clear distinction between the MIC and the MPC measurements could be observed as 
colonies continued to form at or above the MIC drug concentration.  It is postulated that 
resistance due to active efflux can be overcome in vivo with higher fluoroqouinolone 
concentrations or more frequent dosing.  Thus, in the context of minimizing resistance 
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in cells expressing MDR efflux pumps, the key factor will be the relative degree that 
efflux-expressing strains shift the MPC (toward higher drug concentrations) and the 
mutant selection curve.  Direct comparison of the anti-pseudomonal activity for 
ciprofloxacin and levofloxacin, based on the MPC values, revealed that ciprofloxacin 
was on average 2.9-fold more active against first-step mutants selected from strains of 
P. aeruginosa which overexpressed one of four different efflux systems.  The overall 
change in susceptibility (based on differences between the MIC and MPC) for 
ciprofloxacin and levofloxacin was not remarkable for any of the efflux mutants tested, 
but changes in susceptibility to levofloxacin tended to be less than those for 
ciprofloxacin.  Higher MPC values for levofloxacin resulted in low AUC/MIC ratios 
which have been linked to an increased potential of a fluoroquinolone to select for 
resistance (115).  MPC results for nfxB and nfxC mutants of P. aeruginosa suggest that 
mutants selected from strains expressing MexCD-OprJ and MexCD-OprN efflux 
systems may results in clinical resistance.  Sequence analysis of the gyrA and parC 
regions in the recovered mutant are now required to determine if mutants selected from 
nfxB mutants represent gyrA mutants.  Selection of resistant mutants from 1010 CFU/ml 
cultures of P. aeruginosa  which overespressed one of four different efflux pumps 
resulted in lower levofloxacin AUC/MPC values when compared to AUC/MPC values 
obtained for ciprofloxacin.  Differences among levofloxacin MPC results for the four 
efflux mutants tested suggest that activity of levofloxacin against mutants selected from 
strains expressing different efflux pumps is not equal.  Thus, differences in mutant 
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selection between ciprofloxacin and levofloxacin among strains of P. aeruginosa may 
reside in the preferential ability to restrict the growth of specific efflux mutants of P. 
aeruignsoa.  This suggestion is in good agreement with previously reported results by 
Kohler et al  (190) who demonstrated that quinolones vary in their capacity to select 
efflux systems in vitro.  For older quinolones such as flemequine and nalidixic acid, 
nfxC efflux mutants were selected at higher concentrations and were associated with the 
highest MICs.  In contrast, newer quinolones, which included ciprofloxacin, 
trovafloxacin and sparfloxacin, selected nfxB at 2-to-4 times the MIC and nfxB mutants 
were associated with the highest levels of resistance.  A comparison of ciprofloxacin 
and ofloxacin, the parent drug of levofloxacin (levofloxacin is a 50:50 racemate of the 
active ingredient in ofloxacin), revealed that at higher concentrations, ciprofloxacin 
exclusively selected nfxB mutants, while ofloxacin selected combinations of nfxB and 
nfxC mutants.  These results demonstrate the differential selection of efflux systems by 
quinolones in P. aeruginosa and support the hypothesis that differences in mutant 
selection between ciprofloxacin and levofloxacin are attributed to a differential ability 
of a fluoroquinolone to restrict the selection of first-step mutants from P.aeruginosa 
strains which express different efflux pumps.  This hypothesis is of particular 
importance in light of recent publications demonstrating the additive effects of multiple 
MDR efflux pumps on reduced susceptibility in P. aeruginosa (208, 219, 296).  When I 
analyzed the recovery of mutants from 1010 CFU/ml cultures of efflux mutants of P. 
aeruginosa, selection of resistant mutants was approximately 3-fold higher for 
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levofloxacin when nfxB and nfxC efflux mutants were challenged against increasing 
concentrations of ciprofloxacin and levofloxacin and suggests that the MexCD-OprJ 
(nfxC) efflux may be a more efficient pump for levofloxacin than for ciprofloxacin in 
isolates of P. aeruginosa.  This finding is supported by a recent in vivo study by Jumbe 
et al (179) who used type-specific efflux pump inhibitors alone and in combination to 
verify the central role efflux pumps play in the initial emergence of resistance to 
levofloxacin.  With therapy, early time points saw the selection of the MexEF-OprN 
pump. Later time points demonstrated that the predominant pump system overexpressed 
in response to challenge with levofloxacin was MexCD-OprJ.   
In the context of MPC testing, an additional question remains; do efflux mutants 
represent first-step resistant cells as defined by the MPC measurement?  Efflux 
expression in P. aeruginosa is constitutive and thus, is likely to operate to some degree 
in susceptible populations.  It is possible that cumulative decreases in intracellular drug 
concentrations for cultures containing >109 CFU/ml result in increased resistance; an 
observation not seen with lower numbers of cells (i.e., 105 or 106 CFU/ml).  Thus, in a 
population of cells 10,000 times greater than those used in conventional susceptibility 
tests, the cumulative level of efflux expression results in a shift toward higher levels of 
resistance which can be overcome by higher fluoroquinolone concentrations (i.e., the 
MPC).  In this context, efflux mutants may not represent first-step mutants, as defined 
by the conventional definition of MPC, however, in the nalB multidrug-resistant 
mutant, overexpression of the mexA-mexB-oprM operon in strains of P. aeruginosa has 
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been associated with a point mutation in mexR, the regulator gene of the efflux operon, 
leading to a predicted substitution of Trp for Arg at position 69 in the encoded peptide, 
MexR (294).  Additional point mutations in the regulatory genes of nalB, nfxB and nfxC 
have recently been described (219, 347).  Mutations occurring in regulatory efflux 
genes are also affected by mutational frequencies that are likely to be influenced by 
population dynamics.  Thus, mutational events that contribute to efflux expression may 
represent first-step mutants.  As investigation into MPC expands to include additional 
antimicrobial agents, other mechanisms of resistance and specific host-drug-pathogen 
combination, the definition of MPC is likely to expand as well.  Although the MPC was 
initially defined with respect to susceptible populations, the idea applies to any step in 
the process of gradual accumulation of mutations (85).  In a broad sense, the MPC 
correlates with the MIC of the most-resistant mutant present in the bacterial population.   
Reductions in intracellular drug concentrations may raise the MPC in strains expressing 
efflux mechanisms or may then raise the MIC of the target mutants and, thereby, also 
raise the MPC.  The concentration boundaries of the MSW place no restriction on the 
types of mutants selected (i.e., target versus efflux) and the mechanism of resistance 
need not be known to use the selection window idea for restricting the development of 
resistance.  Restricting the selection of resistant mutants of P. aeruginosa is likely to be 
a function of both efflux and target mutations.  Selection of resistant mutants within 
strains expressing efflux pumps revealed that levofloxacin was less active against both 
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first-step resistant mutants (characterized and uncharacterized) and efflux mutants when 
1010 CFU/ml cultures were tested.   
MPC results obtained for 155 clinical isolates of P. aeruginosa indicate that no 
current dosage of ciprofloxacin or levofloxacin is expected to exceed MPC90 results for 
the entire duration of the dosing interval.  Thus, minimizing the selection of resistant 
mutants of P. aeruginosa with fluoroquinolone is likely to require combination therapy; 
however, limited data exists for MPC measurements of other antimicrobial agents alone 
or in combination.   The primary MICs or MPCs are often the criteria utilized by 
clinicians in selecting appropriate combinations of antimicrobials and, many times, only 
those antibiotics to which the organism is interpreted as susceptible are used.  This 
practice appears to assume that synergism is obtained only when the organism is 
susceptible to both antibiotics.  Unfortunately, with the increased incidence of MDR P. 
aeruginosa and other pathogens, the clinician is often faced with only one agent, or 
class of agents, that the pathogen is susceptible to.  Combination 
fluoroquinolone/ceftazidime MPC results restored susceptibility (as determined by a 
NCCLS breakpoints for susceptibility) in at least one of the agents used in combination 
for 66% of the ciprofloxacin plus ceftazidime tested isolates and 50% of levofloxacin 
plus ceftazidime tested isolates.  While the remaining strains did not produce 
combination MPCs that would result in a susceptible designation, all combination 
results increased the length of time inhibitory concentrations are expected to remain in 
excess of the MPC.  The combination of ciprofloxacin plus ceftazidime extended the 
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amount of time ciprofloxacin and ceftazidime inhibitory concentrations are maintained 
for an average of 6.5 and 7.6 hr, respectively, (based on 400 mg T.I.D. ciprofloxacin,  
1 g Ceftazidime once daily).  Levofloxacin/ceftazidime combinations increased the time 
levofloxacin and ceftazidime concentrations are in excess of the combination MPC by 
an average of 1.45 and 3.48 hr, respectively.  Additionally, combination MPC results 
revealed that for every strain tested, at least one of the agents was in excess of the MPC 
for >11 hr of a potential 24 hr dosing interval.   
 The mechanistic difference in anti-pseudomonal activity between ciprofloxacin 
and levofloxacin used in combination with ceftazidime is still undetermined and may 
attributed to differences in inherent activity of each compound which become 
pronounced under combination testing conditions.  In an examination of the activity of 
levofloxacin in combination with ceftazidime, Visalli et al  (345) reported a 12% 
synergy between levofloxacin and ceftazidime, which contrasts sharply with the 75% 
reported by Bustamant et al  (47) with ciprofloxacin/ceftazidime combinations.  These 
studies highlight the observed differences in the anti-pseudomonal activity of 
ciprofloxacin and levofloxacin. In my experiments, half of the isolates tested showed no 
decrease in levofloxacin MPC results obtained in combination.  According to the 
selection window hypotheses, antimicrobial concentrations at the site of infection 
should be kept outside the widow to avoid selective enrichment of resistant mutants.  
For fluoroquinolones and P. aeruginosa, MPC results suggest that neither ciprofloxacin 
nor levofloxacin is expected to maintain concentrations above the MPC90 for a 
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significant duration of the dosing interval, so combination therapy is required to 
effectively lower the MPC and the upper boundary of the MSW.   
 The exact mechanism(s) of action involved in combination therapy with 
different drug combinations is not known with certainty and often times “synergy” is 
used to describe an increase in effect between two agents that could not demonstrate 
activity independently.  Enhanced uptake, mutual killing, macrophage activity and 
increased permeabilization of the outer membrane have all been suggested as possible 
mechanisms in the explanation of success with combination therapies (48, 141, 239).  
Conceptually, a combination treatment regimen containing two or more drugs of 
different classes should require at least two distinct resistance mutations for the 
pathogen to grow. For example, if two agents with differing mechanisms of action 
(which also lack cross-resistance) were to fall within the selection window, organisms 
would still require two resistance-conferring mutations is order to express resistance.  
The simultaneous occurrence of two such mutations is expected to occur much less 
frequently than for a mutational event resulting in a single drug-resistant mutation.   
This rationale has been used effectively in the combination treatment of M. 
tuberculosis.  Consequently, combination therapy with two distinct antibiotic types 
provides a way to reduce mutant selection using moderate concentrations of compound 
that may individually have very high MPC values.  The role of combination testing and 
the MPC requires further investigation and many questions remain.  For example, 
combination MPC testing may produce a synergistic result which effectively reduces 
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the MPC of both antimicrobials such that both agents are expected to remain in excess 
of the MPC for the duration of the dosing interval.  In some cases, such as M. 
tuberculosis, the MPC of the first antimicrobial agent may be outside an achievable 
drug concentration even when used in combination(s) with other agents, but when 
combination therapy with multiple agents that have different molecular targets is 
employed, the ability of the bacteria to develop resistance is reduced.  For this situation, 
matching the PK/PD profiles of multiple agents to ensure that concentrations will rise 
and fall above and below the MIC simultaneously could be used to help restrict the 
selection of resistant mutants.  If at any time during the dosing interval concentrations 
of one of the drugs falls below the MIC and the remaining drug is kept above the MIC, 
then resistant mutants may be selected.  In vitro experiments 
In vitro experiments have illustrated that first-step resistant mutants are selected 
by fluoroquinolone concentrations when 1010 CFU/ml are exposed to increasing 
fluoroquinolone concentrations above the MIC of the wild-type strain.  Experimentally, 
the MPC can be measured in a two-stage decline in CFUs when 1010 cells are applied to 
agar containing increasing fluoroquinolone concentrations.  Mutant enrichment and 
subsequent outgrowth was illustrated in killing experiments preformed using 1010 
CFU/ml cultures tested at the MIC drug concentrations.  However, direct in vivo 
evidence confirming the selection of resistant mutants of P. aeruginosa with 
fluoroquinolone therapy in infections containing >109 cells has not been obtained.  I 
adapted an abscess rat model (306) to test the hypothesis that resistant mutants could be 
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recovered from animals implanted with 1010 CFU/ml cultures of P. aeruginosa when 
given I.V. doses of fluoroquinolones.  An isolate of P. aeruginosa (CBRH 25138) with 
intermediate susceptibility to ciprofloxacin and levofloxacin was chosen as the infecting 
organism since it represented a potentially difficult-to-treat pseudomonal infection.  
Previous in vitro experiments indicated that susceptibility differences between mutants 
selected from this isolate and parental organisms would be large enough to allow me to 
monitor mutant selection using 2-fold susceptibility testing.  P. aeruginosa was 
recovered from a total of 27 specimens (which included infected tissues, swabs, and 
blood cultures) and from 9 different animals given doses of either ciprofloxacin of 
levofloxacin (Table 4.3.10).  Nearly 20% of the total number of recovered organisms 
demonstrated elevated susceptibilities to both ciprofloxacin and levofloxacin, 
suggesting the selection of resistant organisms.  The recovery of P. aeruginosa from the 
infected animals was not a surprising finding and virtually all of the animals tested 
became bacteremic.  Thus, the intent of the experiment was to demonstrate that cultures 
of P. aeruginosa recovered from infected rats represented mutant organisms (with 
respect to parental susceptibility) which were selected from 1010 CFU/ml cultures when 
treated with fluoroquinolones.  Twenty-four percent of the specimens recovered from 
rats given a once a day dose of ciprofloxacin or levofloxacin showed increases in the 
MICs to ciprofloxacin and levofloxacin and correlated with an average 2-fold increase 
in the MIC to ciprofloxacin and 4-fold increase in MIC to levofloxacin.  The MIC of the 
recovered mutants were 4 and 16 μg/ml for ciprofloxacin and levofloxacin, 
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respectively, and were in agreement with the MPC for the initial strain used to create 
infection.  One specimen showed a 4- and 8-fold increase in the ciprofloxacin and 
levofloxacin MICs that may relate to the difference in serum versus tissue 
concentrations of fluoroqouinolones.   
These results are based on preliminary experiments using a single isolate of P. 
aeruginosa and relatively small numbers of animals and, as such, require additional 
testing.  However, based on these results, a number of observations can already be 
made.  Resistant organisms were recovered from 3/9 animals tested and phenotypic 
analysis of resistance was consistent with the hypothesis that first-step resistant mutants 
are selected from within 1010 CFU/ml cultures of P. aeruginosa when tested by 
fluoroquinolones at sub-MPC drug concentrations.  This result is consistent with my in-
vitro experiments.  Resistant organisms were recovered from rats after three days of 
fluoroquinolone treatment, suggesting that mutant organisms pre-exist in populations in 
excess of 107 CFU/ml and can be selected for and enriched by sub-inhibitory drug 
concentrations.  The degree of fluoroquinolone resistance in the recovered mutants was 
4-fold higher for levofloxacin than for ciprofloxacin, which is consistent with MPC90 
results.  Mutant organisms were only recovered from animals given a once daily dose of 
fluoroquinolone.  If fluoroquinolone concentrations drop below the MPC, and if the 
decline of the susceptible populations occurs quickly, either as function of antibiotic 
action or immune deviation, then mutant enrichment is likely to occur for a majority of 
the dosing interval giving rise to the selective enrichment of mutant organisms.  A 
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T.I.D. dose, which results in higher concentrations near or above the MPC for a longer 
period will inhibit first-step resistant mutants and prevent the selection of resistant 
organisms.  For animals give T.I.D. doses of ciprofloxacin or levofloxacin, it is possible 
that mutant populations were not enriched above threshold that would allow them to 
detected during standardized susceptibility testing.  DNA sequence analysis of gyrA and 
parC QRDR regions in the recovered mutants will help to correlate increased 
fluoroquinolone resistance with potential target mutations.  Comparison of target 
sequences in the mutants recovered from infected rats could then be compared with 
those obtained under in vitro testing to demonstrate that the same mutant variant was 
selected in vivo.            
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5.0 Comparison of the MIC, MBC, and MPC Measurements for   
  Ciprofloxacin, Levofloxacin and Garenoxacin Against Enteric  
  Gram-negative UTI Pathogens 
 5.1 Abstract 
 
 Acute, uncomplicated UTIs are among the most commonly encountered 
bacterial infections.  Management of these infections has been made more complicated 
by the trend toward increasing antimicrobial resistance, especially to β−lactams (i.e., 
ampicillin) and trimethoprim/sulfamethoxazole (TMP-SMX), among uropathogens in 
the last decade.  Fluoroquinolones are suggested as alternative antimicrobials for the 
treatment of UTIs in communities for which TMP-SXT resistance is > 10%.  The MPC 
represents a novel susceptibility parameter designed to minimize the selection of first-
step resistant mutants present in large, >1010 CFU/ml, cultures.  In the following work, I 
measured MPC results for 80 clinical enteric, Gram-negative urinary isolates and 20 
isolates of P. aeruginosa against ciprofloxacin, levofloxacin and an experimental 
fluoroquinolone, garenoxacin.  Ciprofloxacin MPC results for C. freundii, E. cloacae, 
E. coli, K. pneumoniae, and P. aeruginosa were 0.5, 1, 1, 1 and 4 μg/ml, respectively.  
MPC results for levofloxacin against C. freundii, E. cloacae, E. coli, , K. pneumoniae 
and P. aeruginosa were 1, 2, 4, 2 and 16 μg/ml, respectively. MPC results for 
garenoxacin against C. freundii, E. cloacae, E. coli, K. pneumoniae, and P. aeruginosa 
were 1, 8, >8, 4 and >32 μg/ml, respectively.  For ciprofloxacin against E. cloacae,  
E. coli, and K. pneumoniae and for levofloxacin against  C. freundii, E. coli, and K. 
pneumoniae, MPC results were below susceptible breakpoints.  Analysis of MPC 
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results in relation to the PK for garenoxacin, suggests that concentrations are in excess 
of MPC results for the entire length of the dosing interval for E. coli.   Overall, the MPC 
results for ciprofloxacin and levofloxacin were within clinically achievable and 
sustainable drug concentrations for > 24 hr of the dosing interval against all organisms 
tested.  These results further demonstrate that MPC is a novel susceptibility 
measurement, reflecting drug activities against first-step resistant organisms present as 
sub-populations within overall susceptible populations and, as such, is distinct from 
MIC and MBC measurements of susceptibility.  The application of the MPC to 
fluoroquinolones and the management of UTI represents a situation where high levels 
of in vitro activity, based on low MICs, is reflected in low MPC values for most of the 
organisms tested.  Incorporation of MPC results into current fluoroquinolone dosing in 
UTIs represents a realistic approach for preventing the further selection of resistant 
organisms associated with these infections.          
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 5.2 Introduction 
 
UTIs are one of the most commonly infectious diseases for which antibiotic 
therapy is prescribed (350).  In the United States, UTIs account for nearly 8 million 
physician visits per year and > 100,000 hospital admissions (182, 350).  Gram-negative 
bacteria typically account for a large proportion of UTIs with E. coli accounting for 75-
to-90% of all UTIs (139, 169, 261).  A number of different antimicrobials are used in 
the treatment of UTI which include (TMP-SMX), amoxicillin, cephalexin, 
nitrofurantoin and fluoroquinolones such as ciprofloxacin, levofloxacin, and, most 
recently, gatifloxacin (29, 261, 350).  Emerging antimicrobial resistance is beginning to 
impact on the empiric treatment of UTIs.  For example, among E. coli isolates, 33-to-
60% of the bacterial strains causing cystitis and phylonephritis demonstrate resistance 
to either amoxicillin or ampicillin (121, 182, 261), and up to 22% of strains may be 
resistant to TMP-SMX (330).  In comparison, resistance to the commonly used 
fluoroquinolones ciprofloxacin and levofloxacin remains low, at approximately 2-to-5% 
(182, 184). 
Many characteristics of the fluoroquinolones make them ideal agents for the 
management of UTIs.  As a class, the fluoroquinolones are highly active in vitro against 
nearly all significant urinary pathogens (30).  They are able to penetrate the prostate 
well and most are renally excreted, allowing them to concentrate to very high 
concentrations in the urine (168, 251).  Fluoroquinolones generally have a high degree 
of oral bioavailability, which allows for oral therapies for infections that traditionally 
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would have been treated with intravenous antibiotics and their long half-lives allow for 
once or twice daily dosing.  Consequently, fluoroquinolones have been and will 
continue to be used extensively in the treatment and prevention of UTIs, particularly in 
situations were TMP-SMX resistance is > 10% (350). 
When fluoroquinolones were first introduced in the 1980s, nearly all organisms 
recovered from patients with UTIs were considered susceptible in vitro.  Even today, 
fluoroquinolones remain among the most active oral agents against urinary tract  
isolates (26, 101).  However, over the past decade a number of studies have reported a 
substantial increase in the prevalence of fluoroquinolone resistance among urinary tract 
isolates and the prevalence of fluoroquinolone resistance has progressively risen.  For 
example, fluoroquinolone resistance levels among urinary isolates of E. coli have been 
reported as high as 25% within Latin America (121).  More disturbingly, many isolates 
commonly now have single point mutations in gyrA that presage progression to full 
resistance with additional mutations.  Therefore, minimizing the step-wise selection of 
fluoroquinolone-resistant Gram-negative bacteria is an important factor in preventing 
further increases in fluoroquinolone resistance among Gram-negative uropathogens.  
The MPC is a novel susceptibility measurement designed to identify and inhibit the 
most-resistant first-step resistant organisms present in large (>1010 CFU/ml). 
heterogeneous bacterial cultures.  In the following work, I measured MIC, MBC and 
MPC results for 100 Gram-negative urinary tract isolates for two commonly prescribed 
fluoroquinolones, ciprofloxacin and levofloxacin, and for a developmental 
 188
fluoroquinolone garenoxacin (BMS 284756) which has been shown to possess activity 
against Gram-negative UTI pathogens in vitro (59, 118).    
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 5.3 RESULTS  
 
Clinical isolates of C. freundii (n=20), E. cloacae (n=20), E. coli (n=20), K. 
pneumoniae (n=20) and P. aeruginosa (n=20) obtained from urinary tract specimens 
were tested by MIC, MBC and MPC as described in the Materials and Methods section.  
Comparison of MPC90 values revealed a relative hierarchy in fluoroquinolone potency 
(table 5.3.1).  
Against the 20 C. freundii isolates, modal MIC values were <0.06, 0.25 and 
<0.06-0.125 μg/ml, respectively, for ciprofloxacin, levofloxacin and garenoxacin, while 
modal MPC values were 0.125-0.5, 0.5 and 0.25 μg/ml, respectively.  For the 20 E.coli 
isolates (Figure 5.3.1) the modal MIC values for ciprofloxacin, levofloxacin and 
garenoxacin was <0.06, while the modal MPC values were 0.125-0.25, 0.25 and 0.25-
0.5 μg/ml, respectively.  Ciprofloxacin and levofloxacin had the same modal MIC 
values against strains of E. cloacae (<0.06 μg/ml), whereas the values for garenoxacin 
were between <0.06-0.125 μg/ml.  The modal MPC values against E. cloacae strains 
were 0.125 μg/ml for ciprofloxacin and 1 μg/ml for levofloxacin and garenoxacin.  
Against the 20 clinical strains of K. pneumoniae, modal MIC values were <0.06 μg/ml 
for ciprofloxacin, <0.06-0.125 μg/ml for levofloxacin and 0.125 μg/ml for garenoxacin; 
modal MPC values were 0.5 μg/ml, 1 μg/ml and 1-4 μg/ml, respectively.  Finally, the 
modal MIC values against the 20 clinical isolates of P. aeruginosa were <0.06 mg/ml,  
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Table 5.3.1  MIC, MBC, and MPC Distributions for UTI Isolates Against Ciprofloxacin, Levofloxacin, and 
Garenoxacin  
 
         Fluoroquinolone Susceptibility μg/ml                                 
Pathogen 
 
 
FQ 
Measurement 
<0.06 0.125 0.25 0.5 1 2 4 8 16 >32 
Mean 
number of 
cells 
tested 
(CFU/ml) 
 
MPC/susceptibililty 
measurement 
Result for 
90% of 
isolates 
Cpx MIC-AD       
MIC-MB       
MBC             
MPC 
14       
16         
15         
0 
4        
2        
1           
5 
1        
0        
0           
3 
1        
2        
1           
5 
0        
1        
1          
3 
0       
0        
0       
4 
0        
0        
0        
0 
0        
0        
0        
0 
  2.33x106     
2.33x106     
2.33x106     
2.87x1010    
16                                 
4                                  
4                                   
---- 
0.125           
0.5               
0.5               
2 
Grx MIC-AD       
MIC-MB       
MBC             
MPC 
5        
3        
3           
0 
5        
5        
5          
0 
2        
3        
3           
4 
0        
1        
1           
2 
3        
2        
2           
4 
1       
2       
2        
3 
4        
3       
3        
4 
0        
1        
1        
4 
  2.33x106     
2.33x106     
2.33x106     
2.87x1010    
2                                   
2                                   
2                                   
---- 
4                 
4                  
4                  
8 
C. freundii 
(n=20) 
Lfx MIC-AD       
MIC-MB       
MBC             
MPC 
5        
9          
5           
0 
5        
3         
5           
1 
6        
5        
5           
0 
4        
3        
3           
8 
0        
0        
2           
3 
0        
0        
0        
8 
0        
0       
0        
0 
0        
0        
0        
0 
  2.33x106     
2.33x106     
2.33x106     
2.87x1010    
4                                   
4                                   
1                                  
---- 
0.5               
0.5               
1                  
2 
Cpx MIC-AD       
MIC-MB       
MBC             
MPC 
18       
18         
18         
4 
1        
0        
0           
7 
0        
0        
0           
5 
1        
1        
1           
1 
0        
1        
1           
1 
0        
0        
0        
1 
0        
0        
0        
1 
0        
0        
0        
0 
  1.60x106     
1.60x106     
1.60x106     
6.62x1010    
16.6                              
16.6                              
16.6                              
---- 
<0.06           
<0.06           
<0.06           
1 
E. cloaceae 
(n=20) 
 
 
Grx MIC-AD       
MIC-MB       
MBC             
MPC 
7        
7        
7           
0 
7        
7        
7           
0 
3        
2        
2           
0 
2        
0        
0           
4 
1        
4        
4           
8 
0        
0        
0        
3 
0        
0        
0        
1 
0        
0        
0        
>4 
  1.60x106     
1.60x106     
1.60x106     
6.62x1010    
>16                              
>8                               
>8                                
---- 
0.5               
1                  
1                  
>8 
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 Lfx MIC-AD       
MIC-MB       
MBC             
MPC 
14      
15        
15         
0 
3        
3        
3           
1 
2        
1        
1           
3 
1         
0        
0           
6 
0        
1        
1           
7 
0        
0        
0        
0 
0        
0        
0        
2 
0        
0        
0        
1 
  1.60x106     
1.60x106     
1.60x106     
6.62x1010    
4                                   
32                                 
32                                 
---- 
0.25             
0.25             
0.25             
4 
Cpx MIC-AD       
MIC-MB       
MBC             
MPC 
17       
19        
19         
1 
2        
1        
1           
8 
1        
0        
0           
8 
0        
0        
0           
3 
0        
0        
0           
0 
0        
0        
0        
0 
0        
0        
0        
0 
0        
0        
0        
0 
  1.63x106     
1.63x106     
1.63x106     
7.78x1010    
4                                 
8.3                               
8.3                                
---- 
0.125           
<0.06           
<0.06           
0.5 
Grx MIC-AD       
MIC-MB       
MBC             
MPC 
15    
19        
19         
0 
4        
1        
1           
0 
0        
0        
0           
8 
1        
0        
0           
8 
0        
0        
0           
3 
0        
0       
0        
1 
0        
0        
0        
0 
0        
0        
0        
0 
  1.63x106     
1.63x106     
1.63x106     
7.78x1010    
8                                  
16.6                             
16.6                              
---- 
0. 125          
<0.06           
<0.06           
1 
E.coli  
(n=20) 
 
Lfx MIC-AD       
MIC-MB       
MBC             
MPC 
16       
19        
19         
0 
2        
1        
1           
0 
1        
0        
0           
12 
1        
0        
0           
5 
0        
0        
0           
2 
0        
0        
0        
1 
0        
0        
0        
0 
0        
0        
0        
0 
  1.63x106     
1.63x106     
1.63x106     
7.78x1010    
4                                  
16.6                              
16.6                              
---- 
0. 25           
<0.06           
<0.06           
1 
Cpx MIC-AD       
MIC-MB       
MBC             
MPC 
14       
19      
18        
1  
2        
0        
1           
3 
3        
1        
0           
7   
1        
0        
1           
3 
0        
0        
0           
4 
0        
0        
0        
2 
    1.06x106     
1.06x106     
1.06x106     
3.42x1010    
4                                   
16                                 
16                                 
---- 
0.25             
<0.06           
<0.06           
1 
Grx MIC-AD       
MIC-MB       
MBC             
MPC 
0        
4        
3          
0   
10      
12       
12         
0   
8        
4        
5           
0   
2         
0        
0          
2 
0        
0        
0           
6 
0        
0        
0        
6 
0        
0       
0        
6 
   1.06x106     
1.06x106     
1.06x106     
3.42x1010    
16                                 
16                                 
16                                 
---- 
0.25            
0.25             
0.25             
4 
K. 
pneumoniae 
(n=20) 
Lfx MIC-AD       
MIC-MB       
MBC             
MPC 
9        
10       
7          
0   
9        
5       
8           
0   
0        
3        
1          
1 
2         
3        
1           
4  
2         
1        
2           
10  
0        
1        
1        
4 
0        
0        
0        
1 
   1.06x106     
1.06x106     
1.06x106     
3.42x1010    
2                                   
2                                  
2                                   
---- 
0.5               
1                  
1                  
1 
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Cpx MIC-AD       
MIC-MB       
MBC             
MPC 
9        
2        
2           
0   
0        
6        
4           
0   
7        
8        
7           
0   
2         
3        
1           
0  
2         
2        
4           
0   
0        
1        
2        
2  
0        
0        
0        
7 
0        
0        
0        
2  
  1.60x106     
1.60x106     
1.60x106     
6.6x1010      
4                                   
4                                   
2                                   
---- 
1                  
1                  
2                  
4  
Grx MIC-AD       
MIC-MB       
MBC             
MPC 
  1        
0        
0           
0   
6        
0        
0           
0   
5        
4        
1           
0   
5        
9        
4        
0   
2        
5        
10      
0   
0        
1        
4        
2   
1        
0        
0        
10  
0        
1        
1        
8  
1.60x106     
1.60x106     
1.60x106     
6.62x101 
>8                                
>4                               
>4                                
---- 
4                  
4                  
8                  
>32 
P. 
aeruginosa 
(n=20) 
Lfx MIC-AD       
MIC-MB       
MBC             
MPC 
  4        
3        
1           
0   
7         
6        
5          
0  
5         
7         
4           
0   
3        
1        
7        
0  
1        
3        
3        
4 
0        
0        
0        
10  
0        
0        
0        
5   
0        
0        
0        
1  
1.60x106     
1.60x106     
1.60x106     
6.62x1010    
8                                   
4                                   
4                                   
---- 
2                  
4                  
4                 
16 
 
Cpx. Ciprofloxacin.  Lfx. Levofloxacin.  Grx. Garenoxacin.  MIC-AD. MIC obtained with agar dilution.  MIC-MB. 
MIC obtained with microbroth dilution.   
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Figure 5.3.1  MIC, MBC and MPC Results for 100 Gram-negative Urinary 
Isolates of C. freundii, E. coli, E. cloacae, K. pneumoniae and P 
aeruginosa for Ciprofloxacin, Garenoxacin, and Levofloxacin   
MIC, MBC and MPC distributions for C. freundii (n=20), E. coli (n=20), E. cloacae (n=20), K. pneumoniae 
(n=20), and P. aeruginosa (n=20) against ciprofloxaicn, levofloxaicn, and garenoxacin.  MIC-agar refers to MICs 
performed using the  agar dilution method, MIC-microbroth refers to performed using the  microbroth dilution 
method.  Lines indicate the number of cells tested for each test. 
C. freundii 
E. coli 
E. cloacae 
K. 
pneumonia
P. 
aeruginosa 
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 0.5 μg/ml and 1-2 μg/ml, respectively for ciprofloxacin, levofloxacin and 
garenoxacin.  The modal MPC values were 4 μg/ml, 8 μg/ml and 16 μg/ml, 
respectively.  MPC distributions did not directly correlate with MIC results.  For 
example, all agents tested had MIC90 values of <0.06 μg/ml against E. coli but 
ciprofloxacin was 2-fold more active by MPC than both levofloxacin and 
garenoxacin.  Based on MIC values, ciprofloxacin was at least 8-fold more active 
than levofloxacin against isolates of K. pneumoniae, but both ciprofloxacin and 
levofloxacin reported MPC90 values of 1 μg/ml.  Garenoxacin was 4-fold more 
active than levofloxacin against K. pneumoniae as determined by the MIC90, but 
was 2-fold less active by MPC.  Low MPC results tended to correlate with low 
MIC results, however, MPC measurements against the Gram-negative organisms 
tested could not be directly extrapolated from MIC results in all instances, which 
were reflected in the ratios of MPC/MIC.  Although all three quinolones 
demonstrated high levels of in vitro activity against strains of E. coli, the range 
between the MIC and the MPC was among the highest observed for any pathogen.  
The MPC results obtained for C. freundii, E. cloacae, E. coli, K. pneumoniae and 
P. aeruginosa for the three quinolones were generally 2-4, 8-16, 16, 16 and 4 times 
greater than the MIC.  The only exception to this trend was found for levofloxacin 
against K. pneumoniae, were a 2-fold difference between the MIC and MPC was 
observed.  As a greater number of organisms are tested, the MPC/MIC ratio may 
serve as a general guideline for assessing quinolone MPCs against different 
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pathogens through batch studies that may eliminate the need for determining an 
individual MPC.      
The lowest MPC results were observed for isolates of E. coli, followed by K. 
pneumoniae, E. cloacae, C. freundii and P. aeruginosa (Table 5.3.1).  MPC results for 
ciprofloxacin and levofloxacin against Gram-negative urinary tract pathogens were 
generally low.  For ciprofloxacin, the MPC results for E. cloacae, E.  coli, and K. 
pneumoniae were all at or below the susceptible breakpoint as set by the NCCLS (< 1 
μg/ml).  The MPC results for C. freundii and P. aeruginosa were at an intermediate (2 
μg/ml) and above a resistant (4 μg/ml) breakpoint.  For levofloxacin, MPCs against C. 
freundii, E.  coli, and K. pneumoniae were below a susceptible breakpoint (<2 μg/ml), 
while MPCs against E. cloacae and P. aeruginosa were at intermediate (4 μg/ml) and 
resistant (8 μg/ml) breakpoints.  No breakpoints for garenoxacin have been developed, 
however, based on the published PK (120) and reports on the in vitro activity (118), it 
is hypothesized that only E. coli may have low enough garenoxacin MPC values to still 
be considered susceptible.   
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  5.4 DISCUSSION 
Acute, uncomplicated UTIs are among the most commonly encountered 
bacterial infections.  Management of these infections has been made more complicated 
by the trend toward increasing antimicrobial resistance, especially to β−lactams and 
TMP-SMX, among uropathogens in the last decade (168).  The current standard of 
therapy for empiric treatment of acute, uncomplicated UTIs is TMP-SXT (350), but the 
prevalence of resistance to TMP-SMX among uropathogens is increasing (168, 169)  
and empiric therapy without the guide of laboratory results can no longer ensure 
success.  Consequently, quinolones are increasingly being used as first line agents for 
the treatment of UTIs and in vitro susceptibility results have become important in the 
management of these infections (26).  Laboratory susceptibility results are a valuable 
tool for clinicians and can be used to guide therapeutic decisions.  MICs obtained via 
microbroth dilution, agar dilution, disk diffusion, or E-tests are typical susceptibility 
tests preformed in clinical settings (258).  The MBC is less commonly preformed and 
represents concentrations which kill 99% of the culture.  The bactericidal action of 
quinolones generally results in a very tight dispersion between MIC and MBC results, 
usually <1 doubling dilution (247, 270, 346).  To date, no studies have specifically 
addressed the relationship between MBC and MPC measurements.  Differences of 2- to 
16-fold were noted between MPC and MBC measurements for ciprofloxacin, 
garenoxacin, and levofloxacin against isolates of C.  freundii, E.  cloacae,  E.  coli, , K. 
pneumoniae, and P. aeruginosa.  MPC results measured for isolates of C. freundii, E. 
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cloacae, E.  coli, K.  pneumoniae, and P.  aeruginosa fell within a susceptible NCCLS 
designation for many of the quinolones tested, however, differences between the 
MIC/MBC and MPC were observed for every drug-pathogen combination which ranged 
from 4-to-16-fold for ciprofloxacin, 2-to 16-fold for levofloxacin and 2-to 16-fold for 
garenoxacin.  With the exception of MBC measurements, all susceptibility tests were 
preformed using identical test volumes, differing only in the number of cells tested.  
Thus, the MPC measurement is fundamentally different from standardized susceptibility 
measurements because it utilizes an inoculum that accounts for the presence of first-step 
resistant cells.  Inhibiting the growth of the most-resistant mutant present in 
subpopulations within susceptible 1010 CFU/ml cultures will minimize the step-wise 
development of fluoroquinolone resistance.  No differences in ciprofloxacin and 
levofloxacin MPC results were seen for C.  freundii, E. coli, and K.  pneumoniae.  
Ciprofloxaicn MPC results were 4-fold lower seen with levofloxacin against isolates of 
E.  cloacae and P.  aeruginosa.   
PK/PD analysis of ciprofloxacin and levofloxacin concentrations in healthy 
volunteers have demonstrated urinary Cmax of 43 and 84 μg/ml, respectively (45, 252).  
Therefore, ciprofloxacin and levofloxacin concentrations are expected to remain in 
excess of the MPC for greater than 24 hr of the dosing interval for all Gram-negative 
uropathogens tested.  No published experiments regarding urine Cmax values for 
garenoxacin have been determined, but it is expected that urinary Cmax concentrations 
will exceed published serum levels. Thus, garenoxacin may be effective at preventing 
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the selection of resistant organisms of E. coli and K.  pneumoniae if concentrations 
above the MPC for these organisms can be achieved and maintained.   
Fluoroquinolone treatment for UTIs can be used as a model to examine the 
clinical utility of the MPC measurement.   Despite nearly 25 years of documented use of 
fluoroquinolones in the treatment of UTI, the incidence of fluoroquinolone resistance 
remains low (112), ranging from 2-to-5% in Canada and the United States (139, 181, 
182).   Correlations between antimicrobial consumption and resistance for other 
antimicrobial classes and examination of fluoroquinolone resistance for Gram-negative 
pathogens outside the urinary tract, implies that a higher incidence of quinolone 
resistance should be expected among urinary tract pathogens.  A possible explanation 
for the low incidence of fluoroquinolone resistance among Gram-negative urinary tract 
pathogens is that urinary concentrations of fluoroquinolones may be 100- to 1000-fold 
higher than those obtained at other anatomical sites (251, 252).  Thus, urinary quinolone 
concentrations are expected to remain in excess of the MPC for a number of Gram-
negative pathogens throughout the majority of the dosing interval.  This argument does 
not preclude resistance from occurring; clearly fluoroquinolone resistance rates among 
Gram-negative pathogens have been described (121).  It is possible, particularly within 
Latin American and developing countries, that quinolone resistance is higher because of 
the use of less active quinolones such as nalidixic acid and or the use of low dosages 
which may select resistant isolates (121).  High-level resistant organisms may be 
selected at different sites of infection where MPC values cannot be achieved or 
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maintained for sufficient periods to prevent the selection of resistant organisms that can 
then infect the urinary tract.  However, high concentrations of quinolones obtained in 
the urine do not guarantee success as is illustrated by the observation that in vitro 
resistance to TMP-SMX predicts an approximate 50% failure rate with TMP-SMX 
therapy despite this agent’s high urine concentrations and long half life (139, 231, 234, 
299, 335, 359).  Thus, clinical failures can be expected with fluoroquinolones as well.  
Sheng et al (325) examined sets of isolates from the mid to late 1980s and mid to late 
1990s to examine fluoroquinolone resistance in clinically important Gram-negative 
bacteria in Japan.  E. coli isolates were highly susceptible to fluoroquinolones prior to 
1996; however, by 1996, 20% of the strains had become resistant to one of the 
fluoroquinolone tested, although ciprofloxacin resistance remained low.  The authors 
also noted a 13-to-20% decline in susceptibility to fluoroquinolones for Enterobacter 
spp. and P.  aeruginosa.  While resistance correlates with the wide spread use of these 
antimicrobial agents in Japan, increased use alone could not account for these 
observations.  Some strains of S. marcescens and P. aeruginosa demonstrated in vitro 
resistance prior to the introduction of fluoroquinolones in Japan (229) and many strains 
demonstrated clonal diversity suggesting that resistance was due to more than one 
resistant clone.  It was further noted that 62% of the patients infected with a 
fluoroquinolone-resistant bacteria had no previous exposure to the drug (229).  
Fluoroquinolone-pathogen combinations that result in small MPC/MIC ratios and 
overall low MPCs (below a breakpoint for resistance) should be targeted in strategies 
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designed to maximize clinical outcomes while minimizing resistance.  Fluoroquinolone 
use in UTIs for the treatment of infections caused by Gram-negative bacteria describes 
situations where the initial degree of resistance (based on the MIC) and the potential to 
selectively amplify resistant subpopulations (based on the MPC) are also low.            
The future role of fluoroquinolones in UTI remains strong and the clinical 
longevity of these agents will be influenced by how resistance evolves.  For 
fluoroquinolones and Gram-negative urinary tract pathogens, the distinction between 
the MIC and the MPC remains relatively small and concentrations of quinolones in the 
urine suggest that MPC drug concentrations can be maintained throughout dosing.  
Therefore, the recognition of spontaneous first-step mutants present within large (i.e., 
>107 CFU/ml) susceptible cultures is an important factor in preventing the step-wise 
selection of quinolone-resistant strains.  MPC results for C.  freundii, E.  coli and K. 
pneumoniae fall beneath a susceptible breakpoint and demonstrate how the MPC 
measurement can be easily incorporating in current dosing regimes.  Urinary 
concentrations of fluoroquinolones suggest that in organisms with high MPCs such as 
E.  cloacae and P.  aeruginosa, minimizing the selection of resistant mutants may still 
be accomplished due to the high urinary concentrations achieved and maintained 
throughout current dosing.    
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6.0 CONCLUDING REMARKS 
 
Since the introduction of sulfa drugs and penicillin in the 1930s and 1940s, 
science and medicine have witnessed more than half a century of development and 
use of antibiotics which have clearly altered the course of medical history and will 
continue to define the antibiotic era.  Past policies for dealing with resistance have at 
best been only partially effective and despite developments, we continue to face the 
same challenges encountered at the beginning of the antibiotic era.  As an example, in 
1960, Gould stated, “we are as yet at an elementary stage in correlating the clinical 
administrations of antibiotics with in vitro sensitivity determinations” (136).   
Based on current knowledge, one can surmise three inherent principals involved 
with antibiotics and resistance: 
1. antibiotic resistance is an undeniable fact and will continue to be a problem as long 
as we use (and misuse) antimicrobial agents,  
2. bacteria are remarkably adaptive and will continue to evolve and acquire new 
mechanisms of resistance to antimicrobial agents, and 
3. prior strategies for dealing with antibiotic resistance have failed to slow the 
progression and in some cases have clearly failed.  Therefore, novel approaches for 
dealing with resistance are required.   
 
In this thesis, I have discussed a novel measure of drug potency that is based on 
a susceptibility parameter termed the MPC and highlighted how incorporation of the 
 202
MPC into the concept of the MSW may be used in an attempt to preserve antimicrobial 
efficacy, minimize resistance, and maximize clinical outcome.   
Experimentally, the MPC can be described in a characteristic two-stage decline in 
bacterial growth.  The first stage of colony decline occurs at fluoroquinolone 
concentrations which approximate the MIC of the wild-type strain.  At fluoroquinolone 
concentrations above the MIC of the wild-type strain, a plateau in cell death occurs 
which corresponds to the emergence of drug-resistant mutants.  Increasing 
fluoroquinolone concentrations results in a second decline in colony recovery, leading 
to the eventual MPC for the given isolate.  For any given fluoroquinolone-pathogen 
combination, the selection of resistant mutants and the corresponding MSW will be 
different.  For example, for organisms which remain highly susceptible to 
fluoroquinolones, such as S. pneumoniae, the plateau in cell death will be relatively 
short, and the MPC may fall within a susceptible breakpoint for the drug.  Conversely, 
P.  aeruginosa represents an organism where the differences between MIC and MPC 
measurements are large and mutant selection occurs over broad concentration ranges.  
However, despite these differences, the potential utility of the MPC measurement for 
restricting the selection of fluoroquinolone resistant mutants remain the same.       
  In chapter 3, I described how the MPC measurement could be used to identify 
key differences in the anti-pneumococcal activity of six fluoroquinolones deemed 
clinically equivalent.  When applied to drug PK/PD profiles, MPC measurements were 
used to predict the potential of each agent to select for resistance.  In order of 
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descending activity, a hierarchy of potency based on the ability to inhibit first-step 
resistant mutants was determined: gemifloxacin>moxifloxacin>gatifloxacin = 
trovafloxacin >grepafloxacin > levofloxacin.  Gemifloxacin, and moxifloxacin were the 
only compounds tested whose serum/tissue concentrations are expected to remain in 
excess of the MPC for >12 hr of the dosing interval, suggesting that they may be 
appropriate for once daily dosing.  Levofloxacin selected mutants at the highest 
concentration of any quinolone tested and serum concentrations of levofloxacin were  
projected to remain in excess of the MPC for approximately 3 hr of the dosing interval 
(the lowest of any quinolone tested).  Thus, a higher (possibly 750 mg) dose of 
levofloxacin and/or more frequent dosing may be required to prevent the selection of 
fluoroquinolone-resistant S. pneumoniae, which is consistent with recent reports of 
levofloxacin-associated clinical failures in the treatment of S. pneumoniae (7, 70, 340, 
351).  Sequence analysis of the QRDR for the parC and gyrA genes of selected clinical 
isolates revealed the presence of target mutants which raises concerns about 
accumulation of fluoroquinolone resistance alleles among clinical isolates of S. 
pneumoniae that are not detected in traditional susceptibility testing procedures.   
Fluoroquinolone killing of S. pneumoniae at the MPC drug concentration resulted in 
increased killing and bacterial eradication by 24 hr, indicating that targeting the MPC 
may also have an impact on the speed of clinical resolution.  There is little doubt that 
fluoroquinolone resistance in strains of S. pneumoniae has increased during the past 
decade (53).  For example, a number of studies have shown that once the prevalence of 
 204
resistance begins to increase noticeably, it can advance from below 5% to above 20% 
within a few years (13, 175) .   
Currently, fluoroquinolone resistance among clinical isolates of S. pneumoniae 
remains relatively low and new strategies/susceptibility testing procedures, such as the 
MSW and the MPC, can impact the degree of resistance and the rate at which it 
develops.  Past lessons, such as the escalation of penicillin resistance within S. 
pneumoniae have shown us that low dose therapy caused an increase in the carriage of 
resistant isolates and, after mutant spread to fresh hosts, curing infections required 
higher doses of penicillin or new derivatives having greater potency or different binding 
targets.  Prolonged and gradual step-wise selection with β-lactams coupled with 
dissemination of plasmid-borne factors resulted in the selective enrichment of resistant 
isolates which has made penicillin ineffective against a third of the S. pneumoniae 
isolates in some areas (79, 160).  Therefore, MPC testing for fluoroquinolones and S. 
pneumoniae represents a realistic approach for dealing with resistance before it 
becomes highly disseminated among clinical isolates and is of particular importance in 
light of the fact that fluoroquinolone treatment for S. pneumoniae is often administered 
in culture-negative patients.    
The in vitro susceptibility of P. aeruginosa to ciprofloxacin and levofloxacin has 
not always correlated with clinical outcomes and a number of clinical observations 
suggest that differences in anti-pseudomonal activity are not reflected by the MIC.  
When clinical isolates of P. aeruginosa were tested by the MPC approach, ciprofloxacin 
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was 2 -to 4-fold more active than levofloxacin.  MPC90 results indicate that no current 
dose of levofloxacin is able to exceed the levofloxacin MPC90 result for any length of a 
dosing period.  In contrast, a 400 mg I.V. T.I.D. dose of ciprofloxacin is expected to 
exceed the ciprofloxacin MPC90 result for approximately 5.5 hr of the 24-hr dosing 
interval.  Based on these results, I conclude that: i) neither compound should be used in 
monotherpy, ii) levofloxacin selects and enriches more first step mutants at higher 
concentrations and, iii) for a longer duration of the dosing interval.  Thus, observed 
differences in clinical outcomes may be attributed to the fact that the levofloxacin MPC 
is not achieved or maintained under current dosing regimes, allowing first-step resistant 
mutants to proliferate during therapy.  Sequence analysis of regions of the gyrA and 
parC genes revealed target mutations in recovered mutants that were not present in 
parental isolates.  Differences in the anti-mutant activity between ciprofloxacin and 
levofloxacin may reside in the differential selection of resistant mutants.  Sequence 
analysis of the target genes in recovered mutants revealed that levofloxacin may select 
different target mutants and mutant-selection curves preformed on efflux mutants 
revealed that levofloxacin was more efficient at selecting efflux mutants at low and 
moderate concentrations.  MPC-based killing experiments revealed that killing at the 
MPC drug concentration severely restricted mutant growth when the MPC and MIC 
drug concentrations were directly compared.  Preliminary in vivo experiments 
preformed with a rat abscess model of infection revealed that resistant mutants are 
selected during therapy.   
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Examination of MPC results for Gram-negative urinary tract pathogens 
suggested that the MPC measurement could be practically applied in current dosing to   
prevent the selection of resistant mutants and maximizing clinical outcomes.  The MPC 
measurement and concept of MSW provides a rationale strategy designed to prevent the 
selection and amplification of de novo resistance, however, a number of limitations in 
MPC testing currently exist.  As indicated by Allen (6), the most important difficulty 
encountered in determination of the MPC lies in achieving the targeted inoculums.  
Bacterial organisms which do not readily achieve >1010 CFU/ml may require additional 
numbers of MPC plates, for each concentration tested, to ensure that 1010 CFU/ml are 
tested.   This procedure does not lend itself to a high throughput clinical setting.  If the 
MPC is to gain utility in a typical clinical setting, streamlining of the methodology may 
be necessary (6).  The application of MPC testing to the clinical microbiology 
laboratory may require that batch studies be performed on a representative number of 
bacterial species which could serve as an indicator of activity for the entire species 
population.  If a relationship between MIC and MPC results can be deciphered, then 
clinicians, microbiologist, pharmacologists and scientists may be able to extrapolate 
MPC activity directly from the MIC.  Advances in molecular diagnostics may allow for 
the real-time detection of a single first-step mutant within a background of 108 cells 
(215-217).  Currently, MPC testing relies on an agar dilution method and some drug-
pathogen combinations require broth dilution testing as per NCCLS recommendations.     
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 The application of MPC testing to non-quinolone antimicrobials is an area that 
requires further investigation.  While the majority of experiments describing the MPC 
have been conducted with fluoroquinolones, additional studies on other antimicrobial 
agents have been performed (147, 221).  Zhoa et al  (367) published MPC data for 
chloramphenicol, penicillin G, rifampicin and tobramycin against E. coli .  Recently, 
my colleagues and I described the effect of antimicrobial concentration on colony-
forming ability of resistant mutant subpopulations of Mycobacterium  smegmatis and S. 
aureus for chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline 
(221).  Ongoing investigations of MPC measurements with macrolides and S. aureus 
and S. pneumoniae suggest that MPC studies are relevant to this class of agents (32, 
235)   Azithromycin-susceptible strains (MICs <0.5 µg/ml) were tested by MPC.  For 
some isolates, MPC values ranged from 16->512 µg/ml and were positive for the ermC 
gene, whereas the wild-type parental strains were negative (Blondeau and Metzler, 
unpublished observations).  The ermC-positive isolates also had elevated MIC/MPC 
values to other macrolide compounds (32).  MPC is most easily considered with 
organisms in which resistance arises as a function of single point mutation which 
include fluoroquinolones and third generation cephalosporins among others.  However, 
in the broadest sense, resistance to an antimicrobial agent means that a particular 
microorganism is able to reproduce in the presence of the agent under specified 
conditions.  Resistance may be associated with a specific heritable alteration or 
induction of protective genes such as those encoding β-lactamses.  Heritability would 
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seem to make resistance an absolute term since changes in DNA primary structure are 
unequivocal.  However, in some cases resistance genes are not fully protective and 
some drugs, perhaps used at higher concentrations, prove effective.  Consequently, the 
term resistance must be qualified to take into account the antimicrobial drug 
concentration (85).  As initially proposed in the discussion of efflux resistance in 
Chapter 5, the MSW hypothesis (for which the MPC is the upper boundary) places no 
restriction on the type of resistance mechanism selected.  As bacterial inoculums 
increase, so too does the heterogeneity of the bacterial culture.  Increased inoculums 
may dilute intracellular targets or enzymatic activity of resistance mechanisms which 
serve to increase resistance beyond what is measured by the MIC.  If under these 
conditions, higher concentrations of antimicrobial are required to inhibit cultures, then a 
MPC measurement may apply.  In a recent clarification of the mutant selection window, 
Zhao (366) suggests that once a small fraction of mutants is present in an infected 
individual or heterogeneous culture, the key idea in preventing the selection of 
resistance will be whether resistant mutants will be enriched; not how they came into 
being.  In this respect, the MPC may apply to a number of different antimicrobial 
agents.   
 The issue of “collateral damage”, or the unwanted selection of resistant 
organisms due to high quinolone concentrations, was an issue raised by Livermore 
(218) in regard to the MPC.  Prolonged low-dose therapy has unquestionably led to the 
development of resistance, however, dosing based on MPC measurements champions 
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higher doses administered over a potentially shorter duration of therapy; a hypothesis 
supported by preliminary killing experiments.  The implication that quinolones may 
directly contribute to the selection of resistant mutants can be inferred based on 
evidence that quinolones are strong inducers of the S.O.S. response (284-286).  
However, a number of observations suggest that quinolones contribute minimally to 
resistance.  For example, maximal induction of the S.O.S. response by fluoroquinolones 
in various organisms typically occurs at concentrations 10-to 15-fold above the MIC 
values for a number of bacterial species (284).  The MPC results, for most bacterial 
species, are generally 2- to 8-fold greater than typical MIC results.  Mutational studies 
on a LexA- strain of E. coli revealed no differences in the mutational frequency at which 
quinolone resistance developed when compared to LexA isogenic strains (Xillin Zhao, 
personal communications).   
 Perhaps the most important question surrounding the MPC concerns its potential 
clinical impact.  Although in vitro observations and retrospective clinical observations 
support the role of MPC in minimizing the selection of resistant mutants,  
no direct evidence from animal or human trials are currently available to test the 
hypothesis that incorporation of MPC-based testing in antimicrobial management will 
correlate with decreased clinical resistance and improved therapeutic outcomes.  In my 
animal studies, organisms displaying elevated resistance could be recovered from 
infected animals when a strain with an intermediate MIC was used to create infection.  
The enrichment of mutant subpopulations in vivo is a reasonable explanation for the 
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recovery of such resistant organisms.  A recent report which used a rabbit model of 
pneumococcal infection to investigate the selection of resistant mutants of S. 
pneumoniae revealed that, after levofloxacin or moxifloxacin treatments, mutants could 
be recovered from strains with a pre-existing parC mutation (99).  The authors 
rationalized this finding by suggesting that strains with a pre-existing parC mutation 
caused drug concentrations to fall below the MPCs of these strains.  Further in vivo 
(animal and human trials) are now required to test theimplicatons of the MPC 
measurement and the MSW concept.   
Conventional wisdom suggests that resistant mutants are inherently less “fit” 
than wild-type cells and as a result, elicit reduced growth rates (129).  However, recent 
data suggests that mutations in parC and gyrA genes may, on some occasions, not be 
associated with a physiological deficit (129).  Furthermore, in some cases resistance 
may associated with an increase in fitness, as assessed by increased growth rate (42).  
The clinical consequence of mutant subpopulations is currently unknown.  The theory 
behind the MPC measurement implies that one resistant mutant is as etiologically 
important as 100,000 mutants; however, from a clinical perspective, this argument may 
not hold true.  The dissemination of penicillin-resistant S. pneumoniae serotypes 3, 14, 
19F and 23F demonstrate how the spread of individual resistant clones can impact on 
global resistance and demonstrates the necessity for minimizing resistance.  In the 
context of S. pneumoniae, recent evidence (7, 70)  indicates that treatment failures are 
associated with resistant organisms which were not present at the start of therapy.  In 
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light of these observations, strategies designed to minimize the impact of resistance 
should incorporate ideas which make it difficult for organisms to select and/or acquire 
resistance mechanisms.  In this context, the clinical application of the MPC is clear: 
maintaining serum/tissue concentrations in excess of the MPC (within tolerable doses) 
will require cells to obtain two concurrent resistance mutations for growth and thereby 
severely restrict the likelihood that resistant mutants will be selected during therapy. 
As we learn more about the accumulation of antibiotics in infected tissues, the 
types of resistance mutants selected by different agents within different drug 
concentration spectrums, and the concentrations required to inhibit their growth, the 
practical implications of the MPC will continue to emerge.  A recent review of MPC by 
Blondeau et al (32) noted that the development of MPC is a relatively new concept that 
continues to evolve with every report.  Therefore, with such a new concept and 
relatively limited studies published to date, it may be premature to comment on 
overstretching the limits of MPC when we do not yet know if the limits have been 
defined (32).  Open debates and discussions will help to develop a greater 
understanding of fluoroquinolone resistance and the potential impact of the MPC.  
Based on the development of penicillin-resistant S. pneumoniae, clinical validation may 
come in the form of increased clinical failures and a rapid rise in the rates of resistance.  
Thus, perhaps the most meaningful clinical question regarding the MPC is whether or 
not we can afford to take “a wait and see” approach to fluoroquinolone resistance?  
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8.0  APPENDIX A 
 
 8.1 Solutions and Buffers 
 
  10X TE Buffer 
Dissolve 12.1 g of Tris Base and 3.72 g of EDTA in 750 ml of distilled 
water.  Bring to pH 8.0 using HCl.  Adjust volume to 1 L and autoclave. 
 
10X TBE 
Dissolve 90.8 g of Tris Base, 15.4 g of Boric acid and 0.37 g of  EDTA 
in 1000 ml of distilled water and autoclave. 
 
0.5 M EDTA 
Add 93.05 g of EDTA to 400 ml of distilled water.  Add NaOH pellets 
one at a time until the EDTA is completely dissolved.  Bring the pH to 
8.0 by adding 5 M NaOH.  Adjust volume to 500 ml and autoclave. 
 
0.1 M Cacodylate Buffer 
Combine 16 g of sodium cacodylate (Mol. Wt. 160.0) with 920 ml of 
distilled water.  pH to 7.2 with 0.1 N HCL.  Adjust to 1000 ml with 
distilled water. 
 
10% Sarcosyl 
Dissolve 10 g of sodium sarcosinate in 70 ml distilled water.  Use of heat 
will aid in dissolving the sarcosyl.  Adjust volume to 100 ml and 
autoclave. 
 
1% Pulsed-Field Agarose 
Add 1.0 g pulsed-field agarose to 100 ml 0.5X TBE.  Boil until agarose 
is dissolved and cool to 50°C before pouring the gel.  Allow gel to 
solidify for a minimum of 30 min before use. 
 
1% Agarose Gel for PCR 
Add 0.35 g to 35 ml of TBE Buffer containing ethidium bromide (ETBr).  
Microwave on high until the agarose is completely dissolved.  Pour gel 
and allow it to solidify for ~30 min.  
 
2% Glutaraldehyde 
Add 10 ml of 25% EM grade Glutaraldehyde to 115 ml of 0.1 M 
cacodylate buffer. 
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Cell Suspension Buffer 
Combine 100 μl of 1 M Tris-HCl (pH 7.2), 200 μl of 1 M NaCl and 1.0 
ml of 0.5 M EDTA (pH 8.0).  Dilute to 10 ml with sterile distilled water. 
 
ETBr Buffer 
Add 50 μl of ETBr at 10 mg/ml to 1 L of TBE Buffer for a final ETBr 
concentration of 500 µg/ml. 
 
ETBr Solution For Staining a Pulsed Field Gel 
Combine 40 μl stock ethidium bromide with 400 ml of distilled of 
distilled water. 
 
Low Melting Point Agarose 
Dissolve 1 g in 100 ml of TE Buffer at pH 8.0.  Boil for 1-to-1.5 min and 
cool to 50-65°C in water bath. 
 
Lysis Buffer 
Combine 100 μl of 1 M Tris-HCl (pH 7.2), 500 μl of 1 M NaCl and 1.0 
ml of 0.5 M EDTA (pH 8.0).  Weigh out 20 mg of deoxycholate and 50 
mg of N-Lauroylsarcosine and add to above mixture.  Dilute to 10 ml 
with sterile distilled water. 
 
PFGE Running Buffer 
Dilute 300 ml of 10X TBE in 2700 ml of distilled water for a 
concentration of 1X TBE. 
 
Proteinase K Buffer 
Combine 50 ml of 0.5 M EDTA (pH 8.0) and 10 ml of 10% N-
Lauroylsarcosine.  Adjust pH to 9.0, then dilute to 100 ml with sterile 
distilled water. 
 
Proteinase K/Proteinase K Buffer 
Add 25 μl of 20 mg/ml of Proteinase K to 10 ml of Proteinase K Buffer. 
   
  Reynold’s Lead Citrate 
Mix 1.33 g lead acetate, 1.76 g of sodium citrate and 30 ml of double 
distilled water that has been boiled to remove CO2.  Shake vigorously for 
1 min then place on a magnetic stirrer for 30 min.  Add 8 ml of 1 N 
NaOH.  Adjust to 50 ml using boiled deionized water.  Mix well.   
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Skim Milk 
Dissolve 200 g of powdered skim milk in 1000 ml of distilled water and 
autoclave. 
 
TE Buffer 
Add 5 ml of 1 M Tris-HCl, pH 8.0, and 8 ml of 0.25 M EDTA, pH 8.0, 
into 494 ml of distilled water. 
 
Toluidine Blue 
Mix 2.5 g of Toluidine Blue, 2.5 g of sodium borate and 250 ml of 
distilled water for several hr. 
 
Tracking Dye 
Add 60 g of sucrose into 100 ml sterile distilled water to make a 60% 
sucrose mixture.  Add 0.25 g of xylene cyanol into 100 ml of sterile 
distilled water.  Add 10 mM Tris at pH 8.0.  Combine the 60% sucrose, 
the 0.25% xylene cyanol.   
 
TSA 
Add 40 g to 1 L of distilled water.  Autoclave. 
 
Wash Buffer 
Combine 10 ml of 1M Tris-HCl (pH 7.6) and 20 ml of 0.5 M EDTA, pH 
8.0.  Dilute to 100 ml with sterile distilled water. 
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8.2  APPENDIX B 
 
8.2  Suppliers 
 
 8.2.1 Media 
 
 Mueller Hinton Broth (MHB)  Becton, Dickinson and Co., Sparks, MD 
 Todd Hewitt Broth (THB)  Becton, Dickinson and Co., Sparks, MD 
 Tryptic Soy Agar (TSA) with  Becton, Dickinson and Co., Sparks, MD 
  5% Sheep Blood 
 
 8.2.2 Antimicrobial Agents 
 
 Moxifloxacin, ciprofloxacin – Bayer pharmaceutical, West Haven, CT 
Levofloxacin – The R. W. Johnson Pharmaceutical Research Institute, Raritan, 
NJ 
 Gatifloxacin – Bristol Myers Squibb, Montreal, QC 
 Grepafloxacin – – Bristol Myers Squibb, Montreal, QC 
 Trovafloxacin – Pfizer Canada, Kirkland, QC 
 Garenoxacin - – Bristol Myers Squibb, Montreal, QC 
 Gemifloxacin – Glaxco Smithkiline pharmaceuticals, Collegeville, PA 
 Ceftazadime – – Glaxco Smithkiline pharmaceuticals, Collegeville, PA 
 Gentamiycin –  Sigma-Aldrich Co., St. Louis, MO 
Tobramycin - Sigma-Aldrich Co., St. Louis, MO 
  
8.2.3 Reagents, Chemicals and Enzymes 
 
25% Glutaraldehyde (EM Grade) Marivac, St. Laurent, QC 
95% Alcohol    Commercial Alcohols Inc., Brampton, ON 
Agarose    Invitrogen, Corisbad, CA 
Ammonium Hydroxide  BDH Inc., Toronto, ON 
Araldite 502    Ted Pella, Inc., Millville, NJ 
Boric Acid    BDH Inc., Toronto, ON 
Buffer A                                             New England BioLabs, Mississauga, ON 
Buprenorphine  Reckitt and Colman Pharmaceuticals Inc. 
Richmond,VI 
CCCP     Sigma-Aldrich, St. Louis, MO 
 Deoxycholate Acid   Sigma-Aldrich Co., St. Louis, MO 
DMP-30    Ted Pella, Inc., Millville, NJ 
[Tri(Dimethylaminoethyl Methacrylate)] 
EDTA     Sigma-Aldrich Co., St. Louis, MO 
Ethidium Bromide   BioRad Loaboratories, Hercules, CA 
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Ethanol    Electron Microscopy Sciences, Fort  
     Washington, PA 
Eyelube     Sabex, Boucherville, QC 
Hydrochloric Acid (HCl)  BDH Inc., Toronto, ON 
InstaGene Matrix   BioRad Laboratories, Hercules, CA 
Kodak D-19 Developer  Kodak, Saint-Laurent, QC 
Kodak Rapid Fixer   Kodak, Saint-Laurent, QC 
Ketamine Warner-Lambert and Co., Bellevelle, ON 
Lambda Ladder   New England BioLabs, Mississauga, ON 
Lead Acetate    Anachem, Bedfordshire, United Kingdom 
Lead Citrate    Ted Pella, Inc., Millville, NJ 
Low Melting Point   BioRad Laboratories, Hercules, CA 
Agarose    Sigma Chemical Co., St. Louis, MO 
Mass Ladder    Invitrogen, Burlington, ON 
N-Laurylsarcosine   Sigma Chemical Co., St. Louis, MO 
Oxidase    Fisher scientific, Nepean, ON 
 Pentobarbital sodium    Bimeda-MTC Animal Health Inc.   
      Cambridge, ON 
PCR Ladder    Invitrogen, Carisbad, CA 
PCR Primers    Sigma-Genosys, Oakville, ON 
PuReTaq Ready-To-Go  Amersham/Pharmacia, Piscataway, NJ 
Pfx platinum taq polymerase  Gibco-BRL, Burlington, ON 
Proteinase K    Sigma Chemical Co., St. Louis, MO 
Pulsed Field Certified Agarose Sigma Chemical Co., St. Louis, MO 
Saline     Baxter, Deerfield, IL 
Skim Milk    Becton, Dickinson and Co., Sparks, MD 
Slidex Pneumo-Kit   bioMerieux, Marcy-l’Etoile, France 
SmaI     New England BioLabs, Mississauga, ON 
SpeI     New England BioLabs, Mississauga, ON 
Sodium Borate   Fisher Scientific, Nepean, ON 
Sodium Cacodylate   Ted Pella, Inc., Millville, NJ 
Sodium Chloride (NaCl)  BDH Inc., Toronto, ON 
Sodium Citrate   BDH Inc., Toronto, ON 
Sodium Hydroxide (NaOH) Pellets BDH Inc., Toronto, ON 
Sucrose    BDH Inc., Toronto, ON 
Tris-HCl    Sigma Chemical Co., St. Louis, MO 
Uranyl Acetate   Ted Pella, Inc., Millville, NJ 
Vetbond tissue adhesive   3M animal care products St. Paul MN 
Wizard Kit    Promega, Madison, WI 
Xylene Cyanol   BioRad Laboratories, Hercules, CA 
 Zylazime  Bayer Veterinary Division, Toronto, ON  
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 8.2.4 Disposable Labware 
  
200 µl Pipette Tips   VWR International, Edmonton, AB 
Corning Cryovials   Corning Inc., Corning, NY 
Cuvettes    Fisher scientific, Nepean, ON 
Disposable scalpels    Fisher scientific, Nepean, ON 
Falcon multiple well tissue   VWR Canlab, Edmonton, AB 
Culture plates 
Glass Tubes    Fisher scientific, Nepean, ON 
Latex Gloves    Fisher scientific, Nepean, ON 
McFarland Tubes   Fisher scientific, Nepean, ON 
Microcentrifuge Tube   Fisher scientific, Nepean, ON 
 Microtitre Plates   Sarstedt, Newton, NC 
Pasteur Pipettes   Fisher scientific, Nepean, ON 
 Sterile Plastic Petri Plates  Fisher Fisher scientific, Nepean, ON 
 Swabs     Fisher scientific, Nepean, ON 
Wooden Applicator Sticks  Puritan, Guilford, ME 
3cc  Monoject Leur Lock Syringe Sherwood Medical, St. Louis, MO 
20 gauge needle   Sherwood Medical, St. Louis, MO 
  
 8.2.5  Equipment 
  
20 ul, 200 μl and 1 ml Pipettors Gilson Company, Inc., Lewis Center, OH 
 -70°C Freezer    Forma Scientific Inc., Marjetta, OH 
Avanti J-E Centrifuge   Beckman Coulter, Palo Alto, CA  
CHEF DRIII PFGE System  BioRad Laboratories, Mississauga, ON 
 Colorimeter    Hach Company, Loveland, CO  
 DNA theromocycler   MJ Research, Waltham, MA 
 Forcepts    Fisher scientific, Nepean, ON 
 Hot Plate/Stirrer-Model 300T  Fisher scientific, Nepean, ON 
 Homegenizer    Labcor Concord ON 
  Hibitane soap    Fisher scientific, Nepean, ON  
 Needle driver    Fisher scientific, Nepean, ON 
 Pediatric Bactec blood culture  Beckton Dickson, Sparks, MD 
bottles  
 PCR Gel Casting Mold  BioRad Laboratories, Mississauga, ON 
PFGE Gel Casting Mold  BioRad Laboratories, Mississauga, ON 
pH Meter    Corning Inc., Corning, NY 
 Pulsed Field Gel   BioRad Laboratories, Mississauga, ON 
Casting Apparatus 
Gel Doc 1000 Illuminator  BioRad Laboratories, Mississauga, ON 
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 Microwave Oven   Samsung, Suwon, Korea 
 pH meter    BioRad Laboratories, Mississauga, ON 
Oxygen Incubator   Hotpack Corp., Philadelphia, PA 
Rat tail vein catheter Becton Dickinson Infusion Therapy Sysem 
Inc., Sandy, UT 
  Shaking Water Bath   Mandel Scientific Co., Guelph, ON 
 Spectrophotometer   Pharmacia, Cambridge, United Kingdom 
 Thermocycler (PCR Express) Thermo Hybaid, Ashford, Middlesex, 
      United Kingdom  
 Vortex (Mini-Shaker Model 58) Fisher scientific, Nepean, ON 
 Vicryl silk sutures    Ethicon, Sommerville, NJ 
 Viteck identification/susceptibility  BioMerieux, St. Laurent, QC 
 Cards  
 Weigh Scale – Mettler PC440 DeltaRange, Zurich, Switzerland  
 
8.2.6 Rats  
  Male, Sprague Dawley white rats Charles River, Wilmington, MA 
 
